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Abstract 
To date more than 15000 Cytochromes P450 have been identified and named so 
far, with one third belonging to the plant kingdom. This is a key biochemical 
resource, providing a wealth of biocatalysts covering a diverse range of 
chemistries. Characterisation, however, has been greatly hindered by the poor 
solubility of many P450s, a result of the membrane anchoring region common to 
all plant P450s. Fusions of plant P450 heme domains to an appropriate reductase 
without the hydrophobic membrane anchor could provide the basis for developing 
robust, soluble plant enzyme systems for substrate screens to discover novel 
activities that are also of benefit to industry. 
In this project, the two predominantly expressed Arabidopsis reductases ATR1 
and ATR2 have been cloned, without the membrane anchor, and expressed in 
Escherichia coli. These two truncated enzymes have been purified and assessed 
for activity with ATR2 found to be more active than ATR1. ATR2 was chosen for 
engineering into a novel plant P450 reductase vector platform for high throughput 
applications, whereby the P450s can be easily and quickly swapped using ligation 
independent cloning techniques. Four different plant P450s (CYP93C1, CYP73A5, 
CYP82E4 and CYP81D8) were selected to validate this technology, and activity 
for the fusions of CYP93C1 (Isoflavone synthase I from Glycine max) and 
CYP73A5 (cinnamate-4-hydroxylase from Arabidopsis) with ATR2 have been 
shown. The presence of CYP73A5 fused to ATR2 was verified through 
purification and further studies showed that it has to be membrane associated for 
activity. 
Additionally, CYP93C1 and CYP73A5 were also fused with the bacterial RhF 
reductase from Rhodococcus sp. and expressed in E. coli and compared to the 
plant P450 – plant reductase fusion protein. These novel plant-bacterial fusion 
P450 systems are the first example of active plant P450s fused to a reductase from 
a bacterium. 
This platform technology will provide the possibility for characterisation studies 
of eukaryotic P450s with unknown function and the discovery of new activities. 
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1 Introduction 
1.1 Biotransformations in Industry 
 
The amazing world of biotechnology was started by humans more than a thousand 
years ago by producing alcohol and vinegar by fermentation without even 
knowing about the presence of microorganisms. Later, living cells, such as yeast, 
bacteria, filamentous fungi and plants were deliberately used to improve the 
stability and taste of food. Industrial biotechnology, also called “white” 
biotechnology, is a relatively new definition and means the fabrication of products 
by using microorganisms or enzymes by reducing energy and waste for the 
creation of a more environmentally beneficial process.
1
 Over the last fifty years, 
many useful ‘biotransformation’ reactions have been identified and applied in 
industrial chemistry for processes including the hydrolysis and synthesis of ester 
and amide bonds, the hydrolysis of nitriles, the asymmetric reduction of prochiral 
ketones and the formation of chiral amines. Biotransformations have the 
advantage of converting substrates under relatively mild reaction conditions 
(neutral pH, room temperature, less activation energy) in comparison to 
conventional harsh chemical reactions. Moreover, enzymes are stereo- and 
regioselective and to recreate this selectivity is often a major challenge for 
synthetic and pharmaceutical chemistry using chemicatalysis. Therefore, enzymes 
are commercials important and often provide a more environmental friendly way 
for the synthesis of chemical compounds. 
 
One particularly valuable class of enzymes are the oxygenase enzymes, which 
catalyse the introduction of oxygen into nonfunctionalised carbon skeletons. 
Oxygenations using conventional abiotic chemistry are energy consuming, often 
require either expensive catalysts and/or toxic reagents and are often neither regio- 
nor stereoselective. Hence there is now a substantial research effort into the 
discovery and application of enzymes that catalyse oxygenation reactions
2
, which 
has included peroxidases
3
, flavin dependent monooxygenases
4
, and heme-
containing enzymes known as cytochromes P450. Amongst these enzymes exist 
biocatalysts capable of the hydroxylation of C-H bonds, heteroatoms such as 
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nitrogen and sulphur and many other useful enzymes that are distinguished by 
their ability to catalyse their reactions with high chemo, regio- and stereo-
selectivity. 
 
1.2 Cytochromes P450 
Cytochromes P450 (P450s) belong to the enzyme class monooxygenases, which 
has the Enzyme Commission number (numeral classification of enzymes based on 
the reaction type
5
) E.C.1.14.-.-. These heme-containing proteins are found in all 
kingdoms of life including humans, plants, insects, fungi, bacteria and also in 
viruses.
6
 In eukaryotes, they are mostly integral membrane bound, whereas 
prokaryotic P450 systems are more likely soluble and located in the cytoplasm.  
P450s require auxiliary reductases for the activation of molecular oxygen for their 
different reactions. These reductases transfer two electrons in single steps from 
the cofactor NAD(P)H to the heme of the P450.  
1.2.1 History and Nomenclature of Cytochromes P450 
Ronald W. Estabrook, one of the pioneers in P450 research, published a summary 
of the outstanding research in the discovery of the cytochromes P450 in 2003.
7
 It 
all began in 1949 with Betty and Jim Miller and their graduate student Gerald C. 
Mueller, who performed in vitro studies on the metabolism of methylated 
aminoazo dyes in rat liver homogenates, to understand the degradation of the 
carcinogen 4-dimethylaminoazobenzene.
8,9
 Later, Jim Gillette and Julius Axelrod 
paved the way for a better understanding of the drug (acetanilide) metabolism, 
which also gave important momentum to the discovery of the P450s.
10
 The latter 
worked on the demethylation of ephedrine and showed that NADPH and oxygen 
are necessary for the reaction in rabbit liver microsomes.
11
 Axelrod obtained the 
Nobel Prize in Physiology and Medicine (1970) together with Sir Bernard Katz 
and Ulf von Euler “for their discoveries concerning the humoral transmitters in 
the nerve terminals and the mechanism for their storage, release and 
inactivation"
12
. Bernard B. Brodie, group leader of Jim Gillette and Julius 
Axelrod, published a classic paper on the hydroxylation of acetanilide and 
demethylation of monomethyl-4-aminoantipyrine in rabbit liver microsomes in 
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1955.
13
 The research in the area of the steroid hormone metabolism also 
contributed to the discovery of P450s, responsible for the C21 hydroxylation of 
progesterone in microsomes from the bovine adrenal cortex (Figure 1.14).
14
 Ryan 
and Engel showed in their studies the reversable inhibition of carbon monoxide by 
light for the first time.
14
 This observation led later to the discovery of P450 
function as an oxidase using molecular oxygen and NADPH for their 
reactions.
15,16
 A breakthrough in P450 research – built on the knowledge and 
techniques found on cytochrome b5 by Britton Chance and G. Ron Williams
17
 – 
was the detection of a shift from 413 nm to 450 nm in the carbon monoxide-
bound form of an unknown pigment from rat liver by Martin Klingenberg in 1958 
(Figure 1.1).
18
  
 
 
Figure 1.1: Original figure of the carbon monoxide difference spectra present in rat 
liver microsomes (from Klingenberg 1958
18
) 
 
Enzymes of the superfamily cytochrome P450 received their name from Omura 
and Sato, who identified them as heme proteins in 1962.
19
 The P stands for 
“pigment” and the 450 for the characteristic absorption maximum at 450 nm 
(Soret peak) of the carbon monoxide bound form. This characteristic was also 
used to investigate a quantitative method for the detection of cytochromes 
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P450.
20,21
 From this time on, there was a steady increase in the numbers of P450 
publications in each year (Figure 1.2). Since 2010, the National Center for 
Biotechnology Information (NCBI, http://www.ncbi.nlm.nih.gov/) has shown that 
more than 2000 papers on P450s have been published each year.  
 
Figure 1.2: Scientific articles published on National Center for Biotechnology 
Information (23th January 2012) 
 
Today, there are more than 15000 P450 genes identified (Figure 1.3).  
 
 
Figure 1.3: Schematic distribution of cytochromes P450 among the different 
kingdoms 
 
One third of all known P450s belong to the plant kingdom and the P450 content in 
angiosperm genomes can reach up to 1%, whereas the typical vertebrate genome 
0
500
1000
1500
2000
2500
1960 1970 1980 1990 2000 2010
re
su
lt
s 
in
 N
C
B
I 
fo
r 
"
P
4
5
0
"
 
year
Animals (4778)
Plants (5769)
Fungi (3045)
Protists (248)
Bacteria (1200)
Archaea (27)
Viruses (Mimivirus) (2)
CHAPTER 1 - INTRODUCTION 
 
20 
 
contains less than 100 (e. g. humans with 57 and Drosophila melanogaster with 
90 P450 genes).
22,23
 A few bacteria, such as the Gram-negative Escherichia coli 
were found to have no P450 gene sequence.
24
  
The first classification of 154 different genes of the P450 family from mammals, 
such as human, bovine, and rat as well as from yeast and bacteria (P450cam from 
Pseudomonas putida) was in 1991.
25,26
 Proteins sharing at least 40% of their 
amino acid sequence are classified into the same family and are assigned with the 
designation CYP for cytochrome P450 followed by a number (Figure 1.4) by 
Nebert and coworkers. The plant genes start at CYP71 through to CYP99 and 
continue again from CYP701-999.
6
 Sequences of the same enzyme family 
members with a similarity of more than 55% in their amino acid sequence were 
arranged into subfamilies such as CYP71A and CYP71B.
27,28
 There are some 
exceptions, especially in plants, where the classification is based on phylogenetic 
data and the organisation of the genes.
23
 The last number in the CYP name is 
unique to a single P450. Discoveries of new P450s resulted sometimes in 
modification of already named P450s. To monitor this, David Nelson (member of 
the Cytochrome P450 nomenclature committee) created a webpage with all 
identified P450s (http://drnelson.uthsc.edu/CytochromeP450.html). 
 
 
Figure 1.4: Nomenclature of P450s 
 
P450 and reductase form the P450 system and they are grouped in three main 
types.  
The members of the eukaryotic P450 superfamily are associated with the 
membrane of the endoplasmatic reticulum and so called ‘microsomes type’24. This 
system has a single flavin adenine dinucleotide / flavin mononucleotide 
(FAD/FMN) as the reductase with a flavoprotein P450 (Figure 1.5A). Both are 
synthesised by membrane-bound ribosomes and then anchored by an uncleavable 
CYP51G1
family
subfamily
isoform
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hydrophobic N-terminus (with around 20 amino acids of the N-terminus
29
) into 
the membrane.
30-32
  
The second type (‘mitochondrial type’24), uniquely found in animals but not in 
plants or fungi, consists of a P450 bound to the inner mitochondria membrane
33
 
and a soluble FAD-containing flavoprotein with a ferredoxin-type iron-sulphur 
protein.
34,35
 However, some P450s have been reported to be present at the outer 
chloroplastic membrane, e. g. the Arabidopsis CYP74
36,37
, CYP86B1
38
 and 
CYP701A3
39
 as well as an unnamed putative chloroplast P450 (AF107765)
6
 from 
Prunus dulcis (almond).  
The third type are the prokaryotic P450s (‘bacterial type’24), where the P450 and 
the reductase parts are located solubly in the cytosol. Bacterial systems mostly 
utilise a ferredoxin reductase (FdR) combined with a ferredoxin (Fdx) as 
reductase part (Figure 1.5B) and generally use NADH as an electron donor.
  
 
 
Figure 1.5: Schematic organisation of A the plant cytochrome and B the bacteria 
P450 systems 
 
The substrates for cytochromes P450 are mostly hydrophobic organic 
compounds.
24
 P450s have different functions and are involved in the biosynthesis 
of endogenous molecules as well as in the metabolism of many pharmaceuticals 
and xenobiotics. Across the kingdoms, P450s take part in a diverse range of 
processes: in prokaryotes, they participate in the assembly of antibiotics, in the 
catabolism of different carbon sources and in the metabolism of fatty acids.
28
 By 
contrast in eukaryotes, P450s are involved in the biosynthesis of membrane sterols. 
In animals, they are part of the biosynthesis of signal molecules and steroid 
hormones as well as vitamin D3.
28 
In fungi, they carry out important roles in the 
synthesis of mycotoxins and in the metabolism of lipids, which are used as carbon 
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source.
40
 Furthermore, in plants, they are found in the biosynthesis and catabolism 
of hormones and secondary plant compounds.
41
  
 
1.2.2 Structure and Function of Cytochromes P450 
P450s between the different families share low sequence identity (often less than 
20%). However their structural organisation shows a strong conserved topology 
and three-dimensional fold.
42-44
 The number of crystal structures known for P450s 
is increasing rapidly since the first structure, of CYP101A1 (P450cam) from 
Pseudomonas putida was determined.
42,43
 Today, there are more than 70 crystal 
structures of P450s available on the Research Collaboratory for Structural 
Bioinformatics (RCSB) webpage (http://www.rcsb.org, 09/12/2011). The only 
solved crystal structure so far for Arabidopsis P450s is the allene oxide synthase 
(CYP74A1, Figure 1.6).
45
  
 
 
Figure 1.6: Ribbon diagram of Arabidopsis allene oxide synthase (CYP74A1) crystal 
structure  
heme in grey, fatty acid substrate in green 
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The structure of allene oxide synthase in Figure 1.6 illustrates the general 
conserved topology of P450 structures. They contain approximately thirteen α-
helices and four β-sheets ranged into two domains: the α domain is rich in helices 
and consists of the catalytic centre, a four-helix core (D, E, I and L) and another 
two helices (J and K), whereas the β domain has two β-sheets (β1 and β2) 
containing anti-parallel β-sheets, which are involved in the formation of the 
hydrophobic substrate channel (Figure 1.7).
46
  
 
Figure 1.7: Topographic map showing the secondary elements represented for the 
CYP102 and commonly found among P450 enzymes.  
The α-helices are represented in red while β-strands are in yellow.46 
 
The comparison of two distantly related P450s, the eukaryotic CYP2C5 and the 
prokaryotic P450cam, revealed longer surface loops for the eukaryotic P450, 
whereas the catalytic centre and the L- and I-helices are the mostly conserved 
regions.
47
 The I-helix is involved in the substrate binding and the activation of the 
atomic oxygen.
48
 
 
All P450s share the same catalytic centre, which consists of a heme B molecule 
(Figure 1.8) as a prosthetic group, which in almost all P450s is connected to the 
protein by a thiolate bond to a highly conserved cysteine residue. If this thiolate 
bond is missing, the characteristic absorbance maximum at 450 nm for the active 
conformational state shifted to 420 nm – the inactive species of P450s.  
β-domain
α-domain
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Figure 1.8: Ribbon diagram catalytic P450 centre with the 5-coordinated cysteine   
heme in grey, nitrogens in blue, oxygens in red, sulphur in yellow, Cysteine carbon 
skeleton in orange 
 
The hydrophobic heme iron environment (β-bulge segment) is a very conserved 
region, where the cysteine residue is stabilised by hydrogen bonds from peptide 
NH-groups assisting the regulation of the redox potential of the heme.
49-51
 A 
similar structure was also found in other enzyme groups such as nitric oxide 
synthase (NOS)
52
 and chloroperoxidase (CPO)
53
.  
Six substrate recognition sites (SRS) were identified by Gotoh using 
bioinformatics as dynamic protein regions opening and closing the substrate 
channel: SRS1 is on the B’helix, SRS2 and 3 are regions of the F- and G-helices, 
SRS4 is situated on the I-helix, SRS5 is the β4 hairpin and SRS6 the K-helix β1 
connecting part.
54,55
 
  
Eukaryotic P450 have usually a longer hydrophobic N-terminus of 25-50 residues 
for the association with a membrane and the amino acid sequence is depended of 
the membrane target and not essential for the P450 function as shown for many 
human P450s.
56-59
  
Plant P450s often form metabolons with other proteins – a non-covalent complex 
of multible enzymes of a metabolic pathway. A substrate can be directly 
transferred into a product without producing high concentration of 
intermediates.
60
 One example for this phenomenon is the formation of a 
metabolon containing CYP79A1, CYP71E1, P450 reductase and the 
glycosyltransferase UGT85B1, which catalysis the reaction from tyrosine to 
dhurrin (a cyanogenic glucoside).
61
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1.2.3 Reaction Mechanism 
P450s are classified by their sequence similarity and not by their reaction type as 
most other enzymes. P450s show a wealth of reactions such as the cleavage of C-
C-single bonds, C-N-double bonds, hydroxylations, sulfoxidations, epoxidations, 
deaminations, dehalogenations, peroxidations or N-oxide-reductions
62,63
 with 
more than thousands of accepted substrates.
64
 The ability to perform so many 
reactions may be due to the properties of the iron atom, which is able to change 
between different oxidation states.
65
 
 
The theory of the catalytic cycle of monooxygenases was developed in analogy 
with the reaction cycle of peroxidases, as P450s also use peroxide for 
monooxygenations.
66,67
 They require one oxygen and two electrons, which were 
usually donated in two single steps from the cofactor NAD(P)H to activate the 
oxygen, for the reduction of the heme iron
28
: 
RH + O2 + NAD(P)H + H
+
 → ROH + H2O + NAD(P)
+ 
At the start of the cycle the iron of the P450 has the oxidation state of +III and the 
sixth coordination centre is occupied by a molecule of water (Figure 1.9). The 
water ligand is displaced when a substrate is bound to the enzyme (1). As a result 
of this increase of the redox potential from a low spin state (S = 1/2) to high spin 
(S = 5/2), the enzyme can be reduced to P450-Fe(+II) by a single electron from 
the redox partner nicotinamide adenine dinucleotide (phosphate) (NAD(P)H) and 
the reductase (2).
68,69
 The result is a five times coordinate high-spin complex, 
which can bind different ligands such as molecular oxygen, carbon monoxide or 
cyanide (3). The oxygen-bound enzyme is similar to the superoxide-Fe(+III)-
complex and is one of the detectable intermediates. The product of the following 
reduction through a single electron derived from the redox partners NAD(P)H and 
reductase (4) builds an unstable peroxo complex. After a protonation of the distal 
oxygen (5), it becomes a hydroperoxo intermediate (Compound 0), from which a 
water molecule is released after another protonation (6). The resulting product 
(Compound I) is unstable and was not isolated and characterised until recently 
(Rittle and Green 2010
70
). Compound I is a high valent iron-oxo-complex with 
coordinated active oxygen responsible for the substrate conversion.
70,71
 Finally, 
the oxygen is transferred to the substrate (7) and a water molecule is initiated (8) 
so that the oxidised product and the initial state are formed.
72-76
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Figure 1.9: Reaction cycle of a P450 hydroxylation  
(1) substrate binding, (2) reduction of the iron by NAD(P)H and reductase, (3) oxygen 
inserting, (4) reduction by NAD(P)H and reductase, (5) first protonation, (6) second 
protonation by formation of water, (7) substrate oxidation and (8) substrate release 
 
The steps of the catalytic cycle are dependent on the substrate, electrons and 
protons. This avoids a consumption of reduction equivalents without oxygenation 
of the substrate, preventing futile cycling and stopping production of toxic 
superoxides. However, there are three major reactions (called “uncoupling”), 
which abort the catalytic cycle: The first is the autoxidation of the superoxide-
Fe(+III)-complex by forming superoxide radicals. The second uncoupling, known 
as the peroxide shunt, separates hydrogen peroxide from the hydroperoxo 
intermediate. Some P450s use a short cut for their oxygenation reactions by 
introducing the oxygen from hydrogen peroxide into the substrate and using the 
peroxide shunt backwards, for example in fatty acid hydroxylation by CYP152A1 
from Bacillus subtilis and CYP152B1 from Sphingomonas paucimobilis.
77
 The 
third reaction is called oxidase shunt, where the active oxygen species 
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(Compound I) is protonated and reduced again by the dissociation of water instead 
of an insertion of the oxygen into the substrate. 
1.2.4 Cytochromes P450 reactions 
P450s provide a great variety of different regio- and stereospecific reactions, 
which make them interesting for industrial biocatalysis. Almost all P450s depend 
on a partner reductase and equimolar amounts of cofactors (NAD(P)H), which is a 
disadvantage when using these enzymes due to the increase in expense, however 
this problem can be avoided by performing whole cell experiments. The 
regeneration of NAD(P)H is also possible. For example, P450 BM3 (native fusion 
of a P450 and a reductase from Bacillus megaterium) can be coexpressed together 
with a glucose dehydrogenase. Glucose dehydrogenase converts glucose to 
gluconolactone in the process reducing NAD(P)
+
 to NAD(P)H, which is then used 
for the conversion of indole to indoxyl by P450 BM3. Indoxyl can dimerise to 
indigo, which is an important textile dye.
78
  
Using the knowledge of computer modeling, genomics and proteomics, P450s 
have been applied in industry for the investigation of new drugs, medicine or 
xenobiotics.
79,80
  
P450s with their wide range of substrate specificity catalyse key steps in many 
different pathways: In humans, they are mainly responsible for drug 
detoxification
81-83
, in plants, for the activation or degradation of xenobiotics
84
 as 
well as for the biosynthesis of biochemical compounds
85 
and in bacteria, for the 
biodegradation of carbon sources
41,86,87
.  
The variety of reactions catalysed by P450s extends from hydroxylation and 
oxidation, which are the most common P450 reactions, to alkylation, dealkylation, 
epoxidation, demethylation, aryl migration and many more (Figure 1.10). P450s 
catalysing hydroxylations, oxidations and epoxidations are an important 
alternative for industry, because chemical problems such as the use of chlorinated 
solvents and heavy metals as part of the catalyst are removed.
88
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Figure 1.10: Variety of reaction types catalysed by cytochromes P450 
 
 
1.2.5 Interactions between Cytochromes P450 and reductases 
Early studies of mammalian P450s and their reductases indicated the formation of 
a complex consisting of one P450 and one reductase molecule.
89-93 
Different 
research groups were studying the different P450 systems to understand the 
electron transfer between reductase and P450. In the microsomal P450 system, 
where the P450 and the reductase are both membrane associated, the electron 
transfer was reported to happen by random collision between P450 and reductase 
on the membrane
94
 or by a transient complex formation of the P450 and the 
reductase
92,95,96
. Additionally, it was noticed that hydrophobic regions on the 
protein surface, such as the F-G loop, interact also with the membrane.
97,98
 
 
The number of mitochondrial P450 genes in animals is much smaller than for 
microsomal P450s. For example, seven mitochondrial P450s out of 57 are present 
in humans.
35
  Mitochondrial P450s lack the hydrophobic membrane anchor and 
therefore their association with the inner mitochondria membrane is weak 
compared to the membrane anchored microsomal P450s. The hydrophobic F-G 
loop (e. g. positions 219-237 for CYP27A1) is thought to be responsible for the 
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interaction between P450 and the inner mitochondrial membrane.
99,100
 The 
reductase part of the mitochondrial system contains two parts: the adrenodoxin 
and the adrenodoxin reductase and both interact via electrostatic interactions. 
Adrenodoxin, a soluble Fe2S2 protein with high affinity to P450s, and the 
adrenodoxin reductase, are associated with the inner mitochondria membrane 
which enables the electron transfer between NADPH, reductase and P450.
101-105
 
 
It was also demonstrated that mitochondrial and microsomal P450s and reductases 
can be interchangeable. A mitochondrial P450 was artificially anchored to the 
endoplasmic reticulum and shown to be supported by a microsomal reductase 
system as well as a microsomal P450 by the mitochondrial reductase.
104,106,107
  
Bacterial P450 systems are soluble due to the fact that they are missing the 
hydrophobic membrane anchor. They are NAD(P)H dependent and consist 
usually of a P450, a ferredoxin and a ferredoxin reductase (Figure 1.5B). The 
genes for the bacterial P450 system are encoded on the chromosome or on 
plasmids, however, some bacteria such as E. coli have no P450. 
There is one example, where the reductase is not required for the P450 reaction: 
androstenedione (4-androstene-3-17-dione) is hydroxylated in vitro by a P450 
from rat liver in presence of NADPH and sodium periodate (NaIO4)
108
. Another 
exception is the soluble P450nor (nitric oxide reductase, CYP55A1) from 
Fusarium oxysporum, which uses electrons directly from the cofactor NADH for 
the reduction of nitric oxide (NO) to nitrous oxide (N2O).
109
 Homologous of 
P450nor have been found in Cylindrocarpon tonkinense
110
, Trichosporom 
cutaneum
111,112
 and Histoplasma capsulatum
113
 possibly as a result of horizontal 
gene transfer
114
. 
1.2.6 Cytochrome P450 Fusion Systems 
As the P450 reaction is typically dependent on the presence of single electrons 
derived from P450 reductases, co-expression is necessary to obtain effective P450 
activity in recombinant systems.
115-118 
In Nature, the difficulty associated with 
using two separate enzymes is avoided by producing fusion P450-reductase 
enzymes, where usually the C-terminus of the P450 is fused to the N-terminus of 
the reductase. This phenomenon has only been found naturally to occur in bacteria 
and fungi so far. 
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The first self sufficient P450, where no additional enzymes are necessary, was the 
P450 BM3 (CYP102A1) from B. megaterium reported in 1986.
119
 The P450 (C-
terminal) region of P450 BM3 is fused naturally into a single polypeptide chain to 
the cytochrome P450 reductase containing a FAD and a FMN. It has shown one 
of the highest turnover rates of all P450s, with about 17000 min
-1
 (when 
arachidonic acid is oxygenated
120
), thus it is an extremely effective biocatalyst and 
this improved efficiency is one possible evolutionary reason for the fusion of 
P450 and reductase.
119-122
 A second advantage may be that the regulation of a 
P450 fusion system is easier than regulating expression of the proteins 
separately.
123
 However, the electron transfer between the three fusion domains of 
P450 BM3 has been shown to be mostly intermolecular by forming a dimer.
124,125
 
 
Several homologues of P450 BM3 from different bacteria have been identified by 
sequencing, such as CYP102A2 and CYP102A3 from Bacillus subtilis
126
, and the 
fusion proteins have been cloned and recombinantly expressedin a active form in 
E. coli.
127-129
  
The P450 BM3 belongs to the P450-diflavin reductase (CPR) fusion systems 
(Figure 1.11A) and showed significant homology to mammalian P450s and 
mammalian P450 reductases.
130
 This fusion type was imitated for the 
development of the first artificial fusion in 1987 containing the rat CYP1A1 and 
an NADPH cytochrome P450 reductase (from rat liver) expressed in 
Saccharomyces cerevisiae.
116
  
Further examples of natural fusion P450s type P450 BM3 are the fungal fatty acid 
hydroxylase P450foxy (CYP505) from Fusarium oxysporum and the Fum6p from 
Fusarium verticillioides (NCBI: Gibberella moniliformis).
131-133
  
Fungi have usually various P450s and one or multiple separate corresponding 
reductase. Additionally, putative fungal P450-CPR fusions have been found in all 
filamentous ascomycetes except Coccioides immitis by analysing fungal 
genomes.
134
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Figure 1.11: Schematic arrangement of natural P450-reductase fusion systems
 
A P450 BM3, a P450-diflavin reductase (CPR) fusion; B P450-RhF, a P450-phthalate 
dioxygenase reductase-like fusion; C MCCYP51FX, a P450-ferredoxin (Fdx) fusion with 
separate ferredoxin reductase (FdR) and D XplA/B, a P450-flavodoxin (Fldx) fusion with 
separate flavodoxin reductase XplB. Fusions are respresented by overlapping spheres. 
 
Through PCR-based screens another type of prokaryotic P450 fusion was found, 
where the P450 N-terminus was fused to a Phthalate Family Oxygenase 
Reductase (PFOR) containing an FMN and an iron-sulphur (2Fe-2S). One 
example belonging to this fusion type is the P450-RhF (CYP116B2) from 
Rhodococcus sp. (Figure 1.11B).
135
 The native substrate of this P450 fusion is not 
known, however it can catalyse the O-dealkylation of 7-ethoxycoumarin 
(Figure 1.12).
136,137
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Figure 1.12: O-dealkylation of 7-ethoxycoumarin to 7-hydroxycoumarin by P450-
RhF 
 
The fusion type MCCYP51FX (CYP51) from Methylococcus capsulatus with 
14α-demethylase activity against lanasterol is fused with its C-terminus to a 
ferredoxin domain (Figure 1.11C).
138,139
  
Another class of P450 fusion identified first in the Rhodococcus rhodochrous 
strain 11Y contains the P450 XplA heme C-terminally fused to a flavodoxin 
domain and its separate flavodoxin reductase XplB (Figure 1.11D). XplA 
catalyses the first step in the degradation of the toxic explosive hexa-hydro-1,2,5-
trinitro-1,3,5-triazine (RDX).
140,141
  
Bacteria are often used as host for the expression of P450 fusion proteins. For 
example, two mammalian cytochrome P450s (bovine adrenal P450 A17 and 
CYP4A1 from rat liver) separately fused to the flavoprotein domain of the rat 
NADPH cytochrome P450 reductase have been expressed in active forms in 
E. coli.
142,143
 This technique of producing artificial fusions was used in the same 
field of animal steroid hydrolases to study the human CYP93A4.
144
  
The FMN/Fe2S2 reductase (RhF) from Rhodococcus sp. strain NCIMB 9784
135,136
, 
which is naturally fused to the CYP116B1, was expressed in E. coli Rosetta 2 
(DE3) and was used to generate fusions with prokaryotic P450s such as 
P450 PikC (CYP107L1, involved in the last step of pikromycin biosynthesis) 
from Streptomyces venezuelae
145
, P450-cam (camphor-5-monooxygenase, 
CYP101) from Pseudomonas putida, XplA (CYP177A1) from Rhodococcus 
rhodochrous Y11, which degrades RDX; Noc4 and Noc10, two P450s from 
Nocardia farcinica, which can dealkylate 7-ethoxycoumarin and hydroxylate 
testosterone, respectively.
146
 The electron transfer between the different domains 
has been shown to be predominantly intramolecular for the artificial reductase-
putidaredoxin-cytochrome P450cam triple fusion
 
and the fusions P450cam-RhF-
Red and XplAP450-RhF-Red.
146,147
 
  
O OOCH3 O OOH
7-ethoxycoumarin                                        7-hydroxycoumarin
P450-RhF
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1.3 Applications of Cytochromes P450 in biocatalysis 
In the last few years, research in cytochromes P450 has expanded to include 
engineering of the biocatalysts for various applications. This has been reviewed in 
recent papers (Gillam 2008
148
, Hlavica 2009
149
, Grogan 2011
150, O’Reilly et al. 
2011
151
). For example, the self-sufficient P450 BM3 was modified at its substrate 
access channel with site-directed mutagenesis to increase the activity up to 40 fold 
towards the polycyclic aromatic hydrocarbons phenanthrene, fluoranthrene and 
pyrene.
152
  
1.3.1 Hydroxylation 
The regio- and stereoselective oxidative activation of a C-H bond is a challenging 
problem for synthetic organic chemistry.
153-155
 Enzymes, especially P450s, are an 
environmental friendly solution for hydroxylations with high selectivity. 
P450-catalysed hydroxylation occurs by an activation of a C-H bond followed by 
the insertion of an oxygen atom and finally the formation of the corresponding 
alcohol. The first solubly expressed P450 derived from Rhizobium with azo-
reductase activity was published in 1967.
156
 One year later, another solubly 
expressed P450, the methylene hydroxylase (P450cam) converting camphor to 5-
exo-hydroxycamphor from Pseudomonas putida was reported (Figure 1.13).
157
 
Another organism, Rhodococcus sp. NCIMB 9784, is also able to use camphor as 
only carbon source. The P450 responsible for this metabolic activity is called 
P450camr, hydroxylating camphor to 6-endo-hydroxycamphor.
158
  
 
 
Figure 1.13: Hydroxylation of camphor by P450cam (Pseudomonas putida) to 5-exo-
hydroxycamphor or P450camr (Rhodococcus sp.) to 6-endo-hydroxycamphor 
 
Generally, bacteria use P450 hydroxylations as the first steps of the 
biodegradation of carbon sources, for example the degradation of cineole by 
P450cam P450camr
5-exo-hydroxycamphor                                        camphor                                             6-endo-hydroxycamphor
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Citrobacter braakii
159
, or for the biosynthesis of secondary metabolites, such as 
antiobiotic or neurotoxine by Streptomyces sp.
160-162
. Another prokaryotic P450, 
the CYP153A6 from Mycobacterium sp. HXN-1500 hydroxylates alkanes with a 
chain-length between C6 and C11 to primary alkanols with a large regiospecificity 
of over 95%.
163 
The alkane hydroxylase of the CYP153 family from Mycobacterium sp. catalyses 
the conversion of limonene to perillyl alcohol, an anticancer drug. The 
hydroxylase can be recombinantly expressed in Pseudomonas putida in large 
bioreactors to produce sufficient enzyme for pharmaceutical applications.
164
  
One of the first discovered P450 with hydroxylation activity was the human 
CYP21A2, which converts progesterone to deoxycorticosterone (Figure 1.14).
14
  
 
 
Figure 1.14: Hydroxylation of progesterone to deoxycorticosterone by CYP21A2 
 
Other human P450s have been shown to be involved in steroid metabolism such 
as CYP2A19, which hydroxylates progesterone to 21-hydroxyprogesterone as the 
main product forming 16α- and 17α-hydroxyprogesterone as minor products. 
Furthermore, it was shown that CYP2A19 converted testosterone to 
androstenedione with low amounts of 2ß -, 6ß- and 16ß-hydroxy testosterones.
165
  
In the plant Arabidopsis thaliana, different cytochromes catalyse hydroxylations 
involved in different biosyntheses. One of the first P450s examined was the 
Arabidopsis cinnamic acid 4-hydroxylase (CYP73A5), which is involved with the 
3’-hydroxylase (CYP98A3) and the 5-hydroxylase (CYP84A1) in the 
phenylpropanoid pathway and the biosynthesis of lignin
166-168
. 
The metabolism of brassinolide involves a 22α-hydroxylase CYP90B1 called 
DWF4 catalysing the conversion of 6-oxo-campestanol to cathasterone
169,170
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(Figure 1.15) and the 23α-hydroxylase CYP90A1 called cpd for 6-oxo-
cathasterone
171,172
. On the other hand, P450s, for example the 26-hydroxylase 
CYP72B1, also take part in the degradation of brassinolide
173
. 
 
 
Figure 1.15: Hydroxylation of 6-oxo-campestanol to cathasterone by Arabidopsis 
CYP90B1 
 
1.3.2 Oxidation 
P450s are monooxygenases and oxidise the substrate following the equation:  
RH + O2 + 2H
+
 + 2e
–
 → ROH + H2O 
Oxidases, dioxygenases and peroxidases catalyse similar reactions, however 
P450s are special, because they are able to introduce oxygen into double bonds, 
allylic positions and also non-activated C-H bonds.
174
 
 
Another typical P450 catalysed reaction is the oxidation of heteroatoms, for 
example nitrogen in tertiary amines to N-oxides or sulphur in thioethers to 
sulfoxides and sulfones (Figure 1.16).  
 
 
Figure 1.16: P450 dependent heteroatom-oxidations of tertiary amines to N-oxides 
and thioether to sulfoxides or sulfones 
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An enzymatic oxidation of methyl groups on aromatic heterocycles, such as 
pyridines, to the corresponding monocarboxylic acids was investigated by 
fermentation of Pseudomona putida on industrial scale by Lonza AG 
(Figure 1.17).
175
 Pyridine-3-carboxylic acid (niacin) is the water-soluble vitamin 
B3 used in animal feed supplementation and medicine.
176,177
 
 
 
Figure 1.17: P450 catalysed oxidation of 3-methylpyridine to pyridine-3-carboxylic 
acid 
 
P450s catalyse also the epoxidation of double bonds, for example the Arabidopsis 
thaliana (Arabidopsis) CYP77A4 can epoxidise unsaturated C18 fatty acids.178 
Epoxidations result in very reactive versatile epoxide species by transferring the 
P450 ferryl-oxygen to the alkene, which builds a radical intermediate followed by 
the epoxide formation (Figure 1.18). 
 
 
Figure 1.18: P450 catalysed epoxidation of an alkene 
 
Epoxide can easily react with complex macromolecules useful for the synthesis of 
polymers
179
 and pharmaceuticals
83
 for industrial applications. 
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1.4 Plant Cytochromes P450 
1.4.1 Cytochromes P450s in Arabidopsis thaliana 
Arabidopsis is a much used model plant in biology, because of its fast growth 
cycle (48 days until the first silique
180
) and ease of transformation. The whole 
genome is sequenced, and it is known that this plant has over 25000 genes, which 
code proteins from 11000 families.
181
 Arabidopsis has 244 P450 genes and 
28 pseudogenes
182
 and represents a fantastic opportunity for a high number of 
different biocatalysts to be discovered.  
The phylogenetic tree (adapted from Bak et al.2011
182
, Figure 1.19) shows the 
evolutionary relationships between the different P450s in Arabidopsis. 
CHAPTER 1 - INTRODUCTION 
 
38 
 
 
Figure 1.19: Phyllogenetic tree of all cytochromes P450 from Arabidopsis
182
 
 
 
The 67 Arabidopsis P450s with known function are listed in Table 1.1. They are 
mainly involved in secondary metabolism, such as in the biosynthesis of 
hormones, pigments, flavours and for the production of complex macromolecules 
such as cutin, lignin and suberin or for defense compounds. Approximately 20 
P450 contain a rich N-terminal Serine-Threonine sequence indicating a 
chloroplast signal.
38
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Table 1.1: Arabidopsis P450s with known function 
P450 (gene locus) reaction pathway  references 
51G1 (At1g11680) obtusifoliol 14α-
demethylase  
sterols/steroids  183,184 
71A12 
(At2g30750) 
hydroxylation and N-
demethylation of 
pyrazoxyfen 
metabolism of herbicide 
pyrazoxyfen, camalexin 
biosynthesis in roots 
185,186
 
71A13 (At2g307700) dehydration of indole 
acetaldoxime to indole-3-
acetonitrile 
camalexin biosynthesis 187 
71B7 (At1g13110) deethylation of 7-
ethoxycoumarin (with 
cumene hydroperoxide as 
electron donor) 
 188 
71B15 (At3g26830) conversion of s-
dihydrocamalexic acid to 
camalexin  
camalexin  189,190 
73A5 (At2g30490) 4-hydroxylation of t-
cinnamic acid to p-
coumaric acid; 
hydroxylation of cinnamic 
acid analogs 
phenylpropanoid pathway, 
lignin biosynthesis 
166,191,192
 
74A1 (At5g42650) allene oxide synthase for 
linoleic acid 
hydroperoxide and 
linolenic acid 
hydroperoxide 
jasmonate acid biosynthesis 37,45,193-196 
74B2 (At4g15440) hydroperoxide lyase for 
linoleic acid 
hydroperoxide and 
linolenic acid 
hydroperoxide  
oxylipin  pathway, 
jasmonate biosynthesis 
197-199
 
75B1 (At5g07990) 3’-hydroxylation of 
narigenin and 
dihydrokaempferol  
phenylpropanoid pathway, 
flavonoid biosynthesis 
200
 
76C1 (At2g45560) 10-hydroxylation of 
geraniol 
terpenoid indole alkaloid 
biosynthesis 
201
 
77A4 (At5g04660) epoxidation of unsaturated 
C18 fatty acids (oleic, 
linoleic, α-linolenic acid) 
fatty acid metabolism 178 
77A6 (At3g10570) in-chain 10-hydroxylation 
of 16-hydroxypalmitate 
cutin biosynthesis 202 
79A2 (At5g05260) conversion of 
phenylalanine to oxime  
benzylglucosinolate 
biosynthesis 
203
 
79B2 (At4g39950) conversion of tryptophan 
and tryptophan analogs to 
oxime  
 
 
indole glucosinolate 
biosynthesis, camalexin 
biosynthesis, auxin 
biosynthesis 
204-209
 
79B3 (At2g22330) conversion of tryptophan 
and tryptophan analogs to 
oxime  
 
indole glucosinolate 
biosynthesis, camalexin 
biosynthesis, auxin 
biosynthesis 
204-209
 
79F1 (At1g16410) N-hydroxylation of homo- 
to tetrahomo-methionine 
(n =  3 to 6)  
(short-chain methionine 
derivatives to 
their aldoximes)  
biosynthesis of aliphatic 
glucosinolates 
210-213
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P450 (gene locus) reaction pathway  references 
79F2 (At1g16400) N-hydroxylation  of long 
chain penta and 
hexahomomethionine to 
their aldoxime  
biosynthesis of aliphatic 
glucosinolates 
211-213
 
81F2 (At5g57220) 4-hydroxylation of indole-
3-ylmethyl to 4-hydroxy-
indole-3-ylmethyl 
glucosinolate 
indole glucosinolate 
biosynthesis 
214-216
 
81F4 (At4g37410) putative P450 possibly involved in the 
indole glucosinolate 
biosynthesis 
217
 
82C2 (At4g31970) 5-hydroxylation of 8-
methoxypsoralen to 5-
hydroxy- 
8-methoxypsoralen 
metabolism of trytophan-
derived secondary 
metabolites, possibley 
involved in jasmonic acid 
induced indole 
glucosinolates 
218,219
 
82C4 (At4g31940) 5-hydroxylation of 8-
methoxypsoralen to 5-
hydroxy- 
8-methoxypsoralen 
Fe deficiency response, 
possibly through an IDE1-
like mediated pathway 
218,220
 
82G1 (At3g25180) (E,E)-geranyllinalool and 
the sesquiterpenoid (E)-
nerolidol into the acyclic 
volatile C16-homoterpene 
4,8, 12-trimethylthdeca-
1,3,7, 11-tetraene (TMTT) 
and the C11-homoterpene 
4,8-dimethyl-1,3,7-
nonathene (DMNT), 
respectively 
 221 
83A1 (At4g13770) oxidation of methionine-
derived oximes  
oxidation of p-
hydroxyphenyl-
acetaldoxime, indole-3-
acetaldoxime, 
conversion of aldoximes to 
thiohydroximates 
biosynthesis of aliphatic 
glucosinolate  
222-224
 
83B1 (At4g31500) oxidation of indole-3-
acetaldoxime  
biosynthesis of  indole 
glucosinolate  
222,223,225
 
84A1 (At4g36220) 5-hydroxylation of 
coniferaldehyde, coniferyl 
alcohol and ferulic acid  
phenylpropanoid pathway, 
biosynthesis of lignin 
 
 
167,226,227
 
84A4 (At5g04330) putative ferulate-5-
hydroxylase 
 228,229 
85A1 (At5g38970) C6-oxidase for 6-
deoxycastasterone to 
castasterone, other steroids  
conversion of castasterone 
to brassinolide 
biosynthesis of brassinolide  
 
230-234
 
85A2 (At3g30180) C6-oxidase for 6-
deoxycastasterone to 
castasterone, other steroids  
conversion of castasterone 
to brassinolide  
biosynthesis of brassinolide  
 
230-233,235,236
 
86A1 (At5g58860) ω-hydroxylation of 
saturated and unsaturated 
fatty acid metabolism, 
biosynthesis of cutin, 
237-240
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P450 (gene locus) reaction pathway  references 
C12 to C20 fatty acids  biosynthesis of suberin 
86A2 (At4g00360) ω-hydroxylation of 
saturated and unsaturated 
C12 to C18 fatty acids 
fatty acid metabolism, 
biosynthesis of cutin 
 
238,241,242
 
86A4 (At1g01600) ω-hydroxylation of 
saturated and unsaturated 
C12 to C18 fatty acids 
fatty acid metabolism, 
biosynthesis of cutin 
 
202,238,242,243
 
86A7 (At1g63710) ω-hydroxylation of lauric 
acid  
fatty acid metabolism, 
biosynthesis of cutin 
 
238,242
 
86A8 (At2g45970) ω-hydroxylation of 
saturated and unsaturated 
C12 to C18 fatty acids 
fatty acid metabolism, 
biosynthesis of cutin 
 
238,242,244
 
86B1 (At5g23190) ω-hydroxylation for long 
chain fatty acid (C22 and 
C24) 
biosynthesis of suberin,  
fatty acid metabolism, 
polyester monomer 
biosynthesis 
38,245
 
86C3 (At1g13140) hydroxylation of fatty 
acids (C12, C14, C14:1, 
C16) 
fatty acid metabolism  246 
88A3 (At1g05160) oxidation of ent-kaurenoic 
acid to gibberillin A12 in 
three steps 
biosynthesis of gibberellins  39,247 
88A4 (At2g32440) oxidation of ent-kaurenoic 
acid to gibberillin A12 in 
three steps 
biosynthesis of gibberellins 39,247 
90A1 (At5g05690) 23α-hydroxylation of 
steroids 
 
biosynthesis of brassinolide  
 
171,172,248,249
 
90B1 (At3g50660) 22α-hydroxylation of C27, 
C28, C29 sterols 
biosynthesis of brassinolide  
 
169,249-251
 
90C1 (At4g36380) C23-hydroxylation of 
sterols (typhasterol to 
castasterone) 
biosynthesis of brassinolide  
 
252-255
 
90D1 (At3g13730) C23-hydroxylation of 
sterols 
biosynthesis of brassinolide  253-255 
94B3 (At3g48520) 12-hydroxylation of 
jasmonoyl-L-isoleucine  
oxidative catabolism of 
jasmonate, jasmonate 
mediated signaling pathway 
256,257
 
94C1 (At2g27690) ω-hydroxylation of 
saturated and unsaturated 
C12 to C18 fatty acids and 
hydroxylation of ω-
hydroxy fatty acid into  
dicarboxylic fatty acid 
fatty acid metabolism 240,258 
96A15 (At1g57750) hydroxylation of midchain 
alkane to alcohols and 
second hydroxylation to 
ketone 
biosynthesis of wax 259 
97A3 (At1g31800) ß-hydroxylation of 
carotene 
carotenoid metabolism 260,261 
97B3 (At4g15110) ß-hydroxylation of ß-
carotene to zeaxanthin via 
ß-cryptoxanthin 
carotenoid metabolism 262 
97C1 (At3g53130) ε-hydroxylation of ß,ε-
carotene 
carotenoid metabolism  260,263 
98A3 (At2g40890) 3-hydroxylation of p-
coumarate to caffeic acid 
phenylpropanoid pathway, 
biosynthesis of lignin 
168,264-267
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P450 (gene locus) reaction pathway  references 
and 3-hydroxylation of 
coumaroyl-esters 
(shikimate and quinate 
esters) 
monomers and soluble 
phenolics 
98A8 (At1g74540) meta-hydroxylation of the 
three triferuloylspermidine 
phenolic rings, 
oxygenation of resveratrol 
alternative phenolic 
pathway, pollen 
development 
268,269
 
98A9 (At1g74550) meta-hydroxylation of the 
three triferuloylspermidine 
phenolic rings, 
oxygenation of resveratrol 
alternative phenolic 
pathway, pollen 
development 
268,269
 
701A3 (At5g25900) oxidation of ent-kaurene to 
ent-kaurenoic acid in three 
steps 
biosynthesis of gibberellin 39,270-273 
703A2 (At1g01280) in-chain 
monohydroxylation of 
saturated fatty acids (C10-
C16) 
biosynthesis of 
sporopollenin, pollen 
development 
274
 
704B1 (At1g69500) ω-hydroxylation of 
saturated, unsaturated and 
epoxy C16 and C18 fatty 
acids 
biosynthesis of 
sporopollenin, pollen 
development 
275,276
 
705A5 (At5g47990) conversion of thaliandiol 
to desaturated thaliandiol 
thalianol metabolic pathway 277 
707A1 (At4g19230) 8-hydroxylation of abscisic 
acid 
abscisic acid catabolism 278-280 
707A2 (At2g29090) 8-hydroxylation of abscisic 
acid 
abscisic acid catabolism 278-281 
707A3 (At5g45340) 8-hydroxylation of abscisic 
acid 
abscisic acid catabolism 278,279,281-286 
707A4 (At3g19270) 8-hydroxylation of abscisic 
acid 
abscisic acid catabolism 278,279 
708A2 (At5g48000) hydroxylation of thalianol 
to thaliandiol 
thalianol metabolic pathway 277 
710A1 (At2g34500) C22-desaturation of ß-
sitosterol to stigmasterol 
biosynthesis of sterols 287-289 
710A2 (At2g34490) C22-desaturation of ß-
sitosterol and 24-epi-
campesterol to 
stigmasterol 
andbrassicasterol 
biosynthesis of sterols 287 
710A4 (At2g28860) C22-desaturation of ß-
sitosterol to stigmasterol 
biosynthesis of sterols 288 
714A1 (At5g24910) C13-hydroxylation of ent-
kaurenoic acid to steviol 
gibberillin catabolism 277,290 
724A1 (At5g14400) 22α-hydroxylation of 
brassinosteroid 
biosynthesis of brassinolide  
 
291
 
734A1 (At2g26710) 
initially classified as 
CYP72B 
C26-hydroxylation  of 
brassinolide and 
castasterone 
brassinolide catabolism 173,292,293 
735A1 (At5g38450) trans-hydroxylation 
ofisopentenyladenine, 
tri/di/monophosphates 
biosynthesis of zeatin, 
cytokinin metabolism 
294
 
735A2 (At1g67110) trans-hydroxylation 
ofisopentenyladenine, 
tri/di/monophosphates 
biosynthesis of zeatin, 
cytokinin metabolism 
294
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The CYP51 is the most conserved P450 family across all kingdoms and counts as 
an eukaryotic P450 of prokaryotic origin.
295
 CYP51 is involved in the 
biosynthesis of sterols, e. g. cholesterol in animals
296
, obtusifoliol in plants
183,184
 
and ergosterol
 
in fungi
297
 by catalysing 14α-demethylation (Figure 1.20). 
In plants, the methyl group of carbon number 14 is hydroxylated to 14α-
carboxyalcohol and then converted to 14α-carboxyaldehyde. In the last step a 
double bond is introduced by an oxidative deformylation with separation of 
formic acid.
298
 
 
 
Figure 1.20: 14α-demethylation of obtusifoliol by plant CYP51 
 
75% of the Arabidopsis P450s are still with unknown function, which shows that 
there is a greater research potential for finding new metabolic pathways and 
reactions in plants. 
1.4.2 Fusions of plant Cytochromes P450 
In Nature there exists no native plant P450 fusion so far. There are now a few 
examples where plant P450s (C-terminus) fused to plant P450 reductase have 
been expressed as active enzymes in E. coli (Table 1.2). The first artificial plant 
fusion contained the cinnamate-4-hydroxylase (CYP73A4) and the P450 
reductase (both enzymes from C. roseus, Madagascar periwinkle) and was 
engineered by Prof. Schröder’s research group in 1995.299 They found activity in 
the insoluble protein fraction after expression in E. coli. A few years later, they 
determined that a fusion of a P450 and the reductase from two different plants 
(Petunia hybrida CYP75 fused to C. roseus reductases) resulted in 50% lower 
specific activity than when the two enzymes are both from C. roseus.
300
 Moreover, 
they demonstrated that their strategy is an alternative technique for expression of 
CH3
CH3
CH3
CH3
CH3
CH3
CH3
CH2
CH3
CH3
CH3
CH3
CH3
CH3
CH3
CH2
CH3
obtusifoliol
plant CYP51
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functional plant P450s and engineered another two fusions of CYP71D12
 
(tabersonine-16-hydroxylase from C. roseus) and CYP72A1 (secologanin 
synthase from C. roseus) fused to the reductase of C. roseus.
301,302
 Tabersonine-
16-hydroxylase catalyses the first reaction in the pathway of vinblastine and 
vincristine, both bisindoles that are important for the pharmaceutical industry 
where they are used as treatments for leukaemia.
301,303
 Secologanin synthase 
converts loganin to secologanin, which is a precursor of terpenoid indole alkaloids 
in various plants important for development of drugs in cancer treatment.
302,304
 
  
Another artificial plant fusion made of CYP71B1 from Thlaspi arvensae (field 
penny cress) and the C. roseus reductases was found to be active for the 
conversion of benzo(a)pyrene to 3-hydroxybenzo(a)pyrene in the membrane 
fraction after expression in E. coli.
305
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More recent publications have specially focused on fusions containing the 
isoflavone synthase I (IFS) from Glycine max (soy bean) and isoflavone synthase 
from red clover.
306,307
 The artificial plant fusion system IFS-CPR (reductase CPR 
from C. roseus) was created by Koffas’s research group by imitating the powerful 
natural fusion P450 BM3 from B. megaterium.
306
 The IFS converts naringenin 
and liquiritigenin to genistein and daidzein, respectively (Figure 1.21). 
 
 
Figure 1.21: Conversion of the flavanones liquiritigenin and naringenin to the 
isoflavones daidzein and genistein, respectively, by the P450 isoflavone synthase I 
 
The reaction mechanism catalysed by IFS starts with an oxidation in the presence 
of NADPH+H
+
 and molecular oxygen to a radical (1, Figure 1.22), followed by an 
aryl ring migration (2) and forming a 2,7,4’-trihydroxyisoflavanone (3). The last 
step is a dehydration (4), which yields genistein and is not performed by the P450. 
It is possible that a specific dehydratase is involved or that the water molecule is 
eliminated spontaneously.
308-310
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Figure 1.22: Reaction mechanism of the conversion of naringenin to genistein by the 
P450 isoflavone synthase I 
 
Another artificial plant IFS-fusion for expression in E. coli BL21 (DE3) was 
developed by Kim et al. 2009
307
. Therefore, the IFS from red clover was fused to 
the rice reductase (rcIFS-riceCPR), deleting the membrane anchors of rcIFS (63 
nucleotides) and riceCPR (49 nucleotides), and activity has been demonstrated in 
a growing cell assay.
307
  
Isoflavones belong to the group of isoflavonoids and are predominantly produced 
as secondary metabolites in legumes.
311
 Isoflavones have a broad bioactivity 
spectrum: inhibition of tyrosine kinases and enzymes in steroid biosynthesis, 
antioxidant activity, prevention of carcinogenesis and inhibition of metastasis. In 
Asia, where soy bean (rich of isoflavones) is eaten much more than in western 
countries, a reduced frequency of heart diseases, osteoporosis, menopausal 
symptoms, breast and prostate cancer was recorded.
312-317  
 
1.5 Recombinant Expression Systems 
There are a number of different expression systems available. The two least 
expensive and most commonly used systems are the bacterium E. coli (which has 
no endogenous P450 or P450 reductase genes) and the yeast Saccharomyces 
cerevisiae (containing three P450 and one associated NAD(P)H P450 reductase 
gene).
28,318
 Furthermore, insect cells, another heterologous eukaryotic expression 
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system, are often used for the expression of plant P450s together with the insect 
NADPH P450 reductase.
319
 Duan and Schuler (2006)
319
 give a useful summary of 
the expression of Arabidopsis P450s in different hosts. 
1.5.1 Expression of P450s in Escherichia coli 
The great advantage of bacterial expression over yeast or insect cells is the 
relatively fast growth rates, inexpensive cost and ease of cultivation. However, 
expression of unmodified plant P450s in E. coli can be complicated due to 
differences in codon preference and because eukaryotic P450s are mostly 
membrane bound and bacteria do not have such a developed membrane system. 
Expression of plant P450s in E. coli is therefore challenging and it is often 
difficult to obtain soluble protein.
320,321
 If the P450 is only anchored in the 
membrane, with the majority of the enzyme, including the catalytic centre in the 
cytosol, then removal of the hydrophobic membrane bound part may result in 
soluble enzyme. Studies on mammalian P450s have shown activity towards their 
specific substrates after the deletion of around 2-20 of the hydrophobic residues 
from the N-terminus.
57,59,322
 Additionally, the microsomal human P450 2C3 could 
be expressed solubly after the modification of the N-terminal hydrophobic 
membrane bound segment.
58
  
Many plant P450s have been expressed in E. coli, none of them soluble, for 
biochemistry studies. The two Arabidopsis CYP79F1 and CYP79F2, both 
involved in the biosynthesis of aliphatic glucosinolates have been characterised 
after recombinant expression in E. coli.
210,212
  
Artificial P450 fusion proteins have been expressed also in E. coli (more 
information in Chapter 1.4.2, page 43).
 
1.5.2 Expression in Yeast 
The yeast Saccharomyces cerevisiae contains an endogenous reductase capable of 
efficient electron transfer to P450s
323
 and was the first host where 
mammalian
324,325
 and plant
326
 P450s were successful expressed. S. cerevisiae 
contains three P450s and has therefore also its own reductases. Additionally, yeast 
supports posttranslational machinery (e. g. glycosylation, membrane association, 
correct protein folding) for the expression of active eukaryotic P450s. 
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More than twenty years ago it was found that the P450 activity is limited by the 
quantity and availability of the P450 reductase. For example CYP71A1 from 
avocado, CYP73A1 from artichoke and CYP73A3 from alfalfa have been 
expressed successfully in S. cerevisiae, however activity was reduced.
326-328
 
Possible reasons for this could be that the yeast reductase is inadequate for the 
amount of expressed P450, and that the electron transfer is not optimal between 
yeast reductase and plant P450.
329
 Thus the activity was increased when the 
partnering plant reductase was expressed simultaneously.
325,330,331 
The group of Ohkawa reported the successful expression of different mammalian 
membrane bound P450 together with the corresponding reductase in yeast.
332-336
 
For example, the 17α-hydroxylase (P450c17) was ten times more active than the 
wild-type when the native P450c17 was fused to the 23 amino acid truncated yeast 
reductase.
333
  
Plant P450 co-expression systems with its corresponding NADPH P450 reductase 
in yeast have been generated. Examples of co-expression include the CYP98A14 
from Coleus blumei, which catalyses the 3-hydroxylation of 4-coumaroyl-3’,4’-
dihydroxyphenyllactate and the 3’-hydroxylation of caffeoyl-4’-hydroxyl-phenyl 
lactate by forming rosmarinic acid.
337
  
One of the first vectors used for expression of plant P450s in yeast was the shuttle 
vector pYeDP60 (Figure 2.3) which has a high copy number when expressed in 
E. coli. This vector, which contains the galactose-inducible GAL10-CYC1 
promoter is coupled with the yeast P450 reductase and is still used due to its high 
stability in rich medium at high cell density.
326,338  
To overcome coupling problems between the plant P450 and the yeast reductase, 
special yeast strains WAT11 and WAT21, which express the Arabidopsis 
NADPH P450 reductase ATR1 and ATR2, respectively, were constructed.
338
 
Over twenty Arabidopsis P450s (CYP71B15, 71A1, 72B1, 73A5, 77A4, 77A6, 
82C2, 82C4, 82F1, 82G1, 83A1, 83B1, 84A1, 85A1-2, 86A2, 86A8, 88A4, 94B1-
3, 94C1, 86A1-4, 97B3, 98A3, 703A2, 704A2, 704B1, 707A1-4, 709C1, 711A1 
and 734A1) have been successfully expressed using the pYeDP60 vector and the 
WAT11 strain.
167,168,178,190,192,202,212,218,221,222,225,230,231,235,236,244,247,256,274,275,279,292,339-
341
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The alternate Pichia pastoris system can also be used to overcome the expression 
problems describe above for plant P450s in E. coli.
342
 The Arabidopsis CYP85A2 
– which converts teasterone and also typhasterol to 7-oxa-teasterone and 7-
oxatyphasterol, respectively – and ATR1 have been expressed simultaneously in 
Pichia pastoris and activity was found.
343
  
 
1.6 Aim of the project 
The plant cytochrome P450 superfamily is a very attractive target for industrial 
applications, due to the high number of different reactions which they are able to 
catalyse. Cytochromes P450 work most efficiently when combined with their 
endogenous cytochrome P450 reductases as electron donor. The development of a 
fusion protein containing plant P450s and appropriate reductase to produce robust 
and efficient biocatalysts would be of relevance to industry. 
The aim of this project is to develop a platform technology by cloning plant P450s 
for recombinant expression, for physiological characterisation studies and 
industrial application. Different expression systems were tested to get functional 
enzymes. The simplest expression system used was E. coli; however, as plant 
P450s are membrane bound, functional expression is more likely to occur in 
eukaryotic expression systems. Therefore, the yeast S. cerevisiae was also tested 
as host. 
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2 Materials and Methods 
2.1 Reagents and consumables 
The reagents and consumables used in this study were purchased from 
AccuStandard (New Haven, US), Bio-Rad Laboratories Ltd. (Hemel Hempstead, 
UK), Bruker Ldt. (Coventry, UK), Carl Zeiss Ltd. (Rugby, UK), Daicel Chemical 
Industries Ldt. (Tokyo, Japan), Difco (BD, Oxford, UK), Expedeon Ltd. (Harston, 
UK), Fisher Scientific UK Ltd. (Loughborough, UK), Finnzymes (Vantaa, 
Finland), Formedium (Norfolk, UK), Invitrogen Ltd. (Paisley, UK), Kartell spa 
(Noviglio, Italy), Levington F2 compost (Scotts, Bamford, Ipswich, UK), Matrix 
Science Ldt. (London, UK), Melford Laboratories Ltd. (Ipswich, Suffolk UK), 
Merck Chemicals Ltd. (Nottingham, UK), Millipore (Tullagreen, Ireland), New 
England Biolabs (Ipswich, UK), Oxoid Ltd. (Basingstoke, UK), Promega UK Ltd. 
(Southampton, UK), Qiagen Ltd. (West Sussex, UK), Sarstedt Ltd. (Leicester, 
UK), Sartoriues AG (Göttingen, Germany), Scientific Laboratory Supplies Ltd. 
(Nottingham, UK), SelectScience Ltd. (Bath, UK), Sigma-Aldrich Company Ltd. 
(Dorset, UK), Starlab Ltd. (Milton Keynes, UK), Sterilin Ldt. (Newport, UK), 
Thermo Fisher Scientific p/a Perbio Science UK, Ltd. (Cramlington, UK), UVItec 
Ltd. (Cambridge, UK) and VWR International Ldt. (Lutterworth, UK).   
TNT was donated by the Defence Science and Technology Laboratory (Dstl; Fort 
Halsted, UK), dinitrotoluenes (Sigma-Aldrich), aminodinitrotoluenes by Supelco 
(Sigma-Aldrich) and hydroxyaminodinitrotoluenes by AccuStandard. 
DNA Polymerases and restriction enzymes were bought from New England 
Biolabs and Finnzymes.  
PCR Primers were synthesised by Sigma-Aldrich and genes by GeneArt 
(Regenburg, Germany). 
The construct of the artificial fusion construct IFS-CPR (IFS = isoflavone 
synthase 1 from Glycine max fused to the P450 reductase from Catharanthus 
roseus) was kindly provided by Prof. Mattheos Koffas (State University of New 
York, Buffalo, USA) and the nicotine-N-demethylase (CYP82E4) from Nicotiana 
tabacum from Prof. Ralph Dewey (Department of Crop Science, North Carolina 
State University, Raleigh, USA). 
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The water used to produce buffers and solutions was molecular biology grade 
water purified using an Elga Purelab Ultra water polisher (Elga Labwater, High 
Wycombe, UK). 
 
2.2 Media, strains and plasmids 
2.2.1 Bacterial media  
Escherichia coli was grown in Lysogeny broth (LB), Terrific broth (TB), auto-
induction and M9 minimal media. Super Optimal broth with Catabolite repression 
(SOC) was used for recovering E. coli cells after plasmid DNA transformation. 
LB contained 10 g/l tryptone (Formedium), 10 g/l sodium chloride (NaCl) (Fisher 
Scientific) and 5 g/l yeast extract (Formedium). For the preparation of the solid 
agar plates, 15 g/l agar (Formedium) was added to LB prior autoclaving and then 
poured into petri dishes (Sterilin). 
TB contained 12 g tryptone (Oxoid), 24 g yeast extract (Oxoid), 4 ml Glycerol 
(Fisher Scientific) and water to a final volume of 900 ml and sterilised. Before 
use, 100 ml of sterile 10x TB salt (170 mM KH2PO4 and 720 mM K2HPO4, Fisher 
Scientific) were added. 
Auto-induction medium
344
 (1 l) was made of 950 ml ZY solution (10 g tryptone, 
5 g yeast extract and water until a final volume of 950 ml), 25 ml 50x M-solution 
(0.25 M sodium sulphate (Fisher Scientific), 2.5 M ammonium chloride (Fisher 
Scientific), 1.25 M monopotassium phosphate (Fisher Scientific), 1.25 M 
disodium phosphate (Fisher Scientific)), 10 ml 50x 5052 solution (25% glycerol 
(Fisher Scientific), 0.14 M glucose (Sigma-Aldrich), 0.3 M α-Lactose (Sigma-
Aldrich)), 1 ml 1 M MgSO4 and 1 ml 1000x trace metal solution.  
100 ml 1000x trace metal solution contained 0.25 M iron(III)chloride hexahydrate 
(Fisons) (in 0.1 M HCl), 20 mM calcium chloride (Fisher Scientific), 10 mM 
manganese(II)chloride tetrahydrate (Sigma-Aldrich), 10 mM zinc(II)sulphate 
(Fisher Scientific), 2 mM cobalt(II)chloride hexahydrate (Sigma-Aldrich), 2 mM 
copper(II)chloride dehydrate (Sigma-Aldrich), 2 mM nickel(II)chloride 
hexahydrate (Sigma-Aldrich), 2 mM sodium molybdate pentahydrate (Sigma-
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Aldrich), 2 mM sodium selenite pentahydrate (Fluka, Sigma-Aldrich) and 2 mM 
boric acid (Fisher Scientific). 
Five times M9 was made of 33.9 g/l Na2HPO4 (Fisher Scientific), 15 g/l KH2PO4, 
2.5 g/l NaCl (Fisher Scientific), 5 g/l NH4Cl (Fisher Scientific) and sterilised by 
autoclaving before use. For 1x M9 media was used 200 ml/l 5x M9, 800 ml/l 
water, 10 ml/l 1 M glucose (sterile filtrated, Fisher Scientific), 2 ml/l 1 M MgSO4 
(Fisher Scientific, sterile filtrated in Millex-MP filter unit, 0.22 μm from 
Millipore) and 100 μl 1 M CaCl2 (sterile filtrated, Fisher Scientific). 
SOC, used for transformation reactions, contained 5 g yeast extract (Formedium), 
0.5 g NaCl (Fisher Scientific), 20 g tryptone (Formedium) and 950 ml water. 
After autoclaving, sterile filtrated glucose was added to a final concentration of 
20 mM. 
2.2.2 Bacterial strains  
Different E. coli strains (Table 2.1) stored in 20% glycerol (Fisher Scientific) at    
-80 ºC or after fresh transformation were streaked onto LB agar plates containing 
the appropriate antibiotics as necessary. Plates were incubated over night at 37 ºC. 
One colony was used to inoculate a 10 ml starter culture, which was grown 
shaking at 250 rpm over night at 37 ºC (Incubators used were from Gallenkamp, 
Jencons and Heraeus). Starter cultures were either used for plasmid preparation 
(Chapter 2.5, page 60) or to inoculate growth media for protein expression as 
described in Chapter 2.10.1 (page 67). TOP10, DH5α and NovaBlue were used 
for cloning and Rosetta 2 (DE3) and Rosetta gami 2 (DE3) for protein expression 
(Table 2.1). 
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Table 2.1: List of E. coli strains used for cloning and recombinant expression in this 
project 
Strain name Genotype Manufacturer 
TOP10 
F
–
 mcrA Δ(mrr-hsdRMS mcrBC) Φ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ(ara leu) 7697 galU galK 
rpsL (StrR) endA1 nupG 
Invitrogen 
DH5α 
F
– Φ80lacZΔM15 Δ(lacZYA-argF) U169 recA1 
endA1 hsdR17 (rK–, mK+) phoA supE44 λ– thi-1 
gyrA96 relA1 
Invitrogen 
JM109 
F´ [traD36 proA
+
B
+
 lacI
q
 Δ(lacZ)M15] supE44 endA1 
hsdR17 gyrA96 relA1 thi Δ(lac-proAB) 
Stratagene 
BL21 (DE3) F
–
 ompT hsdSB(rB
-
, mB
-
) gal dcm (DE3) Invitrogen 
NovaBlue (DE3) 
endA1 hsdR17 (rK12
–
 mK12
+
) supE44 thi-1 recA1 
gyrA96 relA1 lac F′[proA+B+ lacIqZΔM15::Tn10] 
(Tet
R
) 
Novagen-Merck 
Rosetta 2 (DE3) 
F
-
 ompT hsdSB(rB
-
 mB
-
) gal dcm (DE3) pRARE2 
(Cam
R
) 
The pRARE2 plasmid contains tRNA genes for the 
rare codons AUA (Ile), AGG (Arg), AGA (Arg), CUA 
(Leu), CCC (Pro), CGG (Arg) and GGA (Gly). 
Novagen-Merck 
Rosetta gami 2 
(DE3) 
Δ( ara–leu)7697 ΔlacX74 ΔphoA PvuII phoR 
araD139 ahpC galE galK rpsL(DE3) F’[lac+ lacIq 
pro] gor522::Tn10 trxB pRARE2 (Cam
R
, Str
R
, Tet
R
) 
The pRARE2 plasmid contains tRNA genes for the 
rare codons AUA (Ile), AGG (Arg), AGA (Arg), CUA 
(Leu), CCC (Pro), CGG (Arg) and GGA (Gly). 
Novagen-Merck 
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2.2.3 Plasmids for gene cloning and enzyme expression  
Plasmids for gene cloning and enzyme expression are shown in Table 2.2. 
Table 2.2: Plasmids for gene cloning and enzyme expression 
vector 
antibiotica 
resistence 
features source 
pCR2.1-TOPO Kanamycin 
T-overhang vector for cloning 
PCR products, topoisomerase 
Invitrogen 
pTrcHis2/lacZ Ampicillin 
contained  isoflavone synthase 1 
gene from Glycine max, vector  
pTrcHis2/lacZ originall from 
Invitrogen 
Prof. Koffas
306 
LIC Kanamycin 
pETYSBLIC3C vector, 
cleavable his tagged N-terminus
 
Dr. Gideon 
Grogan
345
 
LicRed Kanamycin 
pETYSBLIC3C vector, 
cleavable his tagged N-
terminus, contains RhF 
reductases from Rhodococcus 
sp. 
Dr. Federico 
Sabbadin
146 
 
lamATR2tr Kanamycin 
pETYSBLIC3C vector, 
cleavable his tagged N-
terminus, contains lamda linker 
and truncated ATR2 reductases 
from Arabidopsis 
this work, 
chapter 5 
licATR2tr Kanamycin 
pETYSBLIC3C vector, 
cleavable his tagged N-
terminus, contains lic linker and 
truncated ATR2 reductases 
from Arabidopsis 
this work, 
chapter 5 
pYeDP60 Ampicillin GAL10-CYC1 promoter 
Prof. Daniele 
Werck-
Reichart
338
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The pTrcHis2/lacZ-vector (Figure 2.1, Invitrogen) containing the fusion IFS-CPR 
was derived from Prof. Mattheos Koffas (State University of New York, Buffalo, 
USA).
306
  
 
 
Figure 2.1: Vector map for pTrcHis2/lacZ 
(pTrc = trc promotor, oLAC = Lac operator, RBS = ribosome binding site, 
ATG = expression start codon, MCS = multible cloning site, myc = myc epitope, His = 6x 
histidines residues, lacZ = ß-galactosidase gene, term = terminator, ampR = ampicillin 
resistence gene, pBR322 ori =  origin of replication of the plasmid pBR322, LacI = 
repressor gene for IPTG induction) 
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The LIC-vector (Figure 2.2), LicRed
146
 and the in this work developed 
lamATR2tr and licATR2tr vector are based on pETYSBLIC3C vector
345
, which 
contains an additional cleavable his tagged N-terminus. 
 
 
 
Figure 2.2: Vector map of LIC-vector  
(pT7 = T7 promotor, oLAC = Lac operator, RBS = ribosome binding site, His = 6x 
histidines residues, which can be cleaved HRV 2C protease site = 3C, tT7 = T7 
terminator, f1 ori  = f1 phage origin of replication, pBR322 ori =  origin of replication of 
the plasmid pBR322, kanR = kanamycin resistence gene, LacI = repressor gene for IPTG 
induction) 
 
CHAPTER 2 – MATERIALS AND METHODS 
 
58 
 
The vector pYeDP60 (vector map Figure 2.3) is a shuttle vector for cloning in 
E. coli and an expression in yeast.
338
 
 
 
 
Figure 2.3: pYeDP60 shuttle vector map with an origin of replication for E. coli and 
yeast  
(tPGK = phosphoglycerate kinase terminator, pGAL = galactose promoter, ADE 2d and 
URA3 = selection marker for adenine and uracil auxotrophy, ampR = ampillin resistence 
gene) 
 
 
2.3 Preparation of chemically competent Escherichia coli cells 
All steps were performed with the appropriate antibiotics for the different E. coli 
strains (Table 2.1) in the growth media. For the preparation of chemically 
competent cells, E. coli strains were streaked on agar plates and incubated 
overnight at 37 °C. A starter culture (10 ml LB inoculated by a single colony from 
plate) was used to inoculate 100 ml LB to an OD600 of 0.1. This culture was 
grown to an OD600 of 0.4-0.5 and then centrifuged in 25 ml batches in 50 ml 
falcon tubes (Sarstedt) at 4000 rpm for 5 min and 4 °C in a CR312 Swinging 
Bucket Rotor Centrifuge (Jouan). The pellets were resuspended in 10 ml of an ice 
cold, sterile 50 mM MgCl2/20 mM CaCl2 solution per tube and incubated on ice 
for 30 min. Cells were then centrifuged at 4000 rpm for 5 min (CR312 Swinging 
Bucket Rotor Centrifuge, Jouan) and the pellet resuspended in 1 ml ice cold, 
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sterile 100 mM CaCl2 (Fisher Scientific). Sterile glycerol (10% v/v Fisher 
Scientific) was added and the cells were incubated on ice for further 30 min. 
Aliquots of 50 μl were snap frozen in liquid nitrogen and stored at -80 ºC until 
use. 
 
2.4 Plant media, growth conditions and strains 
Wild type Arabidopsis thaliana (Columbia 0, NASC Stock acc. No. N50193) was 
used for the isolation of CYP81D8, CYP81D11 and the two Arabidopsis 
reductases ATR1 and ATR2. All steps were carried out under sterile conditions by 
preparing media and handling plant material in the laminar flow cabinet.  
Arabidopsis was grown in half MS (0.215% Murashige and Skoog Basal Salt 
mixture, Sigma-Aldrich) liquid culture containing sucrose (0.68%, Fisher 
Scientific), adjusted to pH 5.7 with KOH (Fisher Scientific) and if required 60 µM 
TNT. To solidify the medium, 0.8% (w/v) agar (Formedium) was added.  
Seeds were sterilised in a fume cupboard as follows: Seeds were transferred to 
1.5 ml micro tubes (Sarstedt) which were placed with open lids into a plastic box. 
The lid of the plastic box was closed immediately after the addition of 3 ml 
concentrated hydrochloric acid to 100 ml Bleach haychlor (Scientific Laboratories 
Supplies) in a glass beaker. After 3 h the lid of the plastic box was opened, the 
micro tubes were closed and then placed into the sterile flow hood with opened 
lids for 10 min to allow evaporation of remaining hydrogen chloride. Seeds were 
then transferred to half MS agar plates and imbibed at 4 C for at least three nights.  
Eight one-day-old seedlings were transferred from agar plates into 100 ml sterile 
glass flasks containing 10 ml half MS. Seeds were grown for a further 13 days 
under light condition of 80 mol·m-2·s-1, 16 h photoperiod at 25 C and 130 rpm.  
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2.5 Plasmid DNA preparation 
For a plasmid preparation, 5 ml cultures of E. coli were grown overnight at 37 ºC, 
200 rpm, in LB containing the appropriate antibiotics. The cultures were harvested 
by centrifugation at 4000 rpm for 10 min (Jouan Model CR 312 Centrifuge, 
Swinging Bucket Rotor, SelectScience). The plasmids were purified using the 
QIAprep Spin Miniprep kit (Qiagen) according to the manufacturer’s instructions.  
 
2.6 Purification of DNA fragments 
The DNA fragments resulting from PCR amplification and restriction digest were 
purified using the Wizard SV Gel and PCR Clean-Up System (Promega), 
according to the manufacturer’s protocol. Where required, DNA fragments were 
separated using agarose gel electrophoresis and excised from the gel before 
purification.       
 
2.7 Detection of the mRNA transcript 
2.7.1 RNA extraction from Escherichia coli 
The RNA was extracted by using the RNeasy Mini Kit from Qiagen for RNA 
isolation following by a reverse transcription PCR reaction.  
For the RNA isolation, E. coli Rosetta 2 (DE3) cells containing the plasmid with 
the gene of interest were grown in 100 ml M9 media (37 °C, 200 rpm) until the 
OD600 reached 0.6-0.8 and then induced by adding 1 mM IPTG, 1 mM δ-
aminolevulinic acid (ALA), 0.5 mM FeCl3 (Fisons), 5 μg/l riboflavin and 
incubated at 20 °C shaking (200 rpm) overnight.  
The RNA was protected by using 2 ml RNAprotect Bacteria Reagent (Qiagen) to 
1 ml culture, vortexed for 5 sec, incubated for 5 min at room temperature and 
centrifuged at 5000x g for 10 min (bench top microlitre centrifuge Sigma 1-15P). 
The supernatant was discarded and 200 μl TE buffer (30 mM Tris-HCl, 1 mM 
EDTA, pH 8.0) containing 0.4 mg proteinase K and 4 mg lysozyme were added to 
the cell pellet, resuspended by pipetting and incubated for 10 min at room 
temperature (vortex at least every two min). Then, 700 μl RTL buffer containing 
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ß-mercaptoethanol (10 μl ß-mercaptoethanol/1 ml RTL) were added, vortexed, 
centrifuged for 5 min at full speed (bench top microlitre centrifuge Sigma 1-15P) 
and the supernatant transferred into a new tube. After adding 500 μl 100% ethanol 
and mixing by inverting, the solution was transferred to a column, spun at 8000x g 
for 15 sec (bench top microlitre centrifuge Sigma 1-15P) and the flow-through 
discarded. The column was washed using 350 μl RW1 buffer and spun 15 sec at 
8000x g. DNA was removed by adding 70 μl RDD buffer containing 10 μl 
DNAse stock (RNase free DNase Set, Qiagen) and incubated for 15 min at room 
temperature. The column was washed twice as described above with 350 μl RW1 
buffer followed by adding 500 μl RW1 buffer to the column. The column was 
transferred to a 1.5 ml collection tube, 45 μl RNase free water was added, spun 
1 min at 8000x g and the RNA concentration measured with the Nanodrop ND-
1000 spectrophotometer. 
2.7.2 RNA extraction from plant tissue 
Fourteen-day-old liquid culture grown Arabidopsis plants were harvested after six 
hours incubation with 60 µM TNT (in 10 μl DMSO). 10 μl of DMSO alone were 
added to the cultures for negative control. Arabidopsis RNA was isolated by 
grinding eight whole plants in a pestle and mortar cooled in liquid nitrogen. The 
RNA was isolated using a plant RNeasy Mini Kit from Qiagen according to the 
manufacturer’s instructions. An on-column, DNA digestion using RNAase-free 
DNAase (Qiagen) was included. The RNA content was quantified using a 
Nanodrop ND-1000 Spectophotometer. 
 
Ten g RNA were added to a total of 24 l RNAse free water. 1 l of oligo dT 
primer (Invitrogen) was added and the mixture was incubated in the thermocycler 
for 2 min at 95 ºC and then chilled on ice. Then the following substances were 
added: 8 l 5 x 1st strand buffer (Invitrogen), 2 µl 2.5 mM dNTPs (Bioline), 2 l 
0.1M DTT (Invitrogen), 1 l RNAsin (RNAse inhibitor), 2 l Superscript II 
(Invitrogen). The total volume was brought to 40 l using RNase free water. The 
mixture was incubated at 42 ºC for 2 h. Samples were frozen at -80ºC. 
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2.7.3 Reverse transcription from plant mRNA to cDNA 
To 10 g plant mRNA was added 1 l oligo dT primer (0.5 μg/μl, Invitrogen) and 
RNAse free water to a final volume of 25 l, incubated at 95 ºC for 2 min and 
then chilled on ice. After adding 8 l 5x 1st strand buffer (Invitrogen), 125 µM 
dNTPs (Invitrogen), 5 M DTT (Invitrogen), 40 U RNAsin ribonuclease inhibitor 
(Promega), 400 U Superscript II (Invitrogen), the total volume was brought to 
40 l using RNase free water and the solution was incubated at 42 ºC for 2 h. 
Samples were frozen at -80 ºC until use for PCR. 
 
2.8 Traditional cloning method 
2.8.1 Designing primers for truncated P450 and reductase genes 
Plant P450s and P450 reductases are membrane associated through an N-terminal 
hydrophobic membrane anchor of around 25 to 70 amino acids. The association to 
the membrane is causing mainly the insolubility of these proteins. The catalytic 
centre is situated in the cytoplasm and a removal of the N-terminus potentially 
increasing the solubility will not reduce the enzyme activity.
330,333,346 
 
To design forward primers, the amino acid sequence was analysed with TMHMM 
(http://www.cbs.dtu.dk/services/TMHMM/) and SignalP3.0 software 
(http://www.cbs.dtu.dk/services/SignalP/). The TMHMM program predicts 
membrane regions and SignalP 3.0 can identify the location of a signal peptide 
and cleavage sites.  
2.8.2 Polymerase chain reaction (PCR)  
Primers were designed using primer3 software (http://frodo.wi.mit.edu) and 
synthesised by Sigma-Aldrich.  
PCRs for amplifying the genes of interest were performed using the Phusion DNA 
Polymerase (Finnzymes), which is a highly accurate proof reading polymerase in 
a Peltier Thermal Cycler PTC-200. PCR amplifications were performed in 
volumes ranging from 25 μl to 50 μl using 5x buffer HF. Primers were employed 
at an ultimate concentration of 400 nM, dNTPs (Invitrogen) at a final 
concentration of 200 μM each and template DNA at 200 ng.  
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The programme used was, if not otherwise indicated, 5 min at 98 C for 
denaturation, 30 cycles of 10 sec denaturing at 98 C, 30 sec annealing at 60-
65 C, 1.00-1.20 min extension at 72 C and 10 min at 72 C. PCR products were 
stored at -20 C and a part of each PCR product was visualised on agarose gels. 
By appearance of unspecific PCR products, 400 mM NDSB 201 (3-(1-Pyridinio)-
1-propanesulfonate) was added to improve the specificity of the PCR reaction. 
The Taq polymerase (New England Biolabs) was used for colony PCR after a 
transformation reactions to identify the presence of the gene. Therefore, 2 μl cell 
template from a single colony (preparation according to Chapter 2.8.5, page 64) 
were mixed with 2.5 μl 10x Thermo pol buffer, 200 μM dNTP mix (Invitrogen), 
44 mM DMSO, 400 nM primer (forward and reverse) in a total volume of 25 μl. 
The PCR used a 5 min denaturation at 94 C, followed by 35 cycles of 94 C 
denaturation for 15 sec, 55 C annealing for 30 s and 72 C extension for 1.00-
1.20 min and a final extension step of 72 C for 10 min. 
2.8.3 Preparation of PCR products for cloning 
Immediately after purifying the PCR product (see Chapter 2.6, page 60), A-tail 
overhangs were added to create blunt-ended PCR products. 3 μl cleaned PCR 
product (negative control with water) was added to 0.5 μl 10 x thermo pol buffer, 
0.2 mM dATPs, 0.25 U Taq-polymerase and water to a final volume of 5 μl. After 
incubation at 72 °C for 10 min, 1 μl TOPO vector and 1 μl salt solution (both 
from TOPO TA Cloning Kit from Invitrogen) was added and the whole mix 
placed at room temperature for 30 min.  
2.8.4 Transformation of plasmid DNA into chemically competent 
Escherichia coli cells  
An aliquot 50 l of frozen competent E. coli DH5α was defrosted on ice for 10-
15 min and then 2 μl of plasmid DNA was added, mixed by stirring with pipette 
and left on ice for 5 min. E. coli cells were then heat-shocked, in a water bath at 
42 ºC for 40 sec and again chilled on ice. After 5 min, 200 μl SOC-medium was 
added and the freshly transformed cells were allowed to recover at 37 ºC under 
shaking. After 1 h, aliquots were spread onto LB agar plates, containing 
antibiotics if necessary and grown at 37 ºC overnight. For TOPO blue / white 
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screening cells were spread onto plates containing 64 μg/ml 5-Bromo-4-chloro-3-
indolyl-β-D-galactopyranoside (X-gal). 
2.8.5 Screening transformants for recombinant genes by PCR 
Single colonies were picked with a pipette tip and resuspended in 20 µl sterile 
water. Bacteria cell walls were destroyed by incubation at 95 °C for 5 min and 
then cycled 5 times through 15 °C for 30 sec followed by 95 °C for 30 sec and 
then frozen at -80 °C for 10 min. 2 µl of this solution was used as template for the 
PCR reaction using Taq polymerase (Chapter 2.8.2, page 62). 
2.8.6 Restriction endonuclease digest of DNA 
Restriction enzymes were obtained from New England Biolabs and used with the 
buffer system supplied by the manufacturer. Digests were used to create 
diagnostic restriction maps for construct analysis or in preparation for subsequent 
cloning steps.   
For restriction mapping 200 ng DNA was digested with 10-20 U of enzyme in a 
10 µl reaction and if necessary 1 µg BSA was added. For preparation of DNA 
fragments 1-5 µg DNA was digested with 5-10 U of enzyme and 5 µg BSA.  All 
reactions were incubated for 1.5 h at 37 °C. For restriction mapping, 5 µl of the 
reaction were analysed using agarose gel electrophoresis (0.8% agarose gel, see 
Chapter 2.11, page 72). For preparative digests, products of the reaction were 
purified, if necessary using gel purification (Chapter 2.6, page 60). When 
buffering systems for digests using multiple enzymes, which were not compatible, 
sequential digests with both enzymes on the same plasmid were conducted. 
2.8.7 Dephosphorylation of DNA 5’ end of the vector 
The dephosphorylation of the DNA 5’ ends was performed using 45 μl digested 
vector (cleaned from gel after digestion), 5 μl 10x arctic phosphatase buffer and 
1 μl arctic phosphatase (5000 U/ml, New England Biolabs). The samples were 
incubated at 37 °C for 45 min and then the phosphatase was heat inactivated at 
65 °C for 5 min before the solution was used for the ligation reaction 
(Chapter 2.8.8). 
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2.8.8 DNA ligation reaction 
Ligation reactions were performed with dephosphorylated plasmid DNA 
(Chapter 2.8.7) and phosphorylated insert DNA. Ligation was performed on 100 
ng of DNA, in 3:1, 1:1 or 1:3 ratios of vector to insert. Controls included 
phosphorylated and dephosphorylated vector only. Ligation reactions were 
performed using T4 DNA ligase (New England Biolabs). The reactions were 
buffered in 50 mM Tris-HCl, 10 mM MgCl2, 1 mM ATP (Invitrogen), 
10 mM dithiothreitol (DTT, Invitrogen), pH 7.5 at 25 °C and 400 U of ligase used 
in a total volume of 20 µl.   
2.8.9 DNA sequencing and analysis 
Sequencing reactions were performed by the Genomics Laboratory, Technology 
Facility, University of York (York, UK). A list of primers used for sequencing is 
shown in Table 2.3. PCR primer of the insert were used for the sequencing of the 
yeast shuttle vector pYeDP60. Sequence chromatograms were analysed using 
Applied Biosystems Sequence Scanner 1.0 and sequences were aligned using the 
BLAST packages available at the National Centre for Biotechnology information 
(www.ncbi.nlm.nih.gov/blast/). 
 
Table 2.3: List of primers used for sequencing 
name sequence (5'-->3') 
M13 forward GTAAAACGACGGCCAGTG 
M13 reverse GGAAACAGCTATGACCATG 
T7 TTATACGACTCACTATAGGG 
T7term TATGCTAGTTATTGCTCAGCGGT 
ATR2seq R CATAACGTGCTTTTGCCTCTTCACCCA 
RhF rev TGCCGCCGGCGACGAACACGTAGTGCTC 
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2.9 Ligation independent cloning method 
The Ligation Independent Cloning (LIC) enables a rapid high-throughput cloning 
without any ligation steps due to the complementary long overhangs on insert and 
vector (Figure 2.4).
345
  
 
Figure 2.4: Schematic procedure for ligation independent cloning 
 
Therefore, the LIC-vector, based on pETYSBLIC3C vector
345 
containing six 
cleavable N-terminal histidines, was digested using BseR1. Briefly, 100 ng LIC-
vector, 10 μl NEB4 buffer, 20 U BseRI and water to a final volume of 100 μl were 
incubated for 1 h 50 min, then separated on a 0.6% agarose gel and purified 
(Chapter 2.6, page 60). The insert was amplified by PCR using Phusion 
polymerase (Chapter 2.8.2, page 62) and primers designed using HiTel software 
(TF Protein Production Laboratory, University of York, 
http://bioltfws1.york.ac.uk/cgi-bin/primers.cgi?). The purified insert and vector 
were treated with T4 polymerase (LIC qualified, Novagen-Merck) and the 
complementary bases A and T (Table 2.4) to create the long sticky ends 
(Figure 2.5). The reaction was performed at 22 ºC for 30 min and stopped with 
further incubation of 75 ºC for 20 min.  
vector insert
Cleavage and 
T4 pol reaction PCR
T4 pol 
reaction
insert in LIC-vector
Trans-
formation
pETYSBLIC3C
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Table 2.4: Protocol for T4 polymerase treatment 
         vector 
              insert 
4 pmol linearised vector   0.2 pmol insert 
40 μl 10x T4 pol buffer  2 μl 10x T4 pol buffer 
20 μl 100 mM DTT  1 μl 100 mM DTT 
10 μl 100 mM dTTP   0.5 μl 100 mM dATP 
8 μl T4 DNA polymerase*  0.4 μl T4 DNA polymerase* 
water to a final volume of 400 μl   water to a final volume of 20 μl 
       * 2.5U/ l LIC qualified T4 DNA polymerase, Novagen/Merck 
 
 
 
Figure 2.5: LIC-vector after T4 /dTTP treatment  
(BseRI restriction site in italics) 
 
 
The T4 treated vector was purified (Chapter 2.6, page 60) and diluted to a 
concentration of 50 ng/μl. For the ligation, 1 μl vector and 2 μl insert (negative 
control: 2 μl water) were mixed and incubated at room temperature for 10 min. To 
enable easy transformation, divalent ions such as Mg
2+
 were complexed by adding 
1 μl 25 mM EDTA to the mix and incubated 10 min on ice. 2 μl of ligation 
reaction was added to 50 μl chemical competent E. coli DH5α cells (Chapter 2.8.4, 
page 63), incubated for 5 min on ice, heat shocked for 40 sec at 42 °C and chilled 
for 5 min on ice. SOC medium (200 μl) was added and incubated shaking 
(200 rpm) for 1 h at 37 °C. The DNA will be ligated by repair enzymes, which a 
naturally present in E. coli cells. The sample was spread onto agar plates 
containing 50 μg/ml kanamycin and incubated overnight at 37 °C. 
Positive transformants were analysed using the protocol transcribed in 
Chapter 2.8.5, 2.8.6 and 2.8.9. 
 
2.10 Protein expression and purification 
2.10.1 Expression in Escherichia coli 
The strain E. coli Rosetta 2 (DE3) (Table 2.1) was transformed with the plasmid 
containing the gene of interest (Chapter 2.8.4, page 63). Positive transformants 
were grown in 10 ml LB containing 34 μg/ml chloramphenicol and 100 μg/ml 
GCGGCCTGGAAGTTCTGTT-3’           5’-CGCGCCTTCTCCTCACATATGGCTAGCATGACTGGTGGACAGCAA
CGCCGGACCTTCAAGACAAGGTCCCTGGTCGTT-5’              3’-TGTATACCGATCGTACTGACCACCTGTCGTT
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kanamycin after confirmation of the presence of the insert by PCR and incubated 
overnight at 37 °C and 200 rpm. M9 minimal medium was used to grow bacteria 
cells expressing P450s and fusion enzymes and LB medium for ATR1tr or 
ATR2tr. The main culture was inoculated with the preculture at an OD600 of 0.1 
and incubated shaking at 37 °C until an OD600= 0.6-0.8. Protein expression was 
then induced by adding 1 mM IPTG. Additionally, 5 μg/l riboflavin was added for 
reductases as precursor of FMN and FAD and 0.5 mM FeCl3 (Fisons), 1 mM 
ALA (δ-aminolevulinic acid, a heme ring precursor) for P450 expression. The 
proteins were expressed shaking (200 rpm) at 15 °C or 20 °C overnight.  
2.10.2 Solubilisation buffers 
To increase the solubility of the truncated Arabidopsis reductases, different 
solubilisation buffers were tested following the protocol from Lindwall et al. 
2000
347
. 
The ATR1tr was transformed into E. coli Rosetta 2 (DE3) and expressed in LB 
medium under the conditions described in Chapter 2.8.4. 
Cells were harvested and resuspended in 35 ml 10 mM Tris, pH 8.5 containing 
100 mM NaCl and 1 mM EDTA and then divided in 30 1 ml aliquots. Cells were 
spun (2300x g, 1 min), the supernatant discarded and the cell pellets resuspended 
in 1 ml of the different solubilisation buffers listed in Table 2.5. Buffer 0 was the 
buffer used for the batch purification of the Arabidopsis reductases in 
Chapter 2.10.4, which resulted in precipitated protein after purification. 
CHAPTER 2 – MATERIALS AND METHODS 
 
69 
 
Table 2.5: List of solubilisations buffer adapted from Lindwall et al. 2000
347
 
buffer Reagents to solubilise overexpressed protein 
buffer 0 HIS-binding buffer: 50 mM sodium phosphate pH 8.0, 300 mM NaCl 
buffer 1 100 mM Tris, 10 % glycerol, pH 7.6 
buffer 2 100 mM Tris, 50 mM LiCl, pH 7.6 
buffer 3 100 mM HEPES, 50 mM (NH4)2SO4, 10 % glycerol, pH 7.0 
buffer 4 100 mM HEPES, 100 mM KCl, pH 7.0  
buffer 5 100 mM Tris, 50 mM NaCl, 10 % isopropanol, pH 8.2 
buffer 6 100 mM K2HPO4/KH2PO4, 50 mM (NH4)2SO4, 1% Triton X-100, pH 6.0 
buffer 7 100 mM triethanolamine, 100 mM KCl, 10 mM DTT, pH 8.5 
buffer 8 100 mM Tris, 100 mM sodium glutamate, 10 mM DTT, pH 8.2 
buffer 9 250 mM K2HPO4/KH2PO4, 0.1 % CHAPS, pH 6.0 
buffer 10 100 mM triethanolamine, 50 mM LiCl, 5 mM EDTA, pH 8.5 
buffer 11 100 mM sodium actete, 100 mM glutamine, 10 mM DTT, pH 5.5 
buffer 12 100 mM sodium actete, 100 mM KCl, 0.1% n-octyl-ß-D-glucoside, pH 5.5 
buffer 13 100 mM HEPES, 1 M MgSO4, pH 7.0 
buffer 14 100 mM HEPES, 50 mM LiCl, 0.1% CHAPS, pH 7.0 
buffer 15 100 mM K2HPO4/KH2PO4, 2.5 mM ZnCl2, pH 4.3 
buffer 16 100 mM Tris, 50 mM NaCl, 5 mM calcium actetate, pH 7.6 
buffer 17 100 mM triethanolamine, 50 mM (NH4)2SO4, 10 mM MgSO4, pH 8.5 
buffer 18 100 mM Tris, 100 mM KCl, 2 mM EDTA, 1% Triton X-100, pH 8.2 
buffer 19 100 mM sodium acetate, 1 M MgSO4, pH 5.5 
buffer 20 100 mM Tris, 2 M NaCl, 0.1% n-octyl-ß-D-glucoside, pH 7.6 
buffer 21 100 mM Tris, 1 M (NH4)2SO4, 10 mM DTT, pH 8.2 
buffer 22 100 mM sodium acetate, 50 mM LiCl, 5 mM calcium acetate, pH 5.5 
buffer 23 100 mM HEPES, 100 mM sodium glutamate, 5 mM DTT, pH 7.0 
buffer 24 
100 mM triethanolamine, 100 mM sodium glutamate, 0.02% n-octyl-ß-D-
glucoside, 10% glycerol, pH 8.5 
buffer 25 100 mM Tris, 50 mM NaCl, 100 mM urea, pH 8.2 
buffer 26 100 mM triethanolamine, 100 mM KCl, 0.05% dextran sulfate, pH 8.5 
buffer 27 100 mM K2HPO4/KH2PO4, 50 mM (NH4)2SO4, 0.05% dextran sulfate, pH 6.0 
buffer 28 100 mM HEPES, 50 mM LiCl, 0.1% deoxycholate, pH 7.0 
buffer 29 100 mM Tris, 100 mM KCl, 0.1% deoxycholate, 25% glycerol, pH 7.6 
buffer 30 
100 mM potassium acetate, 50 mM NaCl, 0.05% dextran sulfate, 0.1% CHAPS, 
pH 5.5 
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Lysozyme (from chicken egg white, Sigma) was added and the suspension 
incubated for 5 min on ice. Cells of each aliquot were lysed (Misonix S-4000 
sonicator at 70% maximum amplitude, 1 sec sonication bursts, 4 sec cooling 
intervals at 0 °C for a total processing time of 1 min) and then incubated gently 
shaking for 10 min at 4 °C. After centrifugation at 16000x g for 10 min, the 
soluble proteins in the supernatant were analysed by Bradford assay 
(Chapter 2.12), SDS PAGE (Chapter 2.13) and western blot (Chapter 2.14). 
2.10.3 Cell lysis by sonication 
1 l cell culture was harvest by centrifugation (7 min at 2500 xg, High Speed 
Sorvall RC5B+rotor, SLC-1500) after 20 h of expression and resuspended in 
30 ml HIS-binding buffer (HIS-Binding buffer: 50 mM sodium phosphate pH 8, 
300 mM NaCl) or buffer 18A (100 mM Tris, 100 mM KCl and 1% Triton X-100, 
pH 8.2) containing 37.5 μl 0.1 M PMSF (protease inhibitor solved in isopropanol). 
Lysozyme (from chicken egg white, Sigma) was added to a final concentration of 
2 μg/ml to the cells and incubated on ice for 5 min. Cells were lysed usually in 
35 ml batches with a Misonix S-4000 sonicator at 70% maximum amplitude 
alternating 3 sec sonication bursts with 7 sec cooling intervals at 0 °C for a total 
processing time of 4 min. The effect of the sonication was visualised by light 
microscopy (Carl Zeiss, Axiovert 200, AxioCam HRm) (Figure 2.6). 
 
 
Figure 2.6: E. coli Rosetta 2 (DE3) cells A before and B after sonication 
 
The soluble protein, present in the supernatant after centrifugation (15 min at 
15000 rpm, High Speed Sorvall RC5B+rotor, SS-34) was used for protein 
purification (Chapter 2.10.4 and 2.10.5).  
A                                                 B
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2.10.4 Protein purification in a batch process 
All steps to purify the His-tagged protein were performed at room temperature 
and individual samples were taken for analysis by SDS PAGE (Chapter 2.13) and 
western blot analysis (Chapter 2.14). Protein purification was performed in a 
batch process by using His-Select Nickel Affinity Gel (Sigma) in a 50 ml falcon 
tube (500 μl slurry per 10 ml supernatant containing the protein). The resin was 
equilibrated with 10 resin volumes of buffer, mixed by inverting, spun at 1200 xg 
for 1 min (Jouan Model CR 312 Centrifuge, Swinging Bucket Rotor) and the 
supernatant was discarded. This step was repeated twice. The soluble protein 
fraction after sonication (Chapter 2.10.3, page 70) containing the protein of 
interest was applied to the resin material and gently shaken at room temperature 
for 1 h up to 4 h. After centrifugation at 1200 xg (Jouan Model CR 312 Centrifuge, 
Swinging Bucket Rotor), the supernatant was removed and the resin washed three 
times with fifthteen resin volumes of buffer. To remove non specific bound 
protein, the resin was washed with one resin volume of buffer containing 5 mM 
imidazole (Fisher Scientific) shaking for 5 min. After centrifugation (1200 xg, 
5 min, Jouan Model CR 312 Centrifuge), the supernatant was discarded and the 
His-tagged protein eluted by incubation of one resin volume of buffer containing 
500 mM imidazole (Fisher Scientific) for 10 min to 1 h by gently shaking. After 
centrifugation (2400 xg, 5 min, Jouan Model CR 312 Centrifuge, Swinging 
Bucket Rotor), the supernatant was transferred to a spin column (Agilent 
Technologies, 0.22 μm cellulose acetate) to remove all resin traces by spinning 
2 min at 13000 rpm (table centrifuge). The protein solution was dialysed twice 
against 5 l potassium phosphate (50 mM, pH 7.0) at 4 °C, if not otherwise 
specified.  
2.10.5 Protein purification in a continuous process 
A column (Chromatography column from Novagen) containing 1.5 ml His-Select 
Nickel Affinity Gel (Sigma) was equilibrated with 10 ml buffer.  
The soluble supernatant containing the protein of interest was applied to the resin 
material and then washed twice with 10 ml buffer. Unspecific bound protein was 
eluted with 5 ml of 5 mM imidazole (Fisher Scientific) in buffer and the His-
tagged protein with 500 mM imidazole in buffer. The eluted protein was dialysed 
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against two batches 5 l potassium phosphate (50 mM, pH 7.0) at 4 °C, if not 
otherwise specified.  
 
2.11 Agarose gel electrophoesis 
Agarose gel electrophoresis was used to visualise and to separate digestion and 
PCR products. The concentration of agarose (Melford) was varied between 0.8-
1.0% (w/v), according to the size of the fragments to be separated. Agarose was 
dissolved in 1x Tris-acetate-EDTA (TAE) buffer, made from a 50x TAE stock, 
which contained: 242 g/l Tris (Invitrogen), 57.1 ml/l glacial acetic acid (Fisher 
Scientific) and 100 ml/l 500 mM EDTA (Sigma-Aldrich), pH 7.0. To visualise 
DNA under UV light (UVItec system and the software UVIpro) ethidium bromide 
(Fluka, Sigma-Alrdich) was added to a final concentration of 0.2 g/ml. DNA was 
diluted in 6x loading dye comprising 0.25% w/v bromophenol blue and 30% 
glycerol. To determine the product size 1 kb DNA ladder or 2-Log DNA Ladder 
(both from New England Bioloabs) were used according to the manufacturer’s 
instruction. The DNA was typically separated using a voltage of 90-130 V.  
 
2.12 Protein detection 
Protein concentrations were determined using the Coomassie (Bradford) Protein 
Assay Kit (Thermo Fisher Scientific). For quantification a standard curve was 
prepared using bovine serum albumin (BSA) solutions of known concentrations 
between 0-2 mg/ml measured at 595 nm in the spectrophotometer Varian Cary 50 
Bio UV/Vis Spectrophotometer (Agilent Technologies). Measurements were 
taken in triplicates. 
 
2.13 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
2.13.1 SDS PAGE with the Bio-Rad system 
Standard procedures were followed according to Laemmli.
348
 Gels were poured 
and run with the Mini-Protean 3 system (Bio-Rad). Gels were polymerised with 
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12% w/v acrylamide (Fisher Scientific) in the resolving gel and 4% w/v 
acrylamide in the stacking gel. Four times SDS loading buffer contained 2 ml of 
625 mM Tris (Invitrogen), pH 6.8, 4 ml of 10% (w/v) SDS (Melford), 2 ml of 
glycerol (Fisher Scientific), 1 ml of -mercaptoethanol (Sigma-Aldrich), 30 mg of 
bromphenol blue (Sigma-Aldrich), 1 ml of H2O. Two times loading buffer was 
added in equivalent volumes to the samples, denatured for 5 min at 100 ºC, cooled 
to room temperature, centrifuged to bring down the condensation and pellet any 
insoluble substances and 15 to 20 μl loaded on the gel. Running buffer contained 
25 mM Tris, 180 mM glycin (Fisher Scientific), 0.1% (w/v) SDS (pH 8.3). 
Electrophoresis was perfomed for approximately 45 min at 200 V. Prestained 
protein marker was purchased from New England Biolabs or Fermentas and gels 
were stained with Instant Blue (Expedeon). An UVItec system and the software 
UVIpro was used for the documentation. 
2.13.2 SDS PAGE with the RunBlue system from Expedeon 
SDS gradient gels (4 to 20% (w/v) acrylamide) were purchased from Expedeon. 
As running buffer was used 1x RunBlue RAPID. Twenty times of RunBlue 
RAPID was made of 0.6 M MOPS (Sigma), 1.2 M Tris (Invitrogen), 2% (w/v) 
SDS (Melford) and 130 mM sodium bisulphate (Expedeon). The sample 
preparation was done following the manufacturer’s instructions. The gels were run 
at 90 mA and then stained with Instant Blue (Expedeon) and documentated using 
an UVItec system and the software UVIpro. 
 
2.14 Western blot analysis 
For the western blot transfer a Trans-Blot SD Semi-Dry Transfer Cell (Bio-Rad) 
and a Model 200/2.0 power supply (Bio-Rad) were used. All western Blot 
analysis steps were performed at room temperature under gently shaking on a gel 
rocker (Stuart, Bibby Scientific Limited). An UVItec system and the software 
UVIpro was used for the documentation of the western Blot results. 
2.14.1 Protein detection with anti-poly Histidine peroxidase conjugate 
Protein SDS gels and nitrocellulose membrane (0.45 µM, BioRad) were incubated 
in pre-chilled Towbin transfer buffer (25 mM Tris, 192 mM Glycine, 0.1% (w/v) 
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SDS, 20% (v/v) methanol, pH 8.3) for 15 min, prior assembling the gel/membrane 
sandwich complex. The blotting paper (extra thick, BioRad) briefly soaked in 
Tobwin transfer buffer was placed on to the anode of the transfer unit, followed 
by the membrane, the gel and again by a pre-soaked blot paper avoiding air 
bubbles. For the transfer, the cathode was placed onto the complex and the 
transfer was done with a voltage of 10 V for 1 h. After protein transfer to the 
membrane, the membrane was briefly rinsed in PBS buffer (137 mM NaCl, 
2.5 mM KCl, 10 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4) and then blocked with 
1x PBS containing 3% (w/v) non-fat milk powder (Fluka, Sigma-Aldrich) for 1 h 
at room temperature. After washing the membrane three times with PBS 
containing 0.05% Tween 20 (Sigma-Aldrich), the membrane was incubated with 
PBS, 3% BSA (Fisher Scientific) and the Monoclonal Anti-polyHistidine 
Peroxidase Conjugate (Sigma), followed by three washes for 5 min with PBS 
containing 0.05% Tween 20. The membrane was developed in a solution of 2 ml 
of 4-Chloro-1-naphtol (Sigma-Aldrich, one tablet dissolved in 10 ml methanol), 
10 ml triethanolamine buffer saline (137 mM NaCl, 27 mM KCl, 12 mM 
triethanolamine, pH 7.5) and 5 μl H2O2. The reaction was stopped by washing the 
membrane in water.  
2.14.2 Protein detection with alkaline phosphatase conjugate 
The SDS gel and the nitrocellulose membrane were prepared under the same 
conditions as described in Chapter 2.14.1. After the protein transfer onto the 
membrane, the membrane was washed in PBS buffer (137 mM NaCl, 2.5 mM 
KCl, 10 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4) and then incubated in PBS 
containing 3% BSA (Fisher Scientific) and 2% milk powder (Fluka, Sigma-
Aldrich) for 60 min to block the membrane. The membrane was incubated with 
the primary antibody, specific for the target protein (ATR2tr and RhF reductases 
produced in rabbit, Covalab, 1:10000 dilution) in PBS containing 3% BSA for 
60 min. The membrane was then washed twice in PBS with 0.1% Tween 20 
(Sigma-Aldrich) for 5 min, followed by washes in PBS, 0.5% Tween 20 and 1 M 
NaCl for 5 min, rinsed briefly in PBS and again in PBS containing 3% BSA 
before incubating the membrane with the secondary antibody (goat Anti-rabbit 
IgG conjugated to alkaline phosphatase, Sigma, 1:20000 dilution) for 60 min. The 
membrane was then washed twice in PBS containing 0.1% Tween 20 for 5 min, 
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twice in PBS containing 0.5% Tween 20 and 1 M NaCl for 5 min, briefly rinsed in 
PBS and then incubated in 10 mM Tris pH 9.6 for 5 min. The membrane was 
developed with nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl phosphate 
dipotassium (from Sigma as a tablet containing both ingredients, dissolved in 
10 ml water) and the reaction was stopped by washing the membrane several 
times in water. 
 
2.15 Protein characterisation 
2.15.1 Characterisation of the P450 reductases 
The characterisation of ATR1tr and ATR2tr was done, if not otherwise specified, 
with purified enzyme dialysed in buffer B: 30 mM potassium phosphate buffer 
(pH 7.8), 20% glycerol (Fisher Scientific), 0.1 mM EDTA (Fisher Scientific) and 
20 μM FMN (Sigma-Aldrich). 
2.15.1.1 Spectrophotometric characterisation 
Spectrophotometric work was performed at 30 ºC using a Varian Cary 50 Bio 
UV/Vis Spectrophotometer (Agilent Technologies). High Quality Polystyrene 
Disposable Cells, Semi Micro, (1.5 ml, Kartell) were used for Bradford protein 
quantification and UV-transparent disposable cuvette (ultra-micro, 15 mm 
window height, BrandTech Scientific) for activity assays and wavescan 
measurements. 
The absorption of ATR2tr (5.1 mg/ml, dialysed in 50 mM potassium phosphate 
buffer pH 7.5) was measured between the wavelength 300 and 600 nm with one 
point for each nanometre. Expressed and purified empty LIC-vector (without 
dialysis, protein concentration of 0.4 mg/ml) was used for negative control.  
FMN and FAD were dissolved in 50 mM potassium phosphate buffer pH 7.5 to a 
final concentration of 100 mM. The spectra of 10 μM of both substances were 
recorded between 300 and 600 nm. 
2.15.1.2 Activity assay with cytochrome c  
Activity of ATR2tr to transfer single electrons from the cofactor (NADH or 
NADPH) was detected by using cytochrome c as the electron donor. The protocol 
adapted from Guengerich et al. 2009
349
 was modified to a 500 μl volume and the 
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reaction measured spectrophotometrically by following the increase in absorbance 
at 550 nm. Each reaction contained 50 μM horse heart cytochrome c (Sigma-
Aldrich) with a certain amount of sample to a final volume of 495 μl with 
300 mM potassium phosphate buffer, pH 7.7. A baseline was recorded at 550 nm 
for 1 min and the reaction started by adding 5 μl 10 mg/ml NAD(P)H (Melford). 
NADH and NADPH were tested as cofactor and ferredoxin reductase (from 
spinach, Sigma-Aldrich) as well as cytochrome c reductase (from porcine heart, 
Sigma-Aldrich) as positive control. Expressed and purified empty LIC-vector 
sample was used for negative control. 
2.15.1.3 Temperature and pH optima of ATR1tr and ATR2tr 
The temperature optimum for the two Arabidopsis reductases was determined 
using the activity assay with cytochrome c (Chapter 2.15.1.2) between 10 °C to 
70 °C. The buffer was preheated in a water bath (Grant JB1, Scientific Laboratory 
Supplies) and the cuvette holder tempered. 
For elucidation of the pH optimum of ATR1tr and ATR2tr, the activity for 
cytochrome c reduction was tested in three different buffers (Table 2.6) covering 
the pH range from pH 2.0-11.0. The pH optimum for both reductases was also 
determined in Britton Robinson buffer, which covered a pH range between pH 3.4 
to 11.0.  
 
Table 2.6: Buffers used for analyzing the pH optima of ATR1tr and ATR2tr 
buffer pH region content concentration 
potassium phosphate 4.0 - 10.0 H2KPO4
*
 and HK2PO4
*
 300 mM 
citrate 2.0 - 7.6 
citric acid
*
 and tri sodium 
citrate
*
 
300 mM 
Britton Robinson  3.4 - 11.0 
1:1:1 mixture of boric acid
*
, 
phosphoric acid
#
 and acetic 
acid
*
, pH regulated with NaOH
*
 
300 mM 
*
 chemical from Fisher Scientific, 
#
 from Sigma-Aldrich 
 
For the reaction, 40 μl of a 0.5 mM solution of the cytochrome c (horse heart, 
Sigma, dissolved in water), 1 μg/ml ATR2tr (or 100 μg/ml ATR1tr), 5 μl 10 mM 
NADPH (Melford) and buffer were mixed to a final volume of 500 µl (Table 4.2). 
The absorbance was observed at 550 nm at 30 °C. The activity (mM/min) was 
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calculated by using the average of three measurements divided by the extinction 
coefficient of cytochrome c at 550 nm (ε = 19.6 mM-1cm-1). Each point was 
measured as triplicates to get a standard deviation.  
2.15.1.4 Stability test of ATR2tr in different buffers 
The purified ATR2tr in 500 mM imidazole was divided in two batches and one 
was dialysed against two 5 l volumes of buffer A (50 mM potassium phosphate 
buffer pH 7.5) and the other against buffer B (30 mM potassium phosphate pH 7.8, 
20% glycerol, 0.1 mM EDTA, 2.0 μM FMN) at 4 ºC. Buffer B containing FMN 
should stabilise the activity of ATR2tr due to the low affinity of ATR2 to FMN.
350
 
Glycerol can stabilise enzymes and protect hydrophobic sites of proteins. 
The ATR2tr samples in buffer A or B were aliquoted and stored at -80 °C, -20 °C, 
4 °C and 21 °C. The samples were assayed for activity with cytochrome c 
(see Chapter 2.15.1.2) after 2, 6, 16 and 41 days. 
A Michaelis-Menten-diagram was generated with samples of purified ATR2tr 
before dialysis (containing 500 mM imidazole) and after dialysis in the two 
different buffers A and B using the same substrate concentrations published by 
Hull and Celenza 2000.
351
 Error bars were calculated using the standard derivation 
of three replicas. 
2.15.1.5 Kinetic studies of the reductases  
The reaction was performed at 25 °C and the absorbance change of cytochrome c 
was monitored at 550 nm.  
The reductases ATR1tr and ATR2tr (dialysed in buffer B) were used in a final 
concentration of 1 mg/ml and 0.01 mg/ml, respectively. The protein solution was 
mixed with different cytochrome c substrate concentrations (5, 6, 10, 20, 50, 100 
and 150 μM, from horse heart, Sigma) in a total volume of 495 μl 300 mM 
potassium phosphate buffer (pH 7.7) and the reaction was started by adding 5 μl 
NADPH (10 mg/ml, Melford). Measurements were taken in triplicates. 
Kinetic data (KM and Vmax) were calculated using Michaelis Menten kinetics 
(Software: GraFit) for the substrate concentration of 6 μM up to 100 μM.  
The specific activity is defined by the activity of enzyme per milligram of total 
protein (in μmol min-1mg-1) and was calculated using following formula: 
specific activity = Vmax · [E]     [E] = enzyme concentration 
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The protein concentration of 0.01 mg and 1 mg/ml reaction for ATR1tr and 
ATR2tr, respectively was used for kinetic activity assays. The turnover number 
kcat is the number of moles of substrate, which are converted into product per mol 
of enzyme (per active site) under saturated conditions. 
 
kcat= Vmax/[E] 
 
2.15.2 Protein identification by MALDI-MS analysis 
Protein identification was performed by the Proteomics Laboratory, Technology 
Facility University of York using a Bruker autoflex III MALDI-TOF/TOF and 
data were analysed by Mascot (Matrix Science). 
2.15.3 P450 enzyme activity assays 
A Waters (Milford, USA) HPLC system consisting of a 510 pump, a Waters 
Alliance 2695 separations module and a Waters 2996 Photodiode Array was used, 
if not otherwise specified, to detect the chemical compounds used in the different 
assays. The substrates and products were identified by comparing the spectra 
generated from the Waters photodiode array detector with the retention times and 
spectra of commercial compounds. Data analysis was performed using Empower-
Pro Analysis Software. 
2.15.3.1 Activity assay for CYP71D15 with limonene 
E. coli JM109 whole cells and the total protein fraction containing CYP71D15 
PM2-2 were used for activity assay with the native substrate limonene. Resting 
cell assays were performed in a total volume of 1 ml containing 5 mM limonene, 
0.5 mM NADPH, 20 μg/ml spinach ferredoxin and 10 U/ml spinach ferredoxin 
reductase (Sigma-Aldrich) and buffer (100 mM Tris-HCl (pH 7.4), 250 mM KCl, 
50 mM MgCl2). Samples were taken over a time course, cells spun down and then 
an equal volume of ethyl acetate added, vortexed, centrifuged and the organic 
layer analysed by GC-MS (7890A GC System, 5975C inert XL MSD with Triple-
Axis Detector, 7693 autosampler, Supelco HP5 GC column, software: 
ChemStation) following the temperature program in Figure 2.7.  
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rate 
(°C/min) 
value 
(°C) 
hold time 
(min) 
 100 3 
10 180 4 
total time 15 min 
 
         
 
Figure 2.7: GC-MS program for analysing limonene and its hydroxylated products 
 
 
2.15.3.2 Activity assay for CYP81D8 and CYP81D11 with methyl-tolyl-
suphide 
The native substrate of Arabidopsis CYP81D8 and CYP81D11 are not known, 
however oxidising activity was tested towards the substrate methyl-tolyl-sulphide. 
The reaction contained 250 μg of protein (purified with Ni-chromatography), 
reductase (0.1 ng/ml spinach ferredoxin and 1 U/ml spinach ferredoxin reductase 
(Sigma-Aldrich) or Arabidopsis ATR1tr purified see Chapter 4), 100 mM sodium 
phosphate buffer pH 7.0, 1 mM methyl-tolyl-sulphide and was initiated by the 
addition of 300 μM NADPH. The reaction (100 μl) was stopped by adding 
acetonitrile (30 μl) at different time points and the products were analysed by 
HPLC. As a positive control the heme domain of XplA
141,352
 was used.  
HPLC was performed with 50 μl sample injected to a Techsphere column (column 
temperature: 45 °C, sample temperature: 4 °C, water (Elga Labwater) and 
methanol (Fisher Scientific), flow: 1 ml/min) following the program in Table 2.7. 
The retention time of the substrate methyl-tolyl-sulphide was at 14 min and of 
methyl-tolyl-sulphoxide at 5 min. 
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Table 2.7: HPLC program for the separation of methyl-tolyl-sulphide and its 
oxidised derivates 
time (min) water (%) methanol (%) 
0.00 50 50 
5.00 50 50 
10.00 40 60 
10.01 5 95 
15.00 5 95 
15.01 50 50 
25.00 50 50 
 
 
2.15.3.3 Isoflavone synthase activity assay  
For an in vivo assay in growing cell culture, the substrate naringenin (Sigma-
Aldrich) was added to a final concentration of 50 μM to the growing culture at the 
start of induction. Flavonoids are excreted by E. coli and can be analysed from the 
culture supernatant. Therefore, 5 ml samples were collected at different time 
points during the expression and analysed by HPLC after extraction. 
For activity tests in resting cells, cultures were harvested and resuspended in 
potassium phosphate buffer (50 mM, pH 7.0) with 20 mg wet cells per 1 ml buffer. 
After adding the substrate naringenin (Sigma, final concentration: 100 μM), the 
tubes were incubated at 28 °C and 160 rpm. Samples (2.5 ml) were collected at 
different time points for HPLC analysis after extraction. 
Extraction method: 
The samples were prepared according to the protocol of Leonard and Koffas
306
: 
To 5 ml sample the internal standard (5 μl of 50 mM scopoletin) and 5 ml ethyl 
acetate for extraction was added. After mixing and centrifugation (Jouan Model 
CR 312 Centrifuge, Swinging Bucket Rotor, SelectScience), the organic phase 
was transferred into a glass vial for complete evaporation. To dissolve the 
flavonoids, 500 μl methanol were added and the samples incubated at 60 °C for 
15 min, followed by incubation at room temperature for 20 min. 50 μl were 
injected to a TechSphere ODS 80A 5 μ column (250 x 4.6 mm, Fischer Thermo 
Scientific), with an isocratic flow of 1 ml/min of 50% (v/v) methanol containing 
0.1% (v/v) acetic acid and 50% (v/v) water (column temperature: 25 °C, sample 
temperature: 21 °C). The standards of the substrate naringenin (Sigma-Aldrich) 
and the product genistein (Sigma-Aldrich) eluted at 17.5 min and 12 min, 
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respectively. The peak area was converted into concentration using a calibration 
with commercial available naringenin, genistein and scopoletin purchased from 
Sigma. 
2.15.3.4 Cinnamate-4-hydroxylase (CYP73A5) activity assay  
Cinnamate-4-hydroxylase activity was tested in resting cell assays. Therefore, the 
fusion proteins were expressed in LB and M9 medium following the protocol 
described in 2.10.1 (page 67) overnight at 15 °C and 200 rpm. The activity of the 
73A5-fusions in the resting cell assays were optimised by variation of the 
expression temperature (15 °C and 20 °C) as well as the airation (speed of 50 rpm 
and 200 rpm). 
Cells were harvested by centrifugation (7 min at 4000 rpm, High Speed Sorvall 
RC5B+rotor, SLC-1500) and resuspended in 50 mM potassium phosphate buffer 
pH 7.0 to a final cell concentration of 100 mg/ml.  
The resting cell assays were performed in glass vials in a total volume of 15 ml, 
the reaction started by adding the substrate cinnamic acid (Sigma-Aldrich) to a 
final concentration of 200 μM. Vials were shaken (300 rpm) at 28 °C. Samples 
(100 μl) were taken at different time point, and quenched with equal volume of 
methanol. After centrifugation (5 min at full speed, bench top microlitre 
centrifuge Sigma 1-15P), 20 μl of the supernatant were analysed by HPLC 
following a modified program (Table 2.8) according to Chen and Morgan
353
 using 
a Techsphere column (column temperature: 30 °C, sample temperature: 4 °C, 
buffer: water (Elga Labwater) and methanol (Fisher Scientific) containing 0.1% 
(v/v) acetic acid (Fisher Scientific) buffered to pH 7.25 with triethylamine 
(Sigma-Aldrich). Cinnamic acid (absorption maximum: 278 nm) eluted at 9.4 min 
and coumaric acid (absorption maximum: 310 nm) at 7.7 min under these 
conditions. 
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Table 2.8: HPLC program for the separation cinnamic acid and coumaric acid at 
1 ml/min 
time 
(min) 
water (%) 
methanol containing 0.1% acetic acid, pH 7.25 
with triethylamine (%) 
0.00 90 10 
3.00 90 10 
4.00 55 45 
9.00 55 45 
9.01 90 10 
14.00 90 10 
 
Ni-affinity chromatographic treated 73A5tr-ATR2tr (expressed in M9 at 15 °C 
and 200 rpm and purified in a continued process, see Chapter 2.10, page 67), 
protein bound to the resin material (0.5 ml resin material after two washing steps) 
as well as the insoluble protein (700 mg wet cells after sonication) were used for 
crude extract assays. The reactions were performed in glass vials in a total volume 
of 4 ml containing 4 U alcohol dehydrogenase (ADH, from T. brockii, Sigma-
Aldrich), 2.5% (v/v) isopropanol (Fisher Scientific, substrate for ADH), 500 μM 
substrate cinnamic acid and 300 μM NADPH (Melford) shaking (300 rpm) at 
30 °C. Samples were taken and prepared as described for the resting cell assay 
(see above). 
A standard curve was measured for cinnamic acid and coumaric acid in the range 
of 10 μM to 500 μM with four replicas for each concentration. 
2.15.3.5 Activity assay for CYP82E4 
The N-demethylase (CYP82E4) from Nicotiana tabacum converts nicotine to 
nornicotine, both substances are possible to detect by HPLC analysis according to 
Saunders and Blume 1981.
354
 Samples (sample temperature: 4 °C) were separated 
on a SunFire C18 column (3.5 μm, 4.6 x 150 mm, Waters, column temperature: 
20 °C), 1 ml/min flow of isocratic mobile phase of 70% water containing 0.2% 
phosphoric acid (pH 7.25 with triethylamine) and 30% methanol containing 0.2% 
phosphoric acid (pH 7.25 with triethylamine) with a run time of 28 min. The 
retention time of substrate (±) nicotine (Sigma) was at 18.9 min and of the product 
(±) nornicotine (Sigma) at 4.2 min (Figure 2.8). Both have an absorption 
maximum of 260 nm. 
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Figure 2.8: HPLC chromatogram for the separation of nicotine and nornicotine 
HPLC-conditions: SunFire C18 column, 1 ml/min flow isocratic 70% water (0.2% 
phosphoric acid, pH 7.25 with triethylamine) and 30 % methanol (0.2% phosphoric acid 
pH 7.25 with triethylamine), column temperature: 20 °C, sample temperature: 4 °C 
 
The activity for the fusions 82E4tr-lamATR2tr and 82E4tr-licATR2tr (sequences 
see appendix 2) was tested in a resting cell assay. The assay was performed in 
glass vials containing 25 mg cells per ml 50 mM potassium phosphate buffer 
(pH 7.0) and 100 μM substrate nicotine in a final reaction volume of 20 ml, 
shaking at 28 °C and 300 rpm. Samples of 1.2 ml were taken at different time 
points, centrifuged (5 min at full speed, bench top microlitre centrifuge Sigma 1-
15P) and 1 ml of the supernatant was evaporated completely (Savant SpeedVac 
DNA 110 Concentrator). The pellet was resuspended in 100 μl water : methanol 
(70% : 30%) and 50 μl were analysed by HPLC. 
 
Additionally, HPLC separation of 1 mM nicotine and 1 mM nornicotine was 
tested with a ChiralPak IA column (Daicel Chemical Industries). Compounds 
were separated in a mobile phase of 35% (v/v) ethanol and 65% (v/v) 
(heptane : isopropanol : TFA =90:10:0.1%) with a isocratic flow of 0.5 ml/min 
and a column temperature of 20 °C. The substances were detected at 260 nm. 
2.15.3.6 Activity assay for CYP81D8 with TNT and aminodinitrotoluenes 
The resting cell assay against TNT was performed with CYP81D8tr, 81D8tr-
lamATR2tr, 81D8tr-licATR2tr (all cloned into the LIC-vector) in 50 mM 
potassium phosphate buffer (pH 7.0) after an expression in E. coli Rosetta 2 
(DE3) in M9 medium (2.10.1, page 67). For negative controls lamATR2tr, 
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licATR2tr (both in LIC-vector) and Rosetta 2 (DE3) cells without a plasmid were 
used.  
The total reaction volume of 5 ml contained 50 mg wet cells per ml buffer 
(50 mM potassium phosphate buffer, pH 7.0). TNT (stock: 100 mM TNT in 
DMSO) was added to a final concentration of 100 μM and samples incubated at 
28 °C shaking at 200 rpm. Samples were taken over a time course, quenched by 
adding 10% of 1.5 M trichloroacetic acid (TCA), snap frozen in liquid nitrogen 
and stored at -80 °C, due to the instability of hydroxylaminodinitrotoluenes in 
presence of oxygen.
355,356
 Defrosted samples were centrifuged (10 min at full 
speed, bench top microlitre centrifuge Sigma 1-15P) and 50 μl applied for HPLC 
analysis. For the separation of the TNT derivates a TechSphere ODS 80A 5 μ 
column (250 x 4.6 mm, Fischer Thermo Scientific) was used. 50 μl of each 
sample were run in the solvent conditions of 40% (v/v) water and 60% (v/v) 
methanol with a flow of 1 ml/min for 10 min (column temperature: 35 °C, sample 
temperature: 4 °C). TNT eluted after 5.6 min and the derivates 4-hydroxylamino-
2,6-dinitrotoluene (4-HADNT) at 4.7 min, 2-amino-4,6-dinitrotoluene (2-ADNT) 
at 6.1 min, 4-amino-2,6-dinitrotoluene (4-ADNT) at 5.6 min, 2,4-dinitrololuene at 
6.7 min and 2,6-dinitrololuene at 7.2 min. 
2.15.3.7 Activity assay for CYP81D8 with 7-ethoxycoumarin 
Recombinant expressed CYP81D8 (in E. coli Rosetta 2 (DE3) and M9 medium, 
Chapter 2.10.1, page 67) 81D8tr-lamATR2tr and 81D8tr-licATR2tr (negative 
controls: control-lamATR2tr, control-licATR2tr and Rosetta 2 (DE3) cells 
without a plasmid) were tested in a resting cells assay with 7-ethoxycoumarin, 
which is a common P450 substrate
357
.  
Therefore, 50 mg cells per ml buffer (50 mM potassium phosphate buffer, pH 7.0) 
and 200 μM 7-ethoxycoumarin (Sigma-Aldrich) in a final volume of 5 ml were 
incubated in glass vials at 28 °C shaking at 200 rpm. Samples (300 μl) were taken 
over a time course, centrifuged (10 min at full speed, bench top microlitre 
centrifuge Sigma 1-15P) to remove the cells. Fifty μl of the supernatant were 
analysed by HPLC (Waters 717 Plus Autosampler, 2487 dual λ absorbance 
detector, Waters SunFire C18 column, 3.5 μm, 4.6 x 150 mm) at a wavelength of 
325 nm under isocratic 50% (v/v) water and 50% (v/v) methanol with 0.1% (v/v) 
acetic acid, flow: 0.7 ml/min (run time: 35 min, column temperature: 21 °C, 
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sample temperature: 4 °C).
358 
The retention times of 7-ethoxycoumarin and 3-
hydroxycoumarin (Sigma-Aldrich), a possible product, were 18.2 and 10.2 min, 
respectively.     
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3 Chapter: Expression of Cytochromes P450  
3.1 Introduction 
Hosts such as yeast (eukaryotic host) or bacteria (prokaryotic host) have been 
traditionally used to express recombinant P450s for characterisation studies and 
for industrial applications. Both have advantages and disadvantages: The yeast 
expression is efficient and inexpensive and can be up-scaled for industrial 
applications; moreover, it allows expression of native membrane associated P450s 
in microsomes. The yeast Saccharomyces cerevisiae possesses three endogeneous 
P450s and one reductase representing a potential disadvantage of this system as 
endogeneous P450s could interfere with the P450 of interest. 
The bacterium E. coli lacks P450s and can be more easily, faster and more 
economically cultivated in the lab. Expression problems can occur through 
different codon bias and protein misfolding due to the absence of complex 
membrane systems like the ER and post-translational machinery. 
S. cerevisiae contains an endogenous P450 reductase which is able to efficiently 
transfer electrons to foreign P450s.
323
 S. cerevisiae was the first host used to 
successfully express mammalian
324,325
 and plant
326
 P450s with activity of 
membrane associated proteins being detected in the microsomes. A S. cerevisiae 
strain has been specially modified by introducing the Arabidopsis P450 reductase 
ATR1 and ATR2 genes and silencing the endogeneous yeast P450 reductase. 
These strains were named WAT11 and WAT21 (Table 3.1).
166,338
 More than 20 
Arabidopsis P450s have been expressed using these engineered yeast strains 
(Chapter 1.5.2).  
 
Table 3.1: Saccharomyces cerevisiae strains used in this work 
S. cerevisiae  genotype obtained from 
WAT11 MATa; ade2–1; his3–11,-15; leu2–3,-
112; ura3–1; canR; cyr+ (a derivative of 
the W303-B strain) 
Prof. D. Werck 
Reichhart (CNRS-
Institute de Biologie 
moléculaire des 
plantes, Strasbourg) 
WAT12 MATa; ade2–1; his3–11,-15; leu2–3,-
112; ura3–1; canR; cyr+ (a derivative of 
the W303-B strain) 
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E. coli was also used as host for an expression of membrane-associated 
Arabidopsis P450s such as CYP74A1, 79A2, 79B2, 79B3, 79F1, 90B1, 98A3 and 
701A3,
37,203-205,210,212,243,251,273,359
 however so far, Arabidopsis P450s have been not 
expressed solubly in E. coli. 
Activity of recombinant P450s has mostly been detected using radiolabelled 
substrates.
200,203-205,210,212,222,230,235,237,238,244,292,339,340,360,361
 Other methods used for 
activity detection include HPLC
37,278,362
, LC-MS
294
, GC-MS
37,212,247,287 
and Solid 
State Nuclear Magnetic Resonance (SSNMR)
 243
. 
The two Arabidopsis P450s CYP81D8 and CYP81D11 were selected for this 
project as these enzymes were upregulated in response to TNT (2,4,6-
trinitrotoluene, Figure 3.1) and might play a role in general detoxification via a 
broad substrate specificity (Table 3.2).
363,364
  
 
 
Figure 3.1: Chemical structure of 2,4,6-trinitrotoluene (TNT) 
 
 
Table 3.2: P450s upregulated after TNT treatment from microarray data
363
 
Fold increase Accession number Gene family name 
30.7 At4g37370 CYP81D8 
25.1 At3g28740 CYP81D11 
14.5 At5g57220 CYP81F2 
13.1 At2g30750 CYP71A12 
8.7 At3g26830 CYP71B15 
5.8 At5g67310 CYP81G1 
3.4 At5g45340 CYP707A3 
2.3 At3g26210 CYP71B23 
 
 
The explosive TNT is highly toxic, recalcitrant to degradation in the environment 
and a major world-wide pollutant of our environment. This modern, synthetic 
compound is used for military purposes and also for the demolition industry. The 
TNT molecule is not a natural compound and has existed in the environment for a 
CH3
N
+
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-
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N
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relatively short time. These factors are likely to have contributed to the fact that 
there are not many organisms able to transform TNT to a less toxic compound. It 
is known, using microarray analyses, that expression of genes encoding enzymes 
from Arabidopsis, such as uridine diphosphate glycosyltransferases (UGTs), 
oxyphytodienoate reductases (OPRs), glutathione transferases (GSTs) and P450s, 
are upregulated in response to TNT stress. UTGs, OPRs and GSTs have been 
shown to have activity towards TNT and its metabolites.
364-366
  
Microarray data available on the Internet (Genvestigator, 
www.genevestigator.com) were used to find out details on the expression profiles 
of the two P450s chosen from the microarray experiment. CYP81D8 is expressed 
predominantly in the seedling and the young rosette and again in the mature 
silique (Figure 3.2). CYP81D11 is mainly produced during and after germination 
and in the first stage of rosette growth. Transcripts of CYP81D11 are less 
abundant in the later stages of plant development. 
 
 
Figure 3.2: Occurence of CYP81D8 and CYP81D11 in the development of 
Arabidopsis 
(https://www.genevestigator.com/gv/, 15/12/2011) 
 
CYP81D8
CYP81D11
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Another P450, the (-)-4S-limonene-3-hydroxylase (CYP71D15) from peppermint 
(Mentha x piperta), a hybrid of spearmint (Mentha spicata) and watermint 
(Mentha aquatica), was studied in this chapter, because the limonene activity have 
been measured in vitro by GC-MS after solubilisation of the membrane associated 
protein CYP71D15.
367
  
CYP71D15 hydroxylates (-)-4S-limonene in the C3 position regio- and 
stereospecifically to (-)-trans-isopiperitenol, which is a precursor of (-)-menthol 
(Figure 3.3).
368
 (-)-Menthol is a well studied monoterpene that occurs naturally as 
essential oil in peppermint. It is used in the food industry, for oral health care, 
cosmetics and tobacco due to its pleasant aroma and flavour and the cooling-
anaesthetic effect.
369
  
 
 
Figure 3.3: Regiospecific hydroxylation of (-)-4S-limonene to (-)-trans-isopiperitenol 
within the biosynthesis of (-)-menthol 
 
Prof. Rodney Croteau’s research group studied the limonene-3-hydroxylase after 
recombinant expression in E. coli JM109 and in the yeast strains WAT11 and 
WAT21. Hydroxylation rates of more than 2000 nmol·h-1·mg-1 by the membrane 
associated CYP71D15 were achieved after expression in E. coli, whereas only 
35 nmol·h-1·mg-1 were obtained with yeast microsomes, independent of the strain 
(WAT11 or WAT21).
367,370
 
 
The hydrophobic membrane anchor of P450s and its reductase can be removed to 
increase the solubility with no activity loss as suggested in the literature. Kempf 
et al. reported that the human CYP2D6 was expressed solubly in the cytosol after 
removing the hydrophobic membrane anchor.
371
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3.2 Objectives 
Different strains of E. coli as well as S. cerevisiae were tested as hosts for the 
expression of the plant P450s: CYP81D8 and CYP81D11, both from Arabidopsis 
and the peppermint CYP71D15. Therefore, the native gene sequences were 
expressed in S. cerevisiae and then tested for activity. Truncated versions (without 
the hydrophobic membrane anchor to increase the solubility) of the P450s were 
used for expression in E. coli. 
 
E. coli expression was carried out for the three P450s and the expression yield 
optimised by testing a range of strains and experimental conditions. 
The yeast work was done in York and in Prof. Danièle Werck-Reichhart’s 
laboratory (Institute de Biologie Moléculaire des plants du CNRS, Départment 
Réponses au Stress, Strasbourg, France). Two modified yeast strains, WAT11 and 
WAT21
338
 for coexpression of the Arabidopsis reductases ATR1 and ATR2, 
respectively, were provided by Prof. Danièle Werck-Reichhart for the expression 
of full length plant P450s. 
3.3 Materials and Methods 
3.3.1 Analysis of CYP73D15 PM2-2 construct  
Prof. Rodney Croteau (Institute of Biological Chemistry, Washington State 
University, Pullman, US) provided the CYP71D15 in the vector pCWori+ 
(construct PM2-2
367
). The amino acid sequence of the N-terminus in the construct 
PM2-2 was altered incorporating seven residues of a bovine 17α-hydroxylase 
(Figure 3.4).
321,367
 A vector map is shown in Figure 3.5. 
 
native CYP71D15  MELLQWSALIILV          
PM2-2               MALLLAVFWSALIILV  
native CYP71D15  ATGGAGCTCCTCCAGCTTTGGTCGGCGCTTATAATCCTCGTAG 
PM2-2                                                             ATGGCTCTGTTATTAGCAGTTTTTTGGTCGGCGCTTATAATCCTCGTAG 
Figure 3.4: N-terminal modification of CYP71D15 creating construct PM2-2
367
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Figure 3.5: Vector map for pCWori+ 
LacZ = ß-galactosidase gene, LacI = repressor gene for IPTG induction, tac = tac 
promoter, CYP71D15 PM2-2 = gene of interest, M13 ori = origin of replication of 
filamentous phage M13, ampR = ampicillin resistence gene, NdeI and 
HindIII = restriction sites 
 
The CYP71D15 PM2-2 insert was analysed by a restriction digest using NdeI and 
HindIII  and sequenced using primers listed in Table 3.3 (Chapter 2.8.9).  
 
Table 3.3: Primer used for sequence analysis of CYP71D15 PM2-2 
primer sequence (5’→ 3’) 
Tac promotor F CCATGGTGACAATTAATCATCGGCTC 
PM2-2int1263 F GGGAAATGATTTCGAGTTCGTCCCGTTCGG 
Pm2-2int242 R GGAGAACACCTCACCCAGCTGCACG 
CYP71D15 PM2-2 R GAGGAGAAGGCGCGTCATGATGAAGGATCGTAGGGTGTGGGAAC 
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3.3.2 Materials and Methods for P450 expression in Escherichia coli 
3.3.2.1 Isolation and cloning of the plant P450s 
RNA was isolated from 14 days old Arabidopsis plants grown in liquid medium 
treated with TNT (Chapter 2.7.2) and transcribed into cDNA (Chapter 2.7.3).  
Usually, P450s have a hydrophobic N-terminal region, allowing association with 
the membrane. The P450 amino acid sequences were analysed using the software 
TMHMM and SignalP3.0 (Chapter 2.8.1). The hydrophobic N-termini were 
removed by designing special LIC primers (Chapter 1.1) for the PCR 
amplification of Arabidopsis CYP81D8 and CYP81D11 (Primer see Table 3.4). 
 
Table 3.4: Primer used for PCR amplification of the truncated versions of CYP81D8 
and CYP81D11 
primer sequence  
CYP81D8nat F CCAGGGACCAGCAATGGAAACCAAAACCCTAATTTTCTCAATTCTCTTCG 
CYP81D8tr F CCAGGGACCAGCAATGGGAAAACTCAAGCGAAAGCCAAATCTACCTCC 
CYP81D8 R GAGGAGAAGGCGCGTCAAACGGACTCGTTGAAGATTTTAACAACAGAGG 
CYP81D11nat F CCAGGGACCAGCAATGTCATCAACAAAGACAATAATGGAAACTATATACC 
CYP81D11tr F CCAGGGACCAGCAATGCCACGGCCGCGTAAACTAAACCTACC 
CYP81D11 R GAGGAGAAGGCGCGTTATGGACAAGAAGCATCTAAAACCTTATGGAC 
CYP71D15 PM2-2 F CCAGGGACCAGCAATGGCTCTGTTATTAGCAGTTTTTTGGAGTGCG 
CYP71D15 PM2-2 R GAGGAGAAGGCGCGTCATGATGAAGGATCGTAGGGTGTGGGAAC 
 
The peppermint CYP71D15 PM2-2 and the two truncated versions of Arabidopsis 
P450s (81D8tr and 81D11tr) were amplified using Phusion polymerase 
(Chapter 2.8.2) and primer listed in Table 3.4 before cloning into the LIC-vector 
(Chapter 1.1). 
3.3.3 Expression of PM2-2 in Escherichia coli 
For microsome preparation
367,372
 E. coli JM109 cells transformed with 
CYP71D15 PM2-2 were grown with shaking (200 rpm) at 37 °C in TB 
(Chapter 2.2.1) containing 100 μg/ml ampicillin. Expression was induced at 
OD600nm = 0.85 by adding 1 mM IPTG, 1 mM thiamine and 75 μg/ml ALA 
(E. coli JM109 without the vector was used as negative control) and samples 
incubated with shaking (200 rpm) at 28 °C following the published protocol.
367
 
After 40 h the cells (800 ml) were harvested by centrifugation (5000 rpm, rotor: 
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SLC1500, 10 min at 4 °C), resuspended in 35 ml 100 mM Tris buffer (pH 7.5) 
containing 20% glycerol, 0.5 M EDTA, 1 mM DTT and 0.2 mg/ml lysozyme. 
Cells were incubated with stirring for 10 min at 4 °C. Cell were centrifuged again 
(7000 rpm, rotor: SLC1500, 10 min at 4 °C) and resuspended in 30 ml 100 mM 
Tris buffer (pH 7.5) containing 20% glycerol, 0.5 M EDTA, 1 mM DTT and 
PMSF. Cells were sonicated (Chapter 2.10.3) and centrifuged at low speed (SS34-
rotor, 3250 rpm). The supernatant was then spun in an ultracentrifuge (40 krpm 
for 1 h at 4 °C, rotor type 45Ti) to separate the soluble proteins from the 
membrane fraction. Membrane proteins were resuspended in 100 mM sodium 
phosphate buffer (pH 7.5) containing 30% glycerol using a glass homogeniser and 
proteins were detected by SDS-PAGE and western blot analysis.  
For soluble, non membrane associated expression of the truncated Arabidopsis 
P450s 81D8tr and 81D11tr as well as the peppermint CYP71D15 PM2-2 several 
different strains (DH5α, BL21(DE3), Rosetta 2, Rosetta gami 2) and media (LB, 
TB, M9 and auto-induction) was trialled. Incubations were all performed 
overnight with shaking (200 rpm) at 20 °C following the protocol Chapter 2.10.1. 
The purification was done in a batch process (Chapter 2.10.3-2.10.4). 
3.3.4 Materials and Methods for P450 expression in yeast 
3.3.4.1 Media 
For yeast cultivation YPAG (yeast, bactopeptone, adenine and glucose) medium 
was used containing 10 g/l yeast extract (Formedium), 10 g/l bacto peptone 
(Difco), 20 g/l glucose (Fisher Scientific) and 200 mg/l sterile filtrated adenine 
was added after sterilisation. SGI medium (glucose based yeast minimal medium) 
was used for the selection of transformants on agar containing 1 g/l bacto 
casamino acids, 7 g/l yeast nitrogen base without amino acids (Difco), 20 g/l 
glucose, 20 g/l agar (Formedium) and 20 mg/l sterile tryptophane (Sigma-Aldrich) 
was added after sterilisation. The cultivation of the transformants in liquid culture 
was done in YPGE (yeast, bactopeptone, glucose and ethanol): 10 g/l yeast extract, 
10 g/l bactopeptone and 5 g/l glucose. Ethanol (50.6 ml/l) was added after 
autoclaving. 
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3.3.4.2 Transformation and expression in yeast 
CYP71D15 from peppermint, CYP81D8 and CYP81D11 from Arabidopsis were 
cloned into the pYeDP60 vector. The vector pYeDP60 (vector map see 
Figure 2.3) is a shuttle vector for cloning in E. coli and expression in yeast.
338
  
 
The transformation was carried out following the protocol adapted from Schiestl 
& Gietz, 1989
373
. Briefly, 50 ml YPGA liquid preculture was inoculated with an 
isolated yeast colony and incubated with shaking (140 rpm) at 28 °C over night. 
Then the main YPGA culture was inoculated to an OD700nm 0.2 and incubated for 
five hours with shaking (140 rpm) at 28 °C. Cells were then centrifuged at low 
speed (500x g) for 10 min, the pellet resuspended in sterile water (1/10 of the 
original culture volume), transferred in 2 ml Eppendorf tubes (1 ml/tube) and 
centrifuged at low speed (500x g) for 10 min. The pellet was resuspended in 
1.5 ml 0.1 M LiAc/TE (0.1 M LiAc, 10 mM Tris-HCl, 1 mM EDTA), centrifuged 
at low speed (500x g for 10 min) and the supernatant discarded leaving 
approximately 50 μl yeast cell suspension. To this yeast cell suspension, 1-5 µg 
plasmid-DNA, 10 µl carrier DNA solution (100 µl 10 mg/ml salmon sperm DNA 
in sterile water denatured for 20 min at 100 °C and then chilled on ice) and 40% 
PEG in 0.1 M LiAc/TE were added and cells were incubated gently shaking for 
one hour at 30 °C. After heat shock at 42 °C for 15 min, the suspension was 
centrifuged for 10 sec at low speed, the pellet washed with 1 ml sterile water, 
centrifuged again and resuspended in 200 µl SGI and plated on SGI agar. Agar 
plates were incubated at 30 °C for 3-4 days until colonies appeared. 
For the expression, 10 ml SGI liquid preculture were inoculated with white 
transformants (colonies without a plasmid have a lack in adenine and turn red) and 
incubated at 28 °C with shaking (140 rpm) over night. The main culture was done 
in 6 x 200 ml YPGE, which was inoculated with 1.2-2 ml preculture and 
incubated with shaking (140 rpm) at 28 °C for 24 hours. After this time the 
glucose is used up by the yeast and it is using now the ethanol for its metabolism 
until 20 ml galactose (200g/l) were added for induction to each flask and 
incubated shaking (140 rpm) for 16 hours at 25 °C. Then the yeast was harvested 
and the microsoms isolated (see 3.3.4.3). 
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3.3.4.3 Yeast microsome preparation 
After the expression, the yeast cells were centrifuged for 15 min at 7500 g at 4 °C 
and washed with TEK buffer (1 ml TEK/0.5 g yeast, TEK: 50 mM Tris-HCl 
pH 7.5, 1 mM EDTA, 100 mM KCl). The pellet was washed twice with 1 ml 
TES/0.5 g yeast (TES: 50 mM Tris-HCl pH 7.5, 1 mM EDTA, 600 mM sorbitol, 
fresh added 10 g/l BSA and 120 µl β-mercaptoethanol), glass beads (glass beads, 
0.40-0.60 mm, Sartorius) were added to a fifth of the volume and shaken for 
5 min at 4 °C (1 min shaking, 1 min chilled on ice). Glass beads were allowed to 
settle and the supernatant was transferred into fresh tubes. Glass beads were then 
washed twice with TES and the washings combined with the supernatant. The 
solution containing the shared cells was centrifuged (15 min at 7500x g at 4 °C) 
for removing cell membranes, leaving membrane fractions and soluble proteins in 
the supernatant. The supernatant was filtered with micracloth (Calbiochem, 
Merck) to remove all glass beads and then ultracentrifuged at 100000x g at 4 °C 
(60 Ti-32000 rpm, 45 Ti-30000 rpm) for 45 min to pellet the microsomes. The 
pellet was transferred into a potter homogeniser, 500 µl TEG (50 mM Tris-HCl 
pH 7.5, 1 mM EDTA, 30% glycerol) added and homogenised on ice avoiding the 
build up of air bubbles.  
To test the presence of active P450, sodium dithionite (Fluka, Sigma-Aldrich) and 
CO was added by bubbling the cuvette for 30 sec to create the CO bound form of 
the P450. Absorption was measured between 400 and 500 nm. Purified XplA 
heme
352
 was used as positive control. 
 
3.4 Results 
3.4.1 P450 amino acid sequence analysis  
Plant P450s have a membrane anchor of around 25 amino acids at the N-terminal 
sequence, which is hydrophobic and known to cause the insolubility of these 
proteins. The catalytic centre is situated in the cytoplasm, so that a deletion of the 
N-terminus should not reduce the enzyme activity.  
The amino acid sequence was analysed with SignalP and TMHMM software 
(Chapter 2.8.1, result in Figure 3.6) and primers designed excluding the first 22 
amino acids from the N-terminus in order to clone 81D8tr without the membrane 
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anchor. To ensure expression an ATG start codon was added to the 5’end of the 
forward primer.  
 
Figure 3.6: Analysis of the CYP81D8 amino acid sequence 
A SignalP blot (cleavage prob = probability of cleavage site, n-region prob = probability 
of N-terminus of the signal peptide, h-region prob = probability of hydrophobic region of 
signal peptide, c-region prob= probability of C-terminus of signal peptide) and B 
TMHMM  
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A similar approach was taken to the cloning of CYP81D11. Here the first 
32 amino acids (Figure 3.7) were removed to expressed 81D11tr without a 
membrane anchor. Again an ATG start codon was added to the 5’end of the 
forward primer. 
 
Figure 3.7: Analysis of the CYP81D11amino acid sequence 
A SignalP blot (cleavage prob = probability of cleavage site, n-region prob = probability 
of N-terminus of the signal peptide, h-region prob = probability of hydrophobic region of 
signal peptide, c-region prob= probability of C-terminus of signal peptide) and B 
TMHMM  
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The analysis result of the N-terminal amino acid sequence of CYP71D15 PM2-2 
(Figure 3.8) was similar to the two Arabidopsis P450s described above. The full 
length of the CYP71D15 PM2-2 was used due to the fact that the N-terminus of 
the construct PM2-2 was already optimised for E. coli expression by 
Haudenschild et al. 2000
367
.  
 
Figure 3.8: Analysis of the CYP71D15 amino acid sequence 
A SignalP blot (cleavage prob = probability of cleavage site, n-region prob = probability 
of N-terminus of the signal peptide, h-region prob = probability of hydrophobic region of 
signal peptide, c-region prob= probability of C-terminus of signal peptide) and B 
TMHMM  
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3.4.2 Analysis of CYP71D15 PM2-2 
The pCWori+ vector (5.5 kb) containing the insert CYP71D15 PM2-2 (1.5 kb) 
was digested and fragments separated using an agarose gel (Figure 3.9).  
 
Figure 3.9: Analysis of CYP71D15 PM2-2 in pCWori+-vector after digestion 
1 = no enzyme, 2 = HindIII , 3 = NdeI, 4 = HindIII and NdeI linearised the plasmid and 
isolated the insert CYP71D15 PM2-2 with a size of 1.5 
 
Different internal and external primers were used for sequencing the PM2-2 gene 
and flanking regions. Sequencing confirmed the CYP71D15 PM2-2 gene and C-
terminal His-Tag comprising four histidine residues. The complete nucleotide 
sequence is found in Appendix B. 
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3.4.3 P450 cloning into the LIC-vector 
All three P450s were amplified by PCR using Phusion polymerase (Figure 3.10) 
and then cloned into the LIC-vector. 
 
Figure 3.10: Analysis of PCR products for native CYP81D8 (8nat), N-truncated 
CYP81D8 (8tr), native CYP81D11 (11nat) and N-truncated CYP81D11 (11tr)  
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3.4.4 P450 expression in Escherichia coli 
The peppermint CYP71D15 PM2-2 was expressed in E. coli JM109 following the 
published protocol from Prof. Rodney Croteau’s research group (Chapter 3.3.3). 
SDS-PAGE analysis was performed to verify the expression of CYP71D15   
PM2-2. The expected size of CYP71D15 PM2-2 was 57 kDa, however no signal 
for CYP71D15 PM2-2 was detected (Figure 3.11). 
 
 
Figure 3.11: Analysis of crude extract of JM109 cells after expression of 
CYP71D15 PM2-2 (57 kDa) 
JM109 cells without plasmid was used for negative control (1 = cells before induction, 
2 = cells after induction, 3 = disrupted cells after sonication, 4 = supernatant after 
sonication, 5 = soluble protein after ultracentrifugation, 6 = insoluble protein fraction 
containing membrane proteins after ultracentrifugation) 
 
The different fractions were also analysed using a spectrophotometer, but the 
typical shift of the absorption maximum from 420 nm to 450 nm when bound 
carbon monoxide was absent.  
 
All three P450s were expressed in different E. coli strains (DH5α, BL21(DE3), 
Rosetta 2, Rosetta gami 2) and various media were tested. The results are 
summarised in Table 3.5.  
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Table 3.5: Scheme of the test expression of the Arabidopsis P450s in the Lic-vector 
using different E. coli strains and media 
 LB-medium TB-medium M9-medium  
CYP71D15 
PM2-2 
no expression no expression not tested BL21(DE3) 
no expression no expression not tested Rosetta 2 
no expression no expression not tested Rosetta gami 2 
81D8tr 
no expression not tested not tested BL21(DE3) 
expression not tested no expression Rosetta 2 
no expression no expression not tested Rosetta gami 2 
no expression not tested not tested DH5α 
81D11tr 
no expression not tested not tested BL21(DE3) 
expression not tested no expression Rosetta 2 
no expression no expression not tested Rosetta gami 2 
no expression not tested not tested DH5α 
 
Expression was detected for 81D8tr (54 kDa) and 81D11tr (53 kDa) when 
expressed in E. coli Rosetta 2 and LB medium (Figure 3.12 and Figure 3.13). 
Uninduced culture and induced empty vector culture were used as negative 
control. 
 
 
Figure 3.12: SDS PAGE analysis of crude extract from E. coli Rosetta 2 cells 
expressing 81D8tr (54 kDa) in LB medium with and without induction 
An increase in signal could be seen from 3 h on. 
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Figure 3.13: SDS PAGE analysis of crude extract from E. coli Rosetta 2 cells 
expressing 81D11tr (53 kDa) in LB medium with and without induction 
An increase in signal could be seen from 3 h on. 
 
Additionally auto-induction medium was tested and P450s were purified in a 
single step using Ni-affinity chromatography. Fractions were analysed using SDS 
PAGE gel electrophoresis. No signal was detected for 81D8tr and 81D11tr in 
whole cells, disrupted cells, soluble or insoluble protein fractions, possibly due to 
low expression levels. However, a strong signal was found in the eluted protein 
fractions for both P450s (Figure 3.14). 
 
Figure 3.14: SDS PAGE analysis of protein fractions containing 81D8tr and 81D11tr 
after purification on Ni-resin material 
A 81D8tr (54 kDa) and B 81D11tr (53 kDa) after expression in E. coli Rosetta gami 2 in 
auto-induction medium (1 = whole cells before sonication, 2 = disrupted cells, 3 = soluble 
protein fraction, 4 = insoluble protein fraction, 5 = eluted protein fraction) 
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A similar result was seen after purification of 81D8tr, 81D1tr (Figure 3.15). No 
signal was detected for 71D15 PM2-2 (57 kDa, Figure 3.16A) when expressed in 
E. coli Rosetta gami 2 and LB medium. Cells harbouring the empty were used as 
negative control and purified as the P450s (Figure 3.16B). 
 
 
Figure 3.15: SDS PAGE analysis of protein fractions containing 81D8tr and 81D11tr 
after purification on Ni-resin material 
A 81D8tr (54 kDa) and B81D11tr (53 kDa) after expression in E. coli Rosetta gami 2 in 
LB medium (1 = whole cells before sonication, 2 = disrupted cells, 3 = soluble protein 
fraction, 4 = insoluble protein fraction, 5 = eluted protein fraction) 
 
 
 
Figure 3.16: SDS PAGE analysis of protein fractions containing CYP71D15 PM2-2 
and empty vector control after purification on Ni-resin material 
A CYP71D15 PM2-2 (57 kDa) and B empty vector control after expression in E. coli 
Rosetta gami 2 in LB medium (1 = uniduced cells, 2 = disrupted cells, 3 = soluble protein 
fraction, 4 = insoluble protein fraction, 5 = dialysed protein fraction) 
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Additionally a western blot analysis was performed to check if there were proteins 
possessing a His-Tag, but no signal was detected for any of the three P450s 
(Figure 3.17).  
 
 
Figure 3.17: Analysis of plant P450s after purification on Ni-resin material 
A SDS-PAGE and B western blot of purified P450s (1 = 81D8tr , 2 = 81D11tr,  
3 = potassium phosphate buffer negative control, 4 = CYP71D15 PM2-2)  
 
 
3.4.5 Activity assay for 81D8tr, 81D11tr and CYP71D15 PM2-2 
P450 activity was tested in resting cell assays, disrupted (sonicated) cells and Ni-
chromatography purified protein although P450 expression could be not detected 
by SDS PAGE and western blot analysis, possibly due to too low expression. 
No native substrate is known for the two Arabidopsis CYP81D8 and CYP81D11. 
Thus to test the ability of these P450s to perform an oxidative reaction methyl-
tolyl-sulphide was tested as substrate. The bacterial P450 XplA heme domain 
(with ferredoxin and ferredoxin reductase from spinach as reductase part) can 
oxidise methyl-tolyl-sulphide to methyl-tolyl-sulphoxide and was used as positive 
control. 
For the bacterial P450 XplA the substrate peak decreased and a corresponding 
peak for methyl-tolyl-sulphoxide appeared (Figure 3.16). For all other tested 
samples, the concentration of the volatile methyl-tolyl-sulphide substrate 
decreased over time, but no product peak was detected. Therefore, it is possible 
that a reaction has occurred, however, not producing the predicted reaction 
product methyl-tolyl-sulphoxide. Additionally, whole cells and total protein 
kDa 1  2           3        4             kDa            1           2            3           4
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fraction were tested for activity against methyl-tolyl-sulphide, but no activity 
could be detected (results not shown). 
 
Figure 3.18: HPLC chromatogram of the methyl-tolyl-sulphide assay 
(black line = positive control at time zero) 
 
CYP71D15 PM2-2 was tested with its native substrate limonene using whole cells 
and total protein. The substrate limonene (10 μg/ml) had a retention time of 
3.45 min. No additional peak of hydroxylated limonene was detected for any of 
the samples. Additionally 81D8tr and 81D11tr was tested against limonene, 
however no conversion was found. 
 
3.4.6 P450 expression in yeast 
P450s show a typical absorption maximum at 420 nm. Activity of P450s can be 
determined by measuring a shift in absorption to 450 nm when CO is bound.   
P450 transformation into yeast, expression and microsome isolation for 
CYP71D15 from peppermint was done in Strasbourg and in York and CYP81D11 
from Arabidopsis in York. The diluted, reduced microsomes (1:1 in TEG buffer) 
were analysed by UV/Vis and used for the baseline. The solution was bubbled 
with CO and analysed again. As a positive control, purified XplA heme was 
analysed and the typical shift to 450 nm of the CO bound form was observed 
(Figure 3.19A). There was a higher absorption around 420 nm for CYP71D15 
(Figure 3.19B), implying that the P450 was not correctly folded and therefore 
inactive. 
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Figure 3.19: CO difference spectrum of the microsoms for XplA heme from 
Rhodococcus sp. and CYP71D15 from peppermint 
A XplA heme (ox = oxidised form, red = reduced form, CO = CO bound form) and B) 
CYP71D15  
 
 
The expression of CYP71D15 from peppermint was repeated in York and 
additionally CYP81D11 was expressed. During the microsome preparation, 
surprisingly, the supernatant after the ultracentrifugation of CYP81D11 appeared 
reddish (the microsomes containing the P450 should be in the pellet) and due to 
that it was analysed with the UV/Vis spectrophotometer. 
The supernatant of the ultracentrifugation and the diluted microsomes (1:1 in TEG 
buffer) with sodium dithionite were used for baseline correction. Then the 
solution was bubbled with CO and analysed again. However a P450 characteristic 
spectrum was not obtained (Figure 3.20). 
 
 
Figure 3.20: CO difference spectrum of the microsomes and the supernatant after 
the ultracentrifugation for CYP81A11 from Arabidopsis and CYP71D15 from 
peppermint 
A CYP81A11 and B CYP71D15  
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There was no peak at 450 nm for both P450 microsomes, but again a higher 
absorption around 420 nm. The supernatant (after ultracentrifugation) of 
CYP81D11 showed also an absorption maximum at around 420 nm.  
An SDS PAGE analysis was performed to detect the P450s (Chapter 2.13.2). 
Three different samples were tested: the supernatant after the sonication of the 
cells (1 in Figure 3.21), the supernatant after ultracentrifugation (2) and the 
microsome solution (3).  
 
 
Figure 3.21: SDS PAGE analysis of yeast microsomes containing 
CYP81D11(57 kDa) and CYP71D15 PM2-2 (57 kDa). 
1 = supernatant after the sonication of the cells, 2 = supernatant after ultracentrifugation, 
3 = microsom solution. Bands in the red corners were sent for Maldi-MS analysis, 
 
Signals of the expected sizes for CYP81D11 (57 kDa) and CYP71D15 (57 kDa) 
could be detected, but MALDI-MS analysis identified the samples as bovine 
serum albumin and no P450 sequence was detected (Chapter 2.15.2). 
 
3.5 Discussion 
3.5.1 P450s expressed in Escherichia coli 
The function of CYP81D8 and CYP81D11 from Arabidopsis is not known 
(Appendix A). Both have been found to be induced in response to biotic and 
abiotic stress, such as osmotic stress, treatment with hydrogen peroxide, jasmonic 
acid, salicylic acid, abscisic acid, rose bengal and paraquat.
374,375
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Napier’s research group studied CYP81D11 in more detail and postulated an 
important role of this P450 in the plant defence response and that it is induced by 
cis-jasmone (an activator for genes involved in the pathway of secondary 
metabolic defence chemicals
376
).
377,378
 
 
The P450s CYP81D8, CYP81D11 and the peppermint CYP71D15 PM2-2 were 
expressed in E. coli and were found in the insoluble protein fraction. There was no 
improvement in the solubility when CYP81D8 and CYP81D11 were lacking the 
hydrophobic membrane anchor region. Different E. coli strains were tested to 
increase the yield of the expressed P450s. The E. coli Rosetta 2 strain, containing 
a supplementary plasmid for rare codons, resulted in the highest expression yield 
for 81D8tr and 81D11tr identified by SDS-PAGE when compared with uninduced 
Rosetta 2 cells.  
Additionally, various media were tested for further optimisation of the P450 
expression. No expression was achieved in TB, auto-induction and M9 media. 
The Arabidopsis 81D8tr and 81D11tr have been successfully expressed only in 
LB medium. However, no signal was seen in western blot analysis, possibly due 
to P450 protein folding so that the His-Tag cannot be recognised or through 
detection limitation. 
Oxidative activity of 81D8tr and 81D11tr was tested in resting cell assays towards 
methyl-tolyl-sulphide, because the sulphoxide product is commercial available. It 
was not necessary to co-express a corresponding plant reductase, due to the native 
presence of the bacterial flavodoxin reductase (encoded by FPR
379
 and used as 
protection against oxidative stress
380
), which was shown to support plant P450s, 
for example the CYP97 carotene hydroxylase
381,382
. However, no activity was 
found for Arabidopsis 81D8tr and 81D11tr to methyl-tolyl-sulphide in whole cells, 
which is possibly caused by limitation of the electron transfer through the E. coli 
reductase or through inactive P450s. Another reason may that methyl-tolyl-
sulphide is not a substrate of CYP81D8. Additionally, the P450s, present in the 
disrupted cell solution after sonication, were tested with two different reductases 
(commercially available spinach ferredoxin/ferredoxin reductase and recombinant 
expressed Arabidopsis ATR1tr, Chapter 4), nevertheless no product was detected. 
Although the expression of both P450s was shown by SDS PAGE analysis, 
activity could not been detected. 
CHAPTER 3 – EXPRESSION OF CYTOCHROMES P450 
 
110 
 
The peppermint CYP71D15 (limonene-3-hydroxylase) is part of the complex 
pathway leading to the monoterpene (-)-menthol
383
 and has been recombinantly 
expressed in insect cells, yeast and E. coli by Prof. Rodney Croteau’s research 
group.
367,368
 The CYP71D15 construct PM2-2 (provided by Prof. Rodney 
Croteau) was expressed in E. coli following their publications and tested for the 
hydroxylation of (-)-(4S)-limonene to (-)-trans-isopiperitenol in resting cell assays 
as well as in different fractions containing protein. No hydroxylation activity was 
detected possibly caused by too low expression levels, which gave no signal in 
SDS PAGE and western blot analysis. 
3.5.2 P450s expressed in Saccharomyces cerevisiae 
For yeast expression the two S. cerevisiae strains WAT11 and WAT21, co-
expressing the Arabidopsis reductase ATR1 and ATR2, respectively were used. 
Several research groups using these two strains have found that the amount of 
product is dependent on the P450, e.g. the CYP76B1 (from Helianthus tuberosus) 
worked better with WAT11 in the dealkylation of 7-ethoxycoumarin
384
 and 
CYP88A3 and CYP88A4 with WAT21 in the oxidation of ent-kaurenoic acid
247
. 
Additional to the activity assays, P450s can be characterised for their typical 
carbon monoxide difference spectra by shifting the absorption maximum sodium 
dithionite reduced P450 from 420 nm to the carbon monoxide bound form at 
450 nm. 
The three P450s CYP89A9 (from Arabidopsis with unknown function), 
CYP81D11 and CYP71D15 PM2-2 were expressed in S. cerevisiae WAT11 and 
WAT21 and microsomes containing the membrane associated P450s were isolated. 
P450s were detected by performing a CO difference spectrum. No maximum was 
seen for these P450s at 450 nm implying that incorrectly folded P450 had been 
produced. The reason for this is currently unknown. It was hypothesised that the 
expression of these P450s as fusion proteins would improve expression and 
facilitate the formation of active protein.  
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4 Expression, purification and characterisation of 
truncated, soluble Arabidopsis Cytochrome 
P450 reductases 
4.1 Introduction 
Cytochrome P450 reductases (CPR) are important partner enzymes for P450s 
because they supply electrons for all the different reactions.
385,386
 They are 
dependent on a flavin cofactor and NAD(P)H as a source of reducing equivalents. 
In yeast and animal species, only one single reductase is responsible for providing 
the necessary electrons for all the P450s.
387
 Plant genomes have usually more than 
one reductase (three in Arabidopsis and also in Helianthus tuberosus
388
), possibly 
due to the higher number of P450 genes in plant (246 P450 genes in Arabidopsis 
in comparison to 57 P450 genes in humans or three P450 genes in 
S. cerevisiae).
389
 Angiosperm reductases are usually classified into two distinct 
classes dependent on their N-terminal amino acid sequence. Class I is usually 
targeted to membrane of the ER whereas class II contains often more than 20% of 
the amino acids Serine and Threonine in the N-terminus and is then anchored in 
different membranes, such as chloroplasts.
166,390-392
 
In the late 1990s, two Arabidopsis cytochrome P450 reductases, named ATR1 
(genetic locus: At4g24520) and ATR2 (At4g30210), were characterised after 
recombinant expression.
166,391 
A third reductases, ATR3 (At3g02280), was found 
in the Arabidopsis genome sequence
393
 and was shown to be an authentic 
reductase supporting cinnamate-4-hydroxylase activity in vitro.
 394,395
  
Low sequence identity (33%) in the first 86 or 106 amino acids between ATR1 
and ATR2, respectively, give rise to the suspicion that the reductases are anchored 
in different membranes such as endoplasmic reticulum (ER) or chloroplast 
membrane
351
. The sequence of ATR2 contains two possible start codons, 
separated by a Serine and Threonine rich sequence, which is thought to act as 
membrane signal for chloroplast translocation.
166,351,396
 For this reason, ATR2 
belongs to class II reductases whereas ATR1 to class I. Interestingly, ATR3 lacks 
this hydrophobic N-terminus and is located in the cytoplasm as well as in the 
nucleus, which was demonstrated by fluorescent spectroscopy of transiently 
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expressed ATR3 fused to GFP (together with the ER-located mRFP-HDEL ER 
marker) in tobacco leafs as well as in tobacco By-2 cells.
395
  
Amino acid sequence analyses demonstrated that ATR1 and ATR2 share 64% 
sequence identity. The ATR2 amino acid sequence shares an identity of 73% with 
the P450 reductase from Catharanthus roseus
391
, whereas the ATR1 shares 65% 
to this reductase. The reductase ATR3 shares only 26% and 24% sequence 
identity with ATR1 and ATR2, respectively, and belongs rather to the subfamily 
of diflavin reductases with a sequence identity of 42% to the human 
nitroreductase NR1 (Figure 4.1).
395
 ATR3 has been shown to interact with 
CIAPIN1, a mammalian cytokine-induced inhibitor of apoptosis, and therefore 
thought to take part in the cell division and programmed cell death.
395
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Figure 4.1: Phylogenetic tree of eukaryotic cytochrome P450 reductases 
with per cent bootstrap value (1000 bootstrap) of 30 CPR sequences and 12 ATR3-like 
sequences according to Varadarajan et al. 2010
395
 (Aa: Artemisia annua, At: Arabidopsis 
thaliana, Ce: Caenorhabditis elegans, Cery: Centaurium erythraea, Chlamy: 
Chlamydomonas reinhardtii, Cr: Catharanthus roseus, Dm: Drosophila melanogaster, 
Gm: Glycine max; Hs, Homo sapiens; Ht, Helianthus tuberosus; Mm, Mus musculus; Mt, 
Medicago truncatula, Os: Oryza sativa, Ostta: Ostreococcus tauri, Pc: Petroselinum 
crispum, Pm: Pseudotsuga menziesii, Ps: Pisum sativum, Pso: Papaver somniferum, Ptd: 
Populus balsamifera subsp. Trichocarpa x Populus deltoids, Rn: Rattus norvegicus, Sc: 
Saccharomyces cerevisiae, Ta: Triticum aestivum, Tc: Taxus chinensis, Vr: Vigna 
radiate, Vs: Vicia sativa)  
ATR1 and ATR2 have conserved binding motifs for FMN, FAD and NADPH, 
which are shown in Figure 4.2.  
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ATR1                        MTSALYASD LFKQLKSIMG TDSLSDDV-- -VLVIATTSL 36 
ATR2 MSSSSSSSTS MIDLMAAIIK GEPVIVSDPA NASAYESVAA ELSSMLIENR QFAMIVTTSI 60 
C. roseus MDSSSEKLSP F-ELMSAILK GAKLDGSNS- -SDSGVAVSP AVMAMLLENK ELVMILTTSV 57 
  
                                                                                                                  FMN-pyrophosphate 
  
ATR1 ALVAG-FVVL LWKKTTADRS GELKPLMIPK SLMAKDEDDD LDLGSGKTRV SIFFGTQTGT 95 
ATR2 AVLIGCIVML VWRRSGSGNS K--R-VEPLK PLVIKPREE- -EIDDGRKKV TIFFGTQTGT 115 
C. roseus AVLIGCVVVL IWRRSSGS-G K--KVVEPPK LIVPKSVVEP EEIDEGKKKF TIFFGTQTGT 114 
  
  
  
ATR1 AEGFAKALSE EIKARYEKAA VKVIDLDDYA ADDDQYEEKL KKETLAFFCV ATYGDGEPTD 155 
ATR2 AEGFAKALGE EAKARYEKTR FKIVDLDDYA ADDDEYEEKL KKEDVAFFFL ATYGDGEPTD 175 
C. roseus AEGFAKALAE EAKARYEKAV IKVIDIDDYA ADDEEYEEKF RKETLAFFIL ATYGDGEPTD 174 
  
                                   FMN-isoalloxazine-ring 
  
ATR1 NAARFYKWFT EENERDIKLQ QLAYGVFALG NRQYEHFNKI GIVLDEELCK KGAKRLIEVG 215 
ATR2 NAARFYKWFT EGNDRGEWLK NLKYGVFGLG NRQYEHFNKV AKVVDDILVE QGAQRLVQVG 235 
C. roseus NAARFYKWFV EGNDRGDWLK NLQYGVFGLG NRQYEHFNKI AKVVDEKVAE QGGKRIVPLV 234 
  
    cytochrome c 
  
ATR1 LGDDDQSIED DFNAWKESLW SELDKLLKDE DDKSVATPYT AVIPEYRVVT HDPRFT---- 271 
ATR2 LGDDDQCIED DFTAWREALW PELDTILREE GDTAVATPYT AAVLEYRVSI HDSEDAKFND 295 
C. roseus LGDDDQCIED DFAAWRENVW PELDNLLRDE DDTTVSTTYT AAIPEYRVVF PDKSDSLISE 294 
  
                                                                                               FAD-pyrophosphate 
  
ATR1 TQKSMESNVA NGNTTIDIHH PCRVDVAVQK ELHTHESDRS CIHLEFDISR TGITYETGDH 331 
ATR2 INMANGNGY- ---TVFDAQH PYKANVAVKR ELHTPESDRS CIHLEFDIAG SGLTYETGDH 351 
C. roseus AN-GHANGYA NGNTVYDAQH PCRSNVAVRK ELHTPASDRS CTHLDFDIAG TGLSYGTGDH 353 
 
 
  
ATR1 VGVYAENHVE IVEEAGKLLG HSLDLVFSIH ADKEDGSPLE SA-VPPPFPG PCTLGTGLAR 390 
ATR2 VGVLCDNLSE TVDEALRLLD MSPDTYFSLH AEKEDGTPIS -SSLPPPFP- PCNLRTALTR 409 
C. roseus VGVYCDNLSE TVEEAERLLN LPPETYFSLH ADKEDGTPLA GSSLPPPFP- PCTLRTALTR 412 
  
ATR1 YADLLNPPRK SALVALAAYA TEPSEAEKLK HLTSPDGKDE YSQWIVASQR SLLEVMAAFP 450 
ATR2 YACLLSSPKK SALVALAAHA SDPTEAERLK HLASPAGKDE YSKWVVESQR SLLEVMAEFP 469 
C. roseus YADLLNTPKK SALLALAAYA SDPNEADRLK YLASPAGKDE YAQSLVANQR SLLEVMAEFP 472 
  
                                                          FAD-isoalloxazine-ring 
  
ATR1 SAKPPLGVFF AAIAPRLQPR YYSISSSPRL APSRVHVTSA LVYGPTPTGR IHKGVCSTWM 510 
ATR2 SAKPPLGVFF AGVAPRLQPR FYSISSSPKI AETRIHVTCA LVYEKMPTGR IHKGVCSTWM 529 
C. roseus SAKPPLGVFF AAIAPRLQPR FYSISSSPRM APSRIHVTCA LVYEKTPGGR IHKGVCSTWM 532 
  
                                                                                   NADPH-ribose, pyrophosphate 
  
ATR1 KNAVPAEKSH ECSGAPIFIR ASNFKLPSNP STPIVMVGPG TGLAPFRGFL QERMALKEDG 570 
ATR2 KNAVPYEKSE NCSSAPIFVR QSNFKLPSDS KVPIIMIGPG TGLAPFRGFL QERLALVESG 589 
C. roseus KNAIPLEESR DCSWAPIFVR QSNFKLPADP KVPVIMIGPG TGLAPFRGFL QERLALKEEG 592 
  
ATR1 EELGSSLLFF GCRNRQMDFI YEDELNNFVD QGVISELIMA FSREGAQKEY VQHKMMEKAA 630 
ATR2 VELGPSVLFF GCRNRRMDFI YEEELQRFVE SGALAELSVA FSREGPTKEY VQHKMMDKAS 649 
C. roseus AELGTAVFFF GCRNRKMDYI YEDELNHFLE IGALSELLVA FSREGPTKQY VQHKMAEKAS 652 
  
                      NADPH-nicotineamide 
  
ATR1 QVWDLIKEEG YLYVCGDAKG MARDVHRTLH TIVQEQEGVS SSEAEAIVKK LQTEGRYLRD 690 
ATR2 DIWNMISQGA YLYVCGDAKG MARDVHRSLH TIAQEQGSMD STKAEGFVKN LQTSGRYLRD 709 
C. roseus DIWRMISDGA YVYVCGDAKG MARDVHRTLH TIAQEQGSMD STQAEGFVKN LQMTGRYLRD 712 
  
ATR1 VW         692 
ATR2 VW         711 
C. roseus VW         714 
Figure 4.2: Amino acid sequence alignment between the CPR from C. roseus and the 
two Arabidopsis reductases ATR1 and ATR2 modified from Mizutani and Otha 
1998
391 
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The typical absorption maxima of flavoproteins
397
 at 455 and 380 nm, with the 
455 nm peak disappearing when reduced with dithionite had been shown by 
Mizutani and Ohta
391
 for ATR1 and ATR2. 
The ATR1 and ATR2 proteins were recombinantly expressed in Saccharomyces 
cerevisiae
166
 and Spodoptera furugiperda
391
 insect cells and shown to have 
activity in vivo and in vitro with cytochrome c and with the Arabidopsis 
CYP73A5 (cinnamate-4-hydroxylase). Microarray analysis 
(https://www.genevestigator.com/gv/) showed that ATR1 is expressed 
constitutively at all developmental stage whereas ATR2 has more fluctuation in its 
expression pattern and showed the highest expression in young flowers 
(Figure 4.3). Expression of ATR3 is at least six times lower at all developmental 
stages than ATR1 or ATR2. 
 
 
Figure 4.3: Expression levels of the three Arabidopsis cytochrome P450 reductases 
ATR1, ATR2 and ATR3 during the plant life cycle  
(from genevestigator, https://www.genevestigator.com/gv/, 15/12/2011) 
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ATR2
ATR3
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The full length ATR1 contains 692 amino acids with an estimated size of 77 kDa 
and ATR2 712 amino acids (79 kDa).
166 
The molecular weight of both reductases 
is similar to that of other higher plant CPRs.
388,398,399
 
 
4.2 Objectives 
The common host for recombinant expression of plant cytochromes P450 as well 
as for the partnering reductases are yeast cells (S. cerevisiae) or insect cells. Both 
are eukaryotic systems which provide all the post-translational machinery for the 
production of proteins associated with eukaryotic membranes. Expression in 
E. coli, however, has the advantages that it is an easy to use and an inexpensive 
expression system. Interestingly, Barnes et al. 1991
318
 reported that P450 
reactions are supported in E. coli without the additional expression of a specific 
reductase. The use of E. coli also has disadvantages. It is a prokaryotic expression 
system and expression can be hindered by different codon bias. Nevertheless, 
soluble enzyme has been produced in bacteria following deletion of the 
hydrophobic N-terminus encoding the membrane anchor region.
57 
In this chapter, the two membrane-associated reductases ATR1 and ATR2 were 
cloned from Arabidopsis and modified at the N-terminus to increase solubility. 
The truncated versions (ATR1tr and ATR2tr) were overexpressed in E. coli, 
purified and activities compared to find the most effective reductases for 
expression in E. coli. Furthermore, the biochemistry of both reductases was 
studied. 
 
4.3 Results 
4.3.1 Primer design for the N-terminal membrane anchor truncated ATR1 
and ATR2 
The two Arabidopsis P450 reductases ATR1 (77 kDa) and ATR2 (79 kDa) have 
both a hydrophobic N-terminal region in the amino acid sequence, which allows 
association with a membrane. The amino acid sequence of both reductases was 
analysed using the software TMHMM and SignalP3.0 (Chapter 2.8.1) (Figure 4.4) 
and the hydrophobic N-termini removed (46 and 73 aa were deleted for ATR1 and 
ATR2, respectively).  
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Figure 4.4: Amino acid sequence analysis of ATR1 N-terminus. 
A full length amino acid sequence of ATR1, B TMHMM blot for analyzing the amino 
acid sequence of ATR1, which indicated a membrane region for around the first 50 amino 
acids, C result of SignalP 3.0 analysis (cleavage prob = probability of cleavage site, n-
region prob = probability of N-terminus of the signal peptide, h-region prob = probability 
of hydrophobic region of signal peptide, c-region prob= probability of C-terminus of 
signal peptide) 
 
MTSALYASDLFKQLKSIMGTDSLSDDVVLVIATTSLALVAGFVVLLWKKTTADRSGELK
PLMIPKSLMAKDEDDDLDLGSGKTRVSIFFGTQTGTAEGFAKALSEEIKARYEKAAVKV
IDLDDYAADDDQYEEKLKKETLAFFCVATYGDGEPTDNAARFYKWFTEENERDIKLQQL
AYGVFALGNRQYEHFNKIGIVLDEELCKKGAKRLIEVGLGDDDQSIEDDFNAWKESLWS
ELDKLLKDEDDKSVATPYTAVIPEYRVVTHDPRFTTQKSMESNVANGNTTIDIHHPCRV
DVAVQKELHTHESDRSCIHLEFDISRTGITYETGDHVGVYAENHVEIVEEAGKLLGHSL
DLVFSIHADKEDGSPLESAVPPPFPGPCTLGTGLARYADLLNPPRKSALVALAAYATEP
SEAEKLKHLTSPDGKDEYSQWIVASQRSLLEVMAAFPSAKPPLGVFFAAIAPRLQPRYY
SISSSPRLAPSRVHVTSALVYGPTPTGRIHKGVCSTWMKNAVPAEKSHECSGAPIFIRA
SNFKLPSNPSTPIVMVGPGTGLAPFRGFLQERMALKEDGEELGSSLLFFGCRNRQMDFI
YEDELNNFVDQGVISELIMAFSREGAQKEYVQHKMMEKAAQVWDLIKEEGYLYVCGDAK
GMARDVHRTLHTIVQEQEGVSSSEAEAIVKKLQTEGRYLRDVW
C SignalP result
B TMHMM result
A amino acid sequence of ATR1
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4.3.2 Cloning of ATR1tr and ATR2tr  
Genes encoding Arabidopsis reductases ATR1 and ATR2 were cloned following 
RNA extraction and reverse transcription into cDNA. The N-terminal truncated 
cDNAs of ATR1tr and ATR2tr were amplified using PCR (Chapter 2.8.2) and the 
truncated reductases were cloned into the LIC-vector using Ligation Independent 
Cloning (Chapter 1.1).  
4.3.3 Expression of ATR1tr and ATR2tr in Escherichia coli 
ATR1tr and ATR2tr were expressed at 20 °C in the two different E. coli 
expression strains Rosetta 2 (DE3) and Rosetta gami 2 (DE3) (conditions see 
Chapter 2.10.1).  
The induced culture showed inhibited cell growth in comparison to the uninduced 
culture (Figure 4.5).  
 
 
Figure 4.5: Cell growth (OD600) after induction of ATR1tr in E. coli Rosetta 2 grown 
in LB medium 
 
The expression of the 72 kDa ATR1tr in Rosetta 2 (DE3) cells was visible by 
SDS-PAGE (Figure 4.6A) and no expression could be detected in the uninduced 
control (Figure 4.6B). No overexpression of either reductases could be achieved 
when using strain Rosetta gami 2 (DE3), so Rosetta 2 (DE3) was used for the 
following experiments. Low amounts of ATR1tr could be expressed in Rosetta 2 
(DE3) cells when M9 minimal media was used (Figure 4.6C and D). 
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Figure 4.6: Analysis of crude extract by SDS PAGE 
A induced and B uninduced E. coli Rosetta 2 (DE3) cells expressing ATR1tr (72 kDa) in 
LB medium and C induced and D uninduced E. coli Rosetta 2 (DE3) cells expressing 
ATR1tr in M9 minimal medium 
 
ATR1tr was purified with Ni-resin material (Chapter 2.10.4). Purification was 
monitored using SDS PAGE (Figure 4.7) and showed that ATR1tr was partly 
soluble, which was purified using Ni-resin material. ATR1tr precipitated during 
dialysis and was again insoluble. To overcome these problems, different 
solubilisation buffers were tested (Chapter 2.10.2). 
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Figure 4.7: SDS PAGE analysis of ATR1tr (72kDa) during Ni-affinity purification 
M marker, 1 whole cells prior sonication, 2 soluble protein fraction, 3 insoluble protein 
fraction, 4 eluted protein, 5 dialysed protein and 6 precipitated protein fraction after 
dialysis 
 
4.3.4 Solubilisation of overexpressed ATR1tr 
Thirty different buffers (Chapter 2.10.2) were tested to increase the solubility of 
the overexpressed ATR1tr and ten out of 30 buffers increased the concentration of 
soluble protein (Figure 4.8). 
 
 
Figure 4.8: Protein concentration of the soluble total protein after overexpression  in 
E. coli Rosetta 2 (DE3) using different solubilisation buffers 0-30 
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Protein fractions from all 30 buffers were analysed using SDS PAGE. The 
strongest signal for ATR1tr was obtained when using the buffers 1, 2, 6, 16, 17, 
18, 20, 24, 25 and 28 (Figure 4.9). Western blot probing using anti-His antibodies 
confirmed these results (Figure 4.10). No signal was detected for the negative 
control containing the empty plasmid when resuspended in buffer 0 or solubilised 
in buffer 18 (lane 0c and 18c, respectively in Figure 4.10).  
 
 
Figure 4.9: SDS PAGE analysis of the total soluble protein using solubilisation 
buffer 0-30. Red box show the overexpressed ATR1tr (72 kDa) 
 
 
Figure 4.10: Analysis of ATR1tr after sonication in different solubilisation buffers 
A Western blot analysis and B SDS PAGE of soluble protein fraction. Red boxes show 
the overexpressed ATR1tr. (Lane 0c = negative control in buffer 0, 18c = negative control 
in buffer 18, 0-28 = overexpressed ATR1tr in different solubilisation buffers) 
 
 
4.3.5 Purification of ATR1tr and ATR2tr in solubilisation buffer 18A 
ATR1tr and ATR2tr were overexpressed under the same conditions described in 
Chapter 2.10.1 and using buffer 18 to assist in the solubilisation of protein. 
However, buffer 18 contains EDTA, making it unsuitable for the purification with 
His-Select Nickel Affinity Gel column. EDTA can scavenge metal ions and 
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therefore complexes the nickel ions so that the His-tagged protein cannot bind. 
Therefore, buffer 18 without EDTA (buffer 18A) was used for the purification of 
ATR1tr and ATR2tr (Chapter 2.10.5).  
A SDS PAGE analysis was performed after the purification of both reductases and 
ATR1tr and ATR2tr were detected (red box in gel A and B, Figure 4.11). The 
empty vector transformed into Rosetta 2 (DE3) was used as negative control 
(Figure 4.11C). 
 
Figure 4.11: SDS PAGE Analysis of the purification of A) ATR1tr (72 kDa), B) 
ATR2tr (71 kDa) and C) negative control (empty vector expressed in E. coli 
Rosetta 2 (DE3)) 
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4.3.6 Characterisation of Arabidopsis P450 reductase ATR2tr 
4.3.6.1 Activity assay with cytochrome c  
The activity of ATR1tr and ATR2tr with cytochrome c was tested for the two 
different co factors NADH and NADPH following the protocol described in 
(Chapter 2.15.1.2) to analyse the impact on the activity. Both Arabidopsis 
reductases displayed greater activity with NADPH over NADH as cofactor 
(Figure 4.12). 
 
Figure 4.12: ATR1tr and ATR2tr activity dependence on the cofactor NADH and 
NADPH 
Assay conditions: 1mg/ml reductase, 50 μM cytochrome c, 110 μM NAD(P)H in 
300 mM potassium phosphate buffer (pH 7.7). The error bars represent the mean of three 
independent replicas ± standard deviation. 
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ATR1tr and ATR2tr activity was compared with two commercial available 
reductases (ferredoxin reductase from spinach and cytochrome c reductase from 
porcine heart). Both, ATR1tr and ATR2tr, showed higher activity in comparison 
to the positive control reductass (Figure 4.13). ATR2tr was diluted from 1 mg/ml 
to 0.01 mg/ml to get a liniar rate. The activity of cytochrome c reductase was not 
significant due to the fact that it showed a higher activity with the cofactor NADH 
than with NADPH.  
 
 
Figure 4.13: Cytochrome c conversion by different reductases in presence of the 
cofactor NADPH  
Assay conditions: reductase (amount, see legend), 50 μM cytochrome c in 300 mM 
potassium phosphate buffer (pH 7.7). The reaction was started after one minute by adding 
110 μM NADPH (ferr red = ferredoxin reductases from spinach, cytC red = cytochrome c 
reductase from procine heart). 
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ATR2tr was with a conversion of 1500 μM cytochrome c/mg ATR2tr 20 times 
more active than ATR1tr (68 μM cytochrome c/min/mg ATR1tr, Figure 4.14). 
Porcine cytochrome c reductase and spinach ferredoxine reductase was used as 
positive control and showed a conversion of 0.5 μM and 7.5 μM 
cytochrome c/min/mg reductase, respectively. The low activity of cytochrome c 
reductase is caused by the cofactor NADPH. Higher values were detected by 
using the cofactor NADH. 
 
 
Figure 4.14: Cytochrome c conversion by different reductases in presence of the 
cofactor NADPH 
ATR1tr = N-terminal truncated Arabidopsis reductase ATR1, ATR2tr = N-terminal 
truncated Arabidopsis reductase ATR2, cytochrome C red = cytochrome c reductase from 
procine heart, ferredoxin red = ferredoxin reductase from spinach 
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4.3.6.2 Temperature and pH optima of ATR1tr and ATR2tr 
Temperature and pH optima for ATR1tr and ATR2tr were performed as described 
in Chapter 2.15.1.3. The temperature optimum of ATR1tr and ATR2tr was 
determined to be 40 °C (Figure 4.15). 
 
 
Figure 4.15: Temperature optimum for ATR1tr (1 mg/ml) and ATR2tr (0.01 mg/ml) 
The error bars represent the mean of three independent replicas ± standard deviation 
 
The pH optima of both Arabidopsis reductases was analysed in Britton Robinson 
buffer (Chapter 2.15.1.3) covering a pH range of pH 3.4 to 11.0. The extinction 
coefficient of cytochrome c (ε(550nm) = 21 mM-1cm-1) was used to calculate the 
activity.  
 
The pH optima of ATR1tr (100 μg/ml) and ATR2tr (1 μg/ml) were detected in 
300 mM Britton Robinson buffer (Chapter 2.15.1.3). The optima of ATR1tr and 
ATR2tr were found to be pH 7.0 and pH 8.0, respectively (Figure 4.16).  
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Figure 4.16: Activity of 100 μg/ml ATR1tr and 1 μg/ml ATR2tr in 300 mM Britton 
Robinson buffer (1:1:1 mixture of boric acid, phosphoric acid
 
and acetic acid) at 
different pH values 
The error bars represent the mean of three independent replicas ± standard deviation. 
 
The reductase activity of ATR2tr was also tested in citrate and phosphate buffer, 
covering a pH range of 4.0 to 7.6 (Chapter 2.15.1.3). ATR2tr showed 
approximately 10% more activity in the citrate and phosphate buffer when 
compared to Britton Robinson buffer (Figure 4.17). 
 
Figure 4.17: Activity of 1 μg/ml ATR2tr in diverse buffers covering different pH 
values 
The error bars represent the mean of three independent replicas ± standard deviation. 
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The activity of cytochrome c as well as the stability of the cofactor NADPH, both 
part of the reductase activity assay, are also pH dependent and can therefor change 
the pH optima of the two reductases. 
Cytochrome c is changing the conformational stated dependent on the pH and has 
an isoelectric point (number of positive and negative charges of the protein are 
equal) around pH 10.
400-403
 NADPH degrades at low pH values (Figure 4.18) and 
so fewer electrons are available for the reaction. Therefore, the reductases activity 
at a pH lower than pH 6.0 was reduced through the instability of NADPH. 
 
 
Figure 4.18:  Stability of the cofactor NADPH at different pH values 
Assay was performed using 50 μM cytochrome c and 110 μM NADPH in 300 mM 
potassium phosphate buffer (pH 7.7). The error bars represent the mean of three 
independent replicas ± standard deviation. 
 
4.3.6.3 Kinetic studies of the reductases ATR1tr and ATR2tr 
The kinetic data for cytochrome c reduction were accomplished following the 
published protocol from Hull and Calenza
351
 (Chapter 2.15.1.4). Vmax and KM 
values were determined using Michaelis-Menten kinetics (software: GraFit) 
(Table 4.1). ATR2tr followed the common Michealis-Menten kinetic, whereas 
ATR1tr was inhibited by the substrate cytochrome c for concentrations higher 
than 100 μM (Figure 4.19). The sample with the highest substrate concentration 
(150 μM cytochrome c) was ignored for the calculation of the kinetic data for 
ATR1tr by Michaelis-Menten (Figure 4.19A). 
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Table 4.1: Kinetic data for ATR1tr and ATR2tr (calculated by the program GraFit) 
reductase 
Vmax  
(μM/min) 
KM  
(μM) 
inhibition 
constant 
kcat 
(s
-1
) 
ATR1tr   
(Michaelis-Menten) 
51 ± 5 23 ± 6  0.1 ± 0.02  
ATR1tr  
(substrate inhibition) 
261 ± 90 170 ± 68 21 ± 9 0.3 ± 0.1 
ATR2tr  
(Michaelis-Menten) 
38 ± 2 16 ± 3  5.0 ± 0.6 
 
 
 
 
Figure 4.19: Michaelis-Menten blots by GraFit for A) ATR1tr by Michaelis-Menten 
equation and B) ATR1tr by equation for substrate inhibition and C) ATR2tr by 
Michaelis-Menten equation 
 
 
m
M
 c
y
to
ch
ro
m
e 
c/
m
in
m
M
 c
y
to
ch
ro
m
e 
c/
m
in
m
M
 c
y
to
ch
ro
m
e 
c/
m
in
A         B
C
cytochrome c (μM) cytochrome c (μM)
cytochrome c (μM)
CHAPTER 4 – ARABIDOPSIS REDUCTASES 
 
130 
 
To illustrate the accuracy of the kinetic data, the direct linear blot from Eisenthal 
and Cornish-Bowden was used.
404
 Here the median of all samples is used to 
estimate the KM and Vmax. As shown in Figure 4.20A the intersection for ATR1tr 
did not match as good as for ATR2tr (Figure 4.20).  
 
 
Figure 4.20: Cornish-Bowden blot for A) ATR1tr and B) ATR2tr 
The different lines represent substrateconcentrations between 4 μM and 150 μM 
cytochrome c. 
 
The specific activity for ATR1tr considering substrate inhibition was                               
50.5 μM·min-1·mg-1 and for ATR2tr 3770 μM·min-1·mg-1. 
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4.3.6.4 Spectrophotometric characterisation of ATR2tr 
P450 reductases have a typical absorption spectrum with a maximum at 375 and 
450 nm. Dialysed ATR2tr (5.1 mg/ml in 10 mM potassium phosphate buffer, 
pH 7.5) was characterised for the presence of flavin by monitoring the absorption 
between 300 and 600 nm (Figure 4.21).  
 
Figure 4.21: UV/Vis spectra of purified recombinant ATR2tr and negative control  
(expressed and purified empty vector) 
 
The diagram illustrated a similar picture to published data with two absorption 
maxima, characteristic for flavins
391 
at 383 and 458 nm. FMN and FAD alone 
have absorption maxima at around 370 and 452 nm (Figure 4.22). 
 
Figure 4.22: UV/Vis spectra of 10 μM FMN and 10 μM FAD in 50 mM potassium 
phosphate buffer pH 7.5 
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4.3.6.5 Activity test of purified ATR2tr in buffer A and B 
As previously described, ATR2tr was purified using a column containing Ni-resin 
material, eluted with buffer 18A (100 mM Tris, 100 mM KCl and 1% Triton X-
100, pH 8.2) containing 500 mM imidazole and dialysed in buffer A (50 mM 
potassium phosphate buffer pH 7.5). Hull and Calenza (2000) suggested another 
dialysis buffer of 30 mM potassium phosphate pH 7.8, 20% glycerol, 0.1 mM 
EDTA, 2.0 μM FMN (called buffer B) stabilising the Arabidopsis reductase 
ATR2.
351
  
The reductase activity was tested using a cytochrome c assay following the 
protocol from Hull and Calenza 2000 (Chapter 2.15.1.2).
351
 ATR2tr activity was 
inhibited in the presence of 500 mM imidazole in 100 mM Tris, 100 mM KCl and 
1% Triton X-100, pH 8.2 (Figure 4.23). The highest activity for ATR2tr was 
obtained after the dialysis in buffer B. 
 
 
Figure 4.23: Michaelis-Menten-diagram of purified ATR2tr 
In buffer 18A (100 mM Tris, 100 mM KCl and 1% Triton X-100, pH 8.2) containing 
500 mM imidazole (blue rhombi), buffer A (50 mM potassium phosphate buffer pH 7.5, 
green triangles) and buffer B (30 mM potassium phosphate pH 7.8, 20% glycerol, 
0.1 mM EDTA, 2.0 μM FMN, red squares). The error bars represent the mean of three 
independent replicas ± standard deviation. 
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4.3.6.6 Stability test of ATR2tr in different buffers 
The reductase ATR2tr was analysed after dialysis in two different buffers: a 
general potassium phosphate buffer pH 7.5 (buffer A) and a potassium phosphate 
buffer pH 7.8 containing FMN and glycerol (buffer B). The samples were stored 
at four different temperatures (-80 °C, -20 °C, 4 °C and 21 °C) and the activity of 
ATR2tr was measured using a cytochrome c assay (Chapter 2.15.1.4). 
ATR2tr was stable at 21 °C for at least two days and was inactive after less than 
six days independent from the storage buffer (Figure 4.24). A 75% and 50% 
decrease of the reductase activity was observed when stored at 4 °C in buffer A 
and B, respectively. ATR2tr was less stable in buffer A and lost activity steadily 
over time (Figure 4.24A). When ATR2tr was kept at -20 °C for 40 days, the 
activity was reduced to 30%, whereas storage at -80 °C meant that the activity 
was only reduced to 50% after the same period of time.  
A 30% loss in activity of ATR2tr was observed upon freezing at -20 °C or -80 °C 
in buffer B; however, no further reduction in activity was found over time.  
In summary, ATR2tr was more stable in buffer B due to the presence of FMN and 
glycerol. 
 
 
Figure 4.24: Stability of ATR2tr over time in A) buffer A (50 mM potassium 
phosphate buffer pH 7.5) and B) buffer  B (30 mM potassium phosphate pH 7.8, 
20 % glycerol, 0.1 mM EDTA, 2.0 μM FMN) 
The error bars represent the mean of three independent replicas ± standard deviation. 
Sample at time 0 days was not frozen and activity  measured at 21 ºC.  
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4.4 Discussion 
The two Arabidopsis reductases ATR1 and ATR2 are necessary partner enzymes 
for all the different P450 reactions in Arabidopsis and supply electrons in single 
steps from the co-factor NADPH to the heme iron in the catalytic centre of the 
P450 enzyme. Both reductases contain a membrane signal at the N-terminus and 
although active full length forms have been expressed previously in the eukaryotic 
hosts yeast
166
 and insect cells
391
, the proteins were predominantly insoluble. 
Activity assays established high stability for ATR1 while activity for ATR2 
rapidly decreased when expressed in a eukaryotic host.
350
 Therefore, to increase 
the amount of soluble protein the hydrophobic N-termini of both enzymes were 
removed in this project and the two truncated reductases ATR1tr and ATR2tr 
(lacking 46 and 73 amino acids, respectively) expressed in E. coli.  
Different E. coli expression strains were tested and the E. coli Rosetta 2 (DE3) 
strain was found to produce the highest yield for both truncated reductases. The 
recombinant, expressed enzymes were partly insoluble, although the N-terminus 
was deleted, and so 30 different solubilisation buffers were tested with ATR1tr to 
increase the solubility. The highest level of soluble ATR1tr, as confirmed by SDS 
PAGE and western blot analysis, was seen in buffer 18 containing 100 mM Tris, 
100 mM KCl, 2 mM EDTA and 1% Triton X-100 (pH 8.2).  
Both ATR1tr and ATR2tr were subsequently purified in buffer 18A (buffer 
18 without the addition of EDTA). The absence of EDTA in buffer 18A did not 
affect the ability to solublilise ATR1tr and ATR2tr, as this characteristic was due 
to the high concentration (1%) of the detergent Triton X-100. Triton X-100, a 
non-ionic detergent used to solubilise membrane proteins.
405
 
The temperature optima for both reductases was found to be at 40 °C and pH 
optima of ATR1tr and ATR2tr were pH 7.0 and pH 8.0, respectively. This pH 
optimum was also found to be similar for other plant reductases, such as the CPR 
from Coleus blumei with pH 7.5.
337 
Activity studies on the two N-terminal truncated Arabidopsis reductases showed 
that both were active with cytochrome c and NADH or NADPH, whereas the 
activity with NADPH as cofactor was 75 and 830 times higher for ATR1tr and 
ATR2tr, respectively. That NADPH is the more effective cofactor is not always 
the case, cytochrome c activity was better supported by NADH for example for 
CHAPTER 4 – ARABIDOPSIS REDUCTASES 
 
135 
 
the CPR from cotton and the CPR from pea.
406,407 
Recombinant expressed ATR2tr 
was 20 fold more active than ATR1tr, or commercial available ferredoxin 
reductases.  
Kinetic values for ATR1tr and ATR2tr were determined with Vmax 51 and 
38 μM/min and KM 23 and 16 μM, respectively, using Michaelis-Menten kinetics. 
ATR1tr showed substrate inhibition, therefore, the interpretation of the data 
should be treated with caution. The kinetic data of ATR2tr were similar to 
published data of native ATR2 expressed in S. cerevisiae (KM 15 μM)
350
 and of 
solubilised ATR2mod from the membrane fraction expressed in E. coli 
(KM 15 μM and 9 U/mg)
351
. The latter authors deleted only 45 amino acids of the 
predicted chloroplast signal, whereas in this project 73 amino acids (the whole 
hydrophobic membrane anchor) were removed. This shows that the N-terminus is 
not part of the catalytic centre, which was also demonstrated for the reductase of 
S. cerevisiae. The native reductase and a truncated soluble reductase (22 amino 
acids deleted at the N-terminus) of S. cerevisiae resulted in similar kinetic values 
for the activity with cytochrome c and CYP61 (forming ergosta-5,7-dienol to 
ergosterol).
408 
Soluble ATR2tr (KM 16 μM) has a 1.4 to 14 lower affinity to cytochrome c 
compared to the KM values of other soluble and truncated eukaryotic P450 
reductases recombinantly expressed in E. coli (1.1 μM for S. cerevisiae CPR408 
and 12 μM for Phanerochaete chrysosporium CPR409). Recombinantly expressed 
and then solubilised full length CPRs showed also a stronger affinity of 
cytochrome c, such as 5 μM for house fly CPR410. Overexpressed and purified 
plant CPRs gave with 7 μM (C. roseus411) two times higher affinity than ATR2tr 
(16 μM, this work). 
ATR2 has two possible start codons, so two possible proteins can be produced. 
ATR2-1 (712 aa) and ATR2-2 (702 aa) were expressed in S. cerevisiae reported 
by Urban et al. 1997
166
. The specific microsomes activity with cytochrome c was 
2.8 μmol·l-1·min-1·mg-1 and 0.3 μmol·l-1·min-1·mg-1 for ATR2-1 and ATR2-2, 
respectively. ATR2tr expressed in E. coli (this project) showed with 3770 μmol·l-
1·min-1·mg-1 more than 1000 higher specific activity than native ATR2-1 
(2.8 μmol·l-1·min-1·mg-1) or ATR2-2 (ten amino acids on the N-terminus deleted, 
0.3 μmol·l-1·min-1·mg-1) expressed in yeast microsomes.166 Albeit, characterisation 
studies of ATR1 and ATR2 resulted in similar specific activity for the conversion 
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of cinnamic acid to coumaric acid when tested with the Arabidopsis P450 
cinnamate-4-hydroxylase (CYP73A5), possibly due to the limited velocity of the 
P450.
166,391 
ATR2tr showed also a higher specific activity when compared with 
other plant reductase, e. g. reductase of Petunia hybrida (30-60 μmol·l-1·min-1·mg-
1
)
412
 and Mentha spicata (43 μmol·l-1·min-1·mg-1)413. Moreover, a lower specific 
activity was reported for P450 reductases from other organisms, for example 
2.85 μmol·l-1·min-1·mg-1 for human reductases recombinant expressed in insect 
cells
414
 or 10.7 μmol·l-1·min-1·mg-1 Candida maltose P450 reductase in 
microsomes after expression in S. cerevisiae
415
. 
The KM value for ATR2tr found in this work was 16 μM and a similar value was 
found when expressed in yeast
350
. The turnover number kcat (the maximum 
number of enzymatic reactions per second) was found to be around three times 
lower for ATR2tr (5 s
-1
) than for native ATR2 expressed in yeast (14 sec
-1
)
 350
. 
ATR2tr, after dialysis in buffer B,
 
exhibited more activity than when assayed in 
general potassium phosphate buffer A due to its low affinity for the coenzyme 
FMN
350
. ATR2tr expressed in E. coli and stored in buffer B at -21 °C or -80 °C 
kept 70% of the original reductases activity using cytochrome c over six weeks 
(Chapter 4.3.6.6). 
In conclusion, the two recombinant expressed Arabidopsis reductases ATR1tr and 
ATR2tr were soluble and active after purification. ATR1tr showed substrate 
inhibition with cytochrome c and was 200 times less active than ATR2tr, which 
performed typical Michaelis-Menten kinetics. The kinetic data of ATR2tr were 
similar to published data, whereas the specific activity was higher and it was 
found to be more stable than reported in the literature. Therefore, ATR2tr was 
selected for the creation of the platform technology containing plant P450s and an 
Arabidopsis reductase (Chapter 5). 
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5 Development of the ATR2tr-LIC platform 
5.1 Introduction 
For industry, E. coli is generally the preferred heterologous host for recombinant 
protein expression and this robust bacterial expression system would be desirable 
for the characterization of Arabidopsis P450s. Plant P450s have been expressed as 
membrane associated proteins in E. coli (more information in Chapter 3). 
Unfortunately, there is no evidence in the literature that plant P450s can be 
soluble and actively expressed in E. coli. The difficulties in expression of plant 
P450s in bacteria are caused by the hydrophobic membrane anchor, the complex 
protein structure and different codon bias between plant and bacteria. Due to this 
challenge, plant P450s have been mainly expressed in mammalian
36
, insect
191,416
 
or yeast
166,328
 cells, but it also has been shown that it is possible to engineer plant 
P450 systems for expression in bacteria as membrane associated proteins
299
. 
As a reductase is necessary for the P450 reaction it would be useful to fuse a P450 
of choice to a reductase to create a self-sufficient system. In 1995, the first 
artificial plant P450 fusion enzyme was recombinantly expressed in E. coli and 
activity detected in membrane preparations.
299
   
 
The following plant cytochromes P450 are described in this Chapter for the 
development of the platform technology where plant P450s are fused to 
Arabidopsis reductase ATR2tr: isoflavone synthase I (IFS), cinnamate-4-
hydroxylase (CYP73A5), N-demethylase (CYP82E4) and CYP81D8 with 
unknown function. 
The native isoflavone synthase I (IFS) from Glycine max, which was already used 
for the artificial fusion of the plant reductases CPR from Catharanthus roseus by 
Prof. Koffas’ group306 was chosen. The enzyme IFS catalyses the two aryl 
migrations (from liquiritigenin to daidzein and from naringenin to genistein) in 
the phenylpropanoid pathway (Figure 5.1). The isoflavones daidzein and genistein 
belong to the class of phytoestrogens and have an antioxidant effect, which 
protects the DNA in the cells from oxidative damage.  
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Figure 5.1: Phenylpropanoid pathway showing the key role of the two P450s IFS 
(CYP93C) and C4H (CYP73A5) used in this project 
PAL = phenylalanine ammonia lyase, C4H = cinnamate-4-hydroxylase, 4CL = 4-
coumarate-CoA-chalcone isomerase, CHS = chalcone synthase, CHR = chalcone 
reductase, CHI = chalcone isomerase, IFS: isoflavone synthase 
 
The construct was kindly provided by Prof. Mattheos Koffas (State University of 
New York, Buffalo, USA) as the artificial fusion IFS-CPR E3
306
 (IFS = isoflavone 
synthase I from G. max fused to the P450 reductase from C. roseus). 
Modifications of the anchor region at the N-terminus of the P450 IFS gene, as 
well as the linker between the P450 and the reductase, were altered to increase the 
isoflavone synthase activity. The highest activity towards naringenin was seen 
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when an N-terminal modified IFS was used. Therefore, the first six N-terminal 
residues were replaced by the synthetic mammalian peptide (amino acid sequence: 
MALLLAVF; ε) and then fused to a truncated C. roseus reductase through the 
linker λ, encoding glycine-serine-threonine (Figure 5.2).306  
 
Figure 5.2: Arrangement of IFS-CPR fusion construct 
IFS = isoflavone synthase I, ε = synthetic sequence encoding mammalian peptide, λ = 
linker, encoding glycine-serine-threonine, CPR = Catharanthus roseus reductases 
(Leonard and Koffas
306
) 
 
 
IFS (GenBank accession number AF195798) belongs to the CYP93C subfamily 
and is closely related to CYP93C1 (97% amino acids sequence, AF022462)
417
.
418
 
The native IFSnat as well as the codon optimised IFSopt (GeneArt) for expression 
in E. coli were both used in these studies. 
The cinnamate-4-hydroxylase (CYP73A5) was selected, because it is a well 
studied P450 from Arabidopsis
419
 and is involved in the phenylpropanoid pathway 
(Figure 5.1), hydroxylating trans-cinnamic acid to p-coumaric acid. It was 
characterised in 1997 after recombinant expression in insect cells.
191 
The CYP82E4 from Nicotiana tabacum was chosen due to its N-demethylase 
activity of nicotine (Figure 5.3), a desired reaction for the pharmaceutical industry. 
Tertiary N-methylamine products from alkaloids are attractive for the 
pharmaceutical industry, such as alkaloids from the opiate family, for example the 
analgesics morphine
420
 and codeine
421
, or tropanes, for example cocaine
422
 and the 
central nerve system stimulating atropine
423
. They are generally produced with 
different chemical methods that often require toxic reagents such as cyanogen 
bromide
422
 or chloroformate esters
424
.  
 
Figure 5.3: N-demethylation of nicotine to nornicotine by CYP82E4 from Nicotiana 
tabacum 
ε IFS                                      CPRλ
nicotine nornicotine
CYP82E4
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The alkaloid nicotine is the main representative in tobacco products. Nornicotine 
can be reduced chemically or when incinerated to nitroso products, such as N’-
nitrosonornicotine, which are toxic and mostly carcinogenic.
425
  
The function of CYP81D8 is not known yet. Nevertheless, this P450 gene was 
found to be more than 30 fold upregulated in Arabidopsis after treatment with the 
explosive 2,4,6-trinitrotoluene (TNT) in a microarray experiment (Chapter 3.1, 
Table 3.2).
363,364
 TNT is an artificial substance, which is highly toxic. It persists in 
the environment and so far no enzyme has been identified able to mineralise this 
compound.
426
 Due to the fact that CYP81D8 is responding to TNT, it may be that 
this P450 is also involved in the transformation of other organic xenobiotics. 
 
5.2 Objectives 
Plant cytochromes P450 are known to catalyse a diverse range of chemistries and 
are attractive targets for oxidative biocatalysis and detoxification of environmental 
pollutants. However, as plant P450s are membrane associated, recombinant 
expression of soluble protein is problematic and as a result very few of these 
enzymes have been characterised.
148
 A strategy to obtain soluble protein when 
expressed in E. coli is the removal of the N-terminal hydrophobic membrane 
anchor region at a molecular level (Chapter 2.8.1). Fusing the N-terminal 
truncated heme domain of plant P450s with an appropriate N-terminal truncated 
reductase could provide the basis for developing robust, soluble redox-self-
sufficient plant enzyme systems for characterisation studies. 
This chapter describes the development of a new technology platform using a 
Ligation Independent Cloning (LIC) vector (Chapter 2.9), in which the truncated 
version of the Arabidopsis P450 reductase ATR2tr was integrated. This novel 
ATR2tr-vector was tested with a selection of plant P450s catalysing different 
P450 reaction types. The technology could be used in a high throughput screen of 
Arabidopsis P450s with the aim of determining plant P450 functions and 
engineering biocatalysts for industrial applications. 
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5.3 Methods 
5.3.1.1 Developing the platform technology of plant P450-ATR2tr fusions 
There are three cytochromes P450 reductases encoded in the Arabidopsis genome. 
A truncated version of the Arabidopsis reductase ATR2 was selected for 
developing the ATR2tr-LIC vector because studies (Chapter 4) had found that 
recombinant ATR2tr had approximately 20 times more activity than ATR1tr. 
ATR3 was not tested, but microarray analysis suggests that it has lower 
expression (Figure 4.3).  
The Arabidopsis reductase ATR2tr was synthesised by GeneArt (Regensburg, 
Germany) to remove the four native BseRI restriction sites and to codon optimise 
the sequence for expression in E. coli. ATR2tr was cloned into the LIC-vector 
using traditional cloning methods (described Chapter 2.8) with BseRI (N-
terminus) and NdeI (C-terminus) restriction sites. 
The linker was inserted at the N-terminal sequence of ATR2tr by PCR. The 
forward primer (Lic_BseRI_F, Table 5.1) was designed to integrate the lic-linker 
and two primers for the lam-linker (lam_BseRI_F1 and lam_BseRI_F2, Table 
5.1), due to its length. The reverse primer (Atr2_NdeI_Lic_R) was designed with 
a NdeI restriction site and lamATR2tr and licATR2tr was amplified by PCR using 
Phusion polymerase (Chapter 2.8.2). 
 
Table 5.1: Primer sequences for cloning ATR2tr into the LIC-vector 
Linker = underlined sequence, restriction site BseRI in forward primer and NdeI in 
reverse primer  = bold, start of ATR2tr synthesised sequence = italics 
primer name sequence 
Lic_BseRI_ F  AGAGAGGGCGCGCCTTCTCCTCAGGTAGCGGTAATAGCAAACGTGTTG 
lam_BseRI_ F1  CTCCTCAGGATCGGGTGGTAGCGGTAATAGCAAACGTGTTG 
lam_BseRI_ F2  AGAGAGGGGGCTCCTGCTCCTCAGGATCGGGTGGTAGCGGT  
Atr2_NdeI_Lic_R  GAGAGACATATG TTACCAAACATCACGCAGATAACG 
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The ATR2tr inserts were purified (Chapter 2.6) and digested sequentially. 
Therefore, 13 μg insert DNA, 15 μl NEB4 buffer (New England Biolabs), 5 U 
NdeI (New England Biolabs) and water to a final volume of 150 μl were 
incubated overnight at 37 °C. Then a further 5 μl NEB4 buffer and 10 U BseRI 
(New England Biolabs) were added and incubated at 37 °C for 1h 50 min. The 
vector (15 μg) was digested under the same conditions as described above in a 
total volume of 300 μl and then separated by agarose gel electrophoresis (0.8% 
w/v agarose, Chapter 2.11) and purified (Chapter 2.6). To avoid re-ligation of the 
vector, the linearised vector (4 μg) was dephosphorylated in a reaction containing 
8 μl 10x arctic phosphatase buffer (New England Biolabs) and 15 U arctic 
phosphatase (New England Biolabs) in a total volume of 80 μl for 1 h at 37 °C 
followed by heat inactivation at 65 °C for 5 min. The ligation of the lamATR2tr or 
licATR2tr insert and the LIC-vector was done in the ratios of 2:1 and 4:1. A total 
volume of 3 μl contained 0.5 μl 10x T4 DNA ligase reaction buffer and 120 U T4 
DNA ligase (New England Biolabs) and the reaction was incubated overnight in a 
2 l water bath with a temperature starting at 21 °C lowered to 4 °C. The ligation 
product was transformed into E. coli DH5α (Chapter 2.8.4), transformants 
screened on selective agar containing kanamycin and verified using the primer 
Lic_BseRI_F, lam_BseRI_F1 and Atr2_NdeI_Lic_R (Table 5.1). Positive clones 
were incubated overnight for plasmid preparation (Chapter 2.5) and a restriction 
digest performed with BseRI and NdeI (Chapter 2.8.6). For final confirmation that 
the right plasmid with the correct sequence was engineered, the gene was 
sequenced (Chapter 2.8.9) using T7 and T7term primers. 
5.3.2 Cloning of P450s into lamATR2tr- and licATR2tr-vector 
5.3.2.1 Primer design  
In cloning experiments, P450 genes were cloned using either their native sequence 
or their codon-optimised sequence for expression in E. coli. Codon optimisation 
was performed by GeneArt (Table 5.2). The full length sequences are found in 
Appendix B. 
CHAPTER 5 – ATR2tr-LIC PLATFORM 
 
143 
 
Table 5.2: List of P450s used for the creation of artificial plant fusions with the 
reductase ATR2tr 
P450 gene origin 
IFSnative  
construct containing the native gene derived from Prof. Mattheos 
Koffas
306
  
IFSopt  synthesized and codon optimized for E. coli expression by GeneArt 
CYP73A5  synthesized and codon optimized for E. coli expression by GeneArt 
CYP82E4  native gene derived from Prof. Ralph Dewey
427
 
CYP81D8  native gene isolated from Arabidopsis thaliana 
 
To each forward primer the sequence CCAGGGACCAGCA was added upstream 
of the start codon of the P450 sequence to create the overhangs for the ligation 
independent cloning. The stop codons of the P450 inserts were removed in order 
to obtain a fusion to ATR2tr. The reverse primers were designed individually for 
each linker (Table 5.3). To prepare the sequence for T4 treatment, as described 
previously, the 3’-end of the sequence was engineered to end with an Adenine (A), 
resulting in a change of the last amino acid: in CYP73A5 the terminal Cysteine 
was changed to a Serine and in CYP82E4 the terminal Tyrosine to a Threonine. 
The last amino acids of IFSori, IFSsyn and CYP81D8 were silent mutations (see 
Appendix B). 
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Table 5.3: Primer sequences for cloning P450 inserts into ATR2tr-LIC-vector  
Lic primer sequence addition in capital letters, insert sequence in small letters 
primer name sequence 
e-IFS for ATR2 fusion F   CCAGGGACCAGCA atggctctgttattagcagtttttcttggtttgttt 
eIFSori-LicATR2tr R GAGGAGAAGGCGCGtgaaaggagtttagatgcaacgccgatccttgc 
eISFori-lamLicATR2tr  R GAGGAGCAGGAGCCtgaaaggagtttagatgcaacgccgatccttgc 
eIFSsyn-native-Lic F     CCAGGGACCAGCA atggcactgctgctggcagtttttctgggtctgtttg 
IFSsyn-trunc-ATR2tr F    CCAGGGACCAGCA gcccgtccgaccccgagcgcaaaaagcaaagcactg 
73A5syn-trunc-Lic F       CCAGGGACCAGCA ctgcgtggtaaaaaactgaaaatgcctccgggtccg 
73A5syn-LicATR2tr R                GAGGAGAAGGCGCG tgagttacgcggtttcatcacaataatgctatg 
73A5syn-lamLicATR2tr R      GAGGAGCAGGAGCC tgagttacgcggtttcatcacaataatgctatg 
82E4-trunc-Lic F       CCAGGGACCAGCA acaaaaaaatctcaaaaaccttcaaaacccttacc 
82E4-LicATR2tr R            GAGGAGAAGGCGCG tgtaagctcaggtgccaggcgaggcgctattatc 
82E4-lamLicATR2tr R      GAGGAGCAGGAGCC tgtaagctcaggtgccaggcgaggcgctattatc 
81D8-trunc-Lic F       CCAGGGACCAGCA ggaaaac tcaagcgaaa gccaaatcta cctccgag 
81D8-LicATR2tr R            GAGGAGAAGGCGCG tacggactcgttgaagattttaacaacagagggac 
81D8-lamLicATR2tr R      GAGGAGCAGGAGCC tacggactcgttgaagattttaacaacagagggac 
 
5.3.2.2 Cloning strategy 
The P450 inserts were amplified by PCR using the high fidelity Phusion 
polymerase. Primers are listed in Table 5.3 and 4 M NDSB 201 (Chapter 2.8.2). 
The purified P450 sequences (Chapter 2.6) as well as lamATR2tr- and licATR2tr-
vector were prepared following the protocol for ligation independent cloning 
(Chapter 1.1). Primer T7 and ATR2seqR (Table 2.4) were used for sequence 
confirmation (Chapter 2.8.9). 
5.3.3 Expression and activity assays of the novel plant fusions 
The expression of the plant P450 fusion was performed overnight at 20 °C 
following the protocol described in Chapter 2.10.1 and activity assay in 
Chapter 2.15.3. 
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5.4 Results 
5.4.1 Developing the platform technology for plant P450-ATR2tr fusions 
5.4.1.1 Designing the linker region between P450 and reductase 
Two different linkers between the P450s and the reductase ATR2tr were tested 
(Figure 5.4).  
 
 
Figure 5.4: Schematic construction of the P450-ATR2tr fusion containing the lam-
linker 
(pT7 = T7 promotor, oLAC = Lac operator, RBS = ribosome binding site, His = 6x 
histidines residues, which can be cleaved HRV 2C protease site = 3C, P450 = cytochrome 
P450, lam = linker between P450 and reductase, ATR2tr = Arabidopsis reductase ATR2 
without hydrophobic N-terminal membrane sequence, tT7 = T7 terminator, f1 ori  = f1 
phage origin of replication, pBR322 ori =  origin of replication of the plasmid pBR322, 
kanR = kanamycin resistence gene, LacI = repressor gene for IPTG induction) 
 
The first linker to be tested was the lic-linker (amino acid sequence: RAFSS), 
which is the necessary overhang in the LIC-vector for the LIC technology 
described in Chapter 1.1. The second linker was the λ-linker (amino acid 
sequence: GST) created by the Koffas group.
306
 The λ-linker and the first five 
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amino acids of the truncated CPR (from C. roseus) resulted in the sequence of 
GSTSSGSG (called lam-linker), which was modified by inserting a BseRI 
restriction site. The codon for the first glycine and for threonine had to be changed 
to be compatible for the ligation independent cloning. Threonine is coded through 
four possible codons (ACN, where N is A, T, G or C), which could not be used, 
because the linker sequence is part of the overhangs created through the T4 
polymerase reaction and therefore must not contain the base adenine. Threonine 
was changed to the similar, neutral, polar amino acid serine and the codon for 
glycine from GGA to GGC in a silent mutation to remove the adenine from the 
nucleotide sequence. However, these changes resulted in four subsequent serines 
and the formation of two BseRI (CTCCTC) sites. Therefore, the threonine was 
changed to cysteine. 
 
 
 
5.4.2 Cloning of ATR2tr into the LIC-vector 
The ATR2tr with the lam-linker or the lic-linker at the N-terminus was cloned into 
the LIC-vector. The lamATR2tr- and licATR2tr-vectors were transformed into 
E. coli DH5α and positive colonies screened using whole cell PCR (Chapter 2.8.2). 
Plasmids of positive clones were purified and digested to verify the correct insert 
(Figure 5.5). 
 
Figure 5.5: Analysis of positive transformants for the presence of the lam-ATR2tr in 
the LIC-vector  
Restriction digest of the LIC-vector (negative control) and lamATR2tr by BseRI (BseR), 
NdeI (Nde) or with both enzymes (2cut) 
 
―   BseR  Nde  2cut    ―   BseR  Nde  2cut
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5.4.3 Cloning of P450 inserts into lamATR2tr and licATR2tr 
The P450 inserts were amplified by PCR using the high fidelity Phusion 
polymerase and cloned into the lamATR2tr- and the licATR2tr-vector. Again 
colonies containing the desired gene were detected by whole cell PCR and correct 
inserts were confirmed by restriction digest of the (Figure 5.6) and sequencing. 
 
 
Figure 5.6: Analysis of positive transformants for the presence of the P450 73A5tr  
Restriction digest with EcoR1 (Eco) of the empty lamATR2tr-vector and the 
transformants 73A5tr-lamATR2tr No1 and 2 containing the insert and No3 with no insert. 
 
 
5.4.4 Expression and activity assays of the novel plant fusions 
5.4.4.1 IFS-ATR2tr fusions 
The isoflavone synthase activity was detected for the conversion of naringenin to 
genistein by HPLC after extraction of the culture supernatant in ethylacetate 
(Chapter 2.15.3.3). Great error bars were received due to the complex extraction 
method and an internal standard war required. Three compounds (syringic acid, 
biochanin A and scopoletin) were chosen to test for their use as internal standard 
for the detection of naringenin and genistein by HPLC (Chapter 2.15.3.3). 
Retention time and absorption maxima for each compound are listed in Table 5.4.  
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Table 5.4: List of chemical compounds considered to use as internal standard 
optimising the extraction method for the two flavonoids naringenin and genistein 
chemical compound                                                     
(IUPAC name) 
molecular 
weight 
absorption 
maximum 
retention 
time 
naringenin                                                                             
(5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one) 
272 g/mol 291 nm 12.0 min 
genistein                                                                           
(5,7-Dihydroxy-3-(4-hydroxyphenyl)chromen-4-one) 
270 g/mol 261 nm 16.8 min 
syringic acid                                                                      
(4-hydroxy-3,5-dimethoxybenzoic acid) 
198 g/mol 276 nm 4.2 min 
biochanin A                                                                               
(5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one) 
284 g/mol 260 nm 16.8 min 
scopoletin                                                                                        
(7-Hydroxy-6-methoxycoumarin) 
192 g/mol 
230 & 346 
nm 
4.8 min 
 
Syringic acid could be not detected after extraction, however it was stable at room 
temperature in methanol over days. Syringic acid was lost during the extraction, 
due to the deprotonation of the carboxyl group and so it was not extracted into the 
organic phase of ethyl acetate. Therefore, syringic acid was not used as internal 
standard when using this method. 
 
Biochanin A is a homologue of genistein and therefore, expected to have similar 
properties. Unfortunately, biochanin A is not very stable at room temperature and 
has the same retention time of 16.8 min as genistein (Figure 5.7) and therefore 
unsuitable as internal standard. 
 
Figure 5.7: HPLC analysis of the flavonoids biochanine A, genistein and naringenin 
HPLC chromatogram at 260 nm for a sample mix of biochanin A (50 μM, retention time: 
16.8 min), naringenin (50 μM, retention time: 12.0 min) and genistein (50 μM, retention 
time: 16.8 min); HPLC conditions: 50 μl sample was applied to HPLC, TechSphere 
column, 1 ml/min isocratic flow 50% water, 50% methanol with 0.1% acetic acid, column 
temperature: 25 °C, sample temperature: 21 °C, run time 23 min 
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Scopoletin elutes earlier than naringenin and genistein with a retention time of 
4.8 min (Figure 5.8). It is stable at room temperature over days and also during the 
extraction step and was therefore chosen as internal standard for the isoflavone 
synthase activity assay (Chapter 2.15.3.3). 
 
Figure 5.8: HPLC analysis of the flavonoids scopoletin, naringenin and genistein 
HPLC chromatogram at 280 nm for scopoletin (50 μM, retention time: 4.8 min), 
naringenin (50 μM, retention time: 12.0 min) and genistein (50 μM, retention time: 
16.8 min); HPLC conditions: 50 μl sample was applied to HPLC, TechSphere column, 
1 ml/min isocratic flow 50% water, 50% methanol with 0.1% acetic acid, column 
temperature: 25 °C, sample temperature: 21 °C, run time 23 min 
 
 
5.4.4.1.1 Activity in a growing cell assay 
The isoflavone synthase I activity of the different artificial fusions was tested in a 
growing cell assay. The conversion of the substrate naringenin (50 μM) to 
genistein was observed by analysing samples of the culture supernatant over time. 
No genistein was produced by the recombinant expressed fusions containing the 
native IFS gene (Figure 5.9). For the codon optimised IFSopt-lamATR2tr and 
IFSopt-licATR2tr 5 μM (10% conversion) and 10 μM (20% conversion) genistein 
were detected after 48 h, respectively. No activity was found for the negative 
controls IFS (in the LIC-vector, data not shown), empty lamATR2tr or empty 
licATR2tr. 
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Figure 5.9: Activity of Glycine max IFS fused to Arabidopsis ATR2tr 
Genistein production in a growing cell assay by artificial plant P450 fusions 
(IFSnat = native isoflavone synthase I from G. max, IFSopt = isoflavone synthase I codon 
optimized for E. coli expression, lamATR2tr = truncated ATR2 with lamda linker, 
licATR2tr = truncated ATR2 with lic-linker). The error bars represent the mean of five 
independent replicas ± standard deviation. 
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The fusions containing the IFS and ATR2tr were analysed by SDS PAGE and 
western blot analysis using anti His-antibodies (Chapter 2.14.1) and anti ATR2-
antibodies (Chapter 2.14.2). No signal was received for the fusions using anti His-
antibodies, possibly a result of a not accessible His-tag. 
The IFS fusions containing the native gene did not show a signal, possibly 
because expression levels were below detection limits. 
The IFSopt-lamATR2tr and IFSopt-licATR2tr were detected only in the insoluble 
fraction (Figure 5.10) and were identified by MALDI-MS analysis (Chapter 
2.15.2). In all sample (total protein, soluble and insoluble protein fraction) was 
found ATR2tr (72 kDa) implying a degradation of the fusions. For positive 
control was used lamATR2tr without IFS.  
 
Figure 5.10: A) SDS-PAGE and B) western blot analysis (anti ATR2-antibodies) of 
Glycine max IFS fused to Arabidopsis ATR2tr  
Analysis of total protein, soluble and insoluble protein (1 = IFSopt-lamATR2tr, 
2 = IFSopt-licATR2tr, 3 = lamATR2tr control). The protein band with the expected size 
of IFSopt-lamATR2tr and IFSopt-licATR2tr (red boxes) from the insoluble protein 
fraction were sent for Maldi-MS analysis. 
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5.4.4.2 CYP73A5tr-ATR2tr fusions 
5.4.4.2.1 Activity in a resting cell assay 
The CYP73A5 codon optimised gene sequence without the hydrophobic N-
terminus (73A5tr) was fused to ATR2tr using two different linkers. Both fusions, 
73A5tr-lamATR2tr and 73A5tr-licATR2tr, converted cinnamic acid to coumaric 
acid in a resting cell assay, when grown in LB medium. The activity was three to 
five times greater when the fusions were grown in M9 minimal medium than in 
LB medium (Figure 5.11). No product was detected for the empty-ATR2tr 
controls, independent of the used linker. 
 
 
Figure 5.11: Activity of Arabidopsis P450 73A5tr fused to Arabidopsis ATR2tr in 
different media 
Production of coumaric acid by 73A5tr-lamATR2tr and 73A5tr-licATR2tr in a resting 
cell assay after expression in M9 minimal or LB medium at 15 °C and 200 rpm. 
 
Different expression conditions were tested in M9 medium to increase the activity 
of the CYP73A5-fusions. When fusions were expressed shaking (200 rpm) at 
15 °C, resting cell assay showed more than 30% of the cinnamic acid was 
converted to coumaric acid in 24 h. Preliminary results indicated that the 73A5tr-
licATR2tr produced approximately 5% more coumaric acid suggesting slightly 
higher activity than 73A5tr-lamATR2tr.  
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Activity was significantly reduced when cells were grown in M9 medium shaking 
(200 rpm) at 20 °C and 200 rpm (Figure 5.12) in comparison to the result above 
(Figure 5.11).  
 
 
Figure 5.12: Activity of Arabidopsis P450 73A5tr fused to Arabidopsis ATR2tr in 
M9 medium  
Production of coumaric acid by 73A5tr-lamATR2tr and 73A5tr-licATR2tr in a resting 
cell assay after expression in M9 minimal medium at 20 °C and 200 rpm. The error bars 
represent the mean of five independent replicas ± standard deviation. 
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Similar amounts of coumaric acid product (30%) were detected for 73A5tr-
lamATR2tr when expressed at 15 °C and 50 rpm (Figure 5.13) compared to 15 °C 
and 200 rpm. The fusion 73A5tr-licATR2tr only converted substrate to 20% 
coumaric acid at 15 °C and 50 rpm, which is 50% of the conversion received at 
15 °C and 200 rpm (Figure 5.11). 
 
 
Figure 5.13: Conversion of cinnamic acid to coumaric acid by artificial plant fusions 
containing Arabidopsis P450 73A5tr and Arabidopsis ATR2tr in a resting cell assay 
Protein expression at 15 °C and 50 rpm (cinn = cinnamic acid, coum = coumaric acid, 
73A5tr = truncated version of CYP73A5, synthesised and codon optimised for the 
expression in E. coli, lamATR2tr = truncated version of ATR2 with lam-linker, 
licATR2tr = truncated version of ATR2 with lic-linker, control-lamATR2tr and control-
licATR2tr = empty vector control containing the ATR2tr with different linkers). The error 
bars represent the mean of four independent replicas ± standard deviation. 
 
 
 
5.4.4.2.2 Purification of 73A5tr-lamATR2tr 
The fusion 73A5tr-lamATRtr (127 kDa) was subjected to nickel-affinity 
chromatography (Chapter 2.10.5) and then detected by SDS PAGE and western 
blot analysis (Figure 5.14). The 73A5tr-lamAR2tr was mainly present in the 
insoluble and in the eluted protein fraction. The protein band of the expected size 
for 73A5tr-lamATR2tr was sent for MALDI-MS analysis (Chapter 2.15.2) and the 
expected two proteins cinnamte-4-hydroxylase (from Arabidopsis) and NADPH-
ferrihemoprotein reductase (Arabidopsis) were identified. 
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Figure 5.14: SDS-PAGE and western blot analysis (anti His-antibody) of 
Arabidopsis P450 73A5tr fused to Arabidopsis ATR2tr  
A SDS PAGE and B western blot analysis of the different steps during the purification of 
73A5tr-lamATR2tr (1 = soluble protein fraction, 2 = insoluble protein fraction, 3 = run 
through, 4 = wash step 1, 5 = wash step 2, 6 = elution of unspecific bound protein, 
7 = elution of 73A5tr-lamATR2tr). The protein band with the expected size of 73A5tr-
lamATR2tr was sent for Maldi-MS analysis 
 
The different fractions were then tested for the ability to convert cinnamic acid. 
Results showed that activity was only found in the insoluble fraction (Figure 5.15). 
 
Figure 5.15: Cinnamate-4-hydroxylase activity in different fractions of the 
purification of 73A3tr-lamATR2tr  
Observation of A the substrate cinnamic acid and B the product coumaric acid 
 
To confirm this result, 73A5tr-lamATR2tr was expressed again in E. coli 
Rosetta 2 (DE3) and fractions of whole cells, sonicated cells (total protein), 
supernatant (soluble protein) and dissolved pellet (insoluble fraction) after 
sonication and centrifugation were tested for activity and analysed by SDS PAGE 
and western blot analysis. The activity found in whole cells (cell concentration: 
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50 mg/100ml, Figure 5.16A) with 170 μM coumaric acid was reduced to 10% in 
total and to 3% in the insoluble protein fraction (Figure 5.16B).  
 
Figure 5.16: Cinnamate-4-hydroxylase activity of 73A3tr-lamATR2tr in different 
fractions after expression in E. coli  
Production of coumaric acid by 73A5tr-lamATR2tr in A resting cells and B different 
fractions after the sonication 
 
The 73A5tr-lamATR2tr fusion was detected by western blot analysis in the whole 
cells, total and insoluble protein fraction (Figure 5.17). No signal was seen in the 
soluble fraction. 
 
Figure 5.17: SDS-PAGE and western blot analysis of Arabidopsis P450 73A5tr fused 
to Arabidopsis ATR2tr as soluble and insoluble protein  
73A5tr-lamATR2tr fusion (127 kDa) and lamATR2tr (negative control) detected by A 
SDS PAGE and B western blot analysis against anti His-antibodies (1 = whole cells, 
2 = total protein fraction, 3 = fraction of soluble protein, 4 = fraction of insoluble protein) 
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5.4.4.3 CYP82E4tr-ATR2tr fusions 
The N-demethylase (CYP82E4) was truncated to remove the membrane anchor 
(sequence, see Appendix B) and cloned into the lamATR2tr- and the licATR2tr-
vector. The expression was performed in E. coli Rosetta2 (DE3) and M9 minimal 
medium (Chapter 2.10.1). The activity of the fusion was tested using resting cell 
assays following the conversion of nicotine to nornicotine (Chapter 2.15.3.5). 
Nicotine was removed from all samples, including negative controls (control-
lamATR2tr, Rosetta 2 cells, and no cell control) within 45 min (Figure 5.18). The 
disappearance of nicotine was found to be due to the instability of nicotine in 70% 
water and 30% methanol (0.2% phosphoric acid, pH 7.25 with triethylamine). 
 
Figure 5.18: Nicotine removal in a resting cell assay  
The error bars represent the mean of three independent replicas ± standard deviation. 
 
Nevertheless, the reaction mixture was analysed to see if nornicotine was 
produced. Nornicotine standard had a retention time of 4.2 min. Nornicotine could 
not be detected in any of the samples, due to other products of E. coli eluting 
between the retention time of 3.3 to 5.7 min and therefore was not detected 
(Figure 5.19). 
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Figure 5.19: HPLC analysis (reversed-phase column) of the crude cell extract for 
nicotine and nornicotine.  
HPLC chromatogram for A 82E4tr-lamATR2tr and B control-lamATR2tr after a reaction 
time of 10 min in a resting cell assay (17.2 min = nicotine), HPLC conditions: SunFire 
C18 column, 1 ml/min flow isocratic 70% water (0.2% phosphoric acid, pH 7.25 with 
triethylamine) and 30 % methanol (0.2% phosphoric acid pH 7.25 with triethylamine), 
column temperature: 20 °C, sample temperature: 4 °C. 
 
 
To improve the identification of nornicotine, a chiral column (ChiralPak IA) was 
used. This column was able to separate a commercial racemic mixture of 
nornicotine (Figure 5.20). The enantiomers of nicotine eluted in one peak at 
15.3 min. However, when extracts were tested, it was not possible to isolate 
nicotine or nornicotine using this method. 
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Figure 5.20: HPLC analysis (chiral column) of the crude cell extract for nicotine and 
nornicotine  
HPLC separation of nicotine (retention time: 15.3 min), (R)-nornicotine (9.9 min) and 
(S)-nornicotine (11.7 min), HPLC conditions:  ChiralPak IA column, isocratic 0.5 ml/min 
flow of 35% ethanol and 65% (heptanes ; isoporpanol : TFA = 90:10:0.1) , 1 mM (R/S)-
nicotine, 1mM (R/S)- nornicotine 
 
 
Both fusions, 82E4tr-lamATR2tr and 82E4tr-licATR2tr (128 kDa, red boxes in 
line 3 and 4, respectively, Figure 5.21), were detected by SDS PAGE and western 
blot analysis (with anti His-antibodies) in the insoluble fraction. 
 
Figure 5.21: SDS-PAGE and western blot analysis of Nicotiana tabacum P450 
82E4tr fused to Arabidopsis ATR2tr  
Analysis of crude extract by SDS-PAGE A in soluble fraction and B in insoluble fraction 
as well as by western blot analysis against anti His-antibodies C in soluble fraction and D 
in insoluble fraction (1 = control-licATR2tr, 2 = Rosetta 2 cells, red boxes: 3 = 82E4tr-
lamATR2tr, 4 = 82E4tr-licATR2tr) 
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5.4.4.4 CYP81D8tr-ATR2tr fusions 
The 81D8tr-lamATR2tr and 81D8tr-licATR2tr were expressed in Rosetta 2 (DE3) 
and tested for activity against 100 μM TNT. There were no differences in TNT 
transformation between the fusion proteins (81D8tr-lamATR2tr and 81D8tr-
licATR2tr) and the negative control (Figure 5.22) and no additional peaks were 
seen. 
 
 
Figure 5.22: TNT removal in a resting cell assay over time 
The error bars represent the mean of four independent replicas ± standard deviation. 
 
As the endogenous function of CYP81D8 is unknown, the 81D8tr-fusions were 
also tested with 7-ethoxycoumarin, a model P450 substrate, in resting cell assays. 
The concentration of 7-ethoxycoumarin remained constant (Figure 5.23) and no 
product peak appeared over time. 
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Figure 5.23: Resting cell assay using 7-ethoxycoumarin as substrate  
The error bars represent the mean of four independent replicas ± standard deviation. 
 
The 81D8tr-lamATR2tr (125 kDa) and 81D8tr-licATR2tr (125 kDa) were 
detected in the insoluble fraction by SDS PAGE and western blot analysis 
(Figure 5.24). No signal was visible in the soluble fraction except for control-
licATR2tr (72 kDa). 
 
 
Figure 5.24: SDS-PAGE and western blot analysis of Arabidopsis P450 81D8tr fused 
to Arabidopsis ATR2tr  
Detection of proteins by SDS A in soluble fraction and B in insoluble fraction as well as 
by western blot analysis against anti His-antibodies C in soluble fraction and D in 
insoluble fraction (1 = control-licATR2tr, 2 = Rosetta 2 cells, red boxes: 3 = 81D8tr-
lamATR2tr, 4 = 81D8tr-licATR2tr) 
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5.5 Discussion 
A platform for expression of plant P450s fused to plant P450 reductases was 
developed by cloning the Arabidopsis reductase ATR2tr. ATR2tr was expressed 
in a soluble form in E. coli and chosen for the development of the platform 
technology due to its higher activity than other plant reductases, such as 
Arabidopsis ATR1tr, ferredoxin reductase and cytochrome c reductase 
(Chapter 4).  
ATR2tr was cloned into the LIC-vector using traditional cloning methods. The 
connection between the P450 and the reductases was realised by a linker. Two 
different linkers (lic-linker and lam-linker) were tested. To test this platform, four 
plant P450s catalysing different reaction types were selected as candidate P450s. 
The hydrophobic membrane anchor regions of the selected P450s, as identified 
using TMHMM and SignalP3.0 software (Chapter 2.8.1) were removed and 
P450s (except CYP93C1 was used with a modified N-terminus
306
) cloned into 
lamATR2tr- and licATR2tr-vector using ligation independent cloning, expressed 
and assayed. 
Expression of the artificial plant fusions in the E. coli host did not affect the cell 
growth under the conditions tested here, although it was reported that the fusion of 
CYP73A4 (cinnamate-4-hydroxylase from C. roseus) to the reductases from 
C. roseus resulted in reduced E. coli growth.
299 
IFS-ATR2tr fusions 
The isoflavin synthase (IFS) was first identified after functional expression in 
yeast and Arabidopsis.
428
 
 
The activity of IFS from Glycine max fused to ATR2tr was tested in a growing 
cell assay for the conversion of naringenin to genistein. No genistein was 
produced using the native IFS gene (IFSnat-lamATR2tr and IFSnat-licATR2tr), 
however a conversion of 10% and 20% was seen after 48 h for the codon 
optimised IFSopt-lamATR2tr and IFSopt-licATR2tr, respectively. The fusion 
IFSsyn-lamATR2tr converted 5.9 μM cinnamic acid to coumaric acid in resting 
cell assays after 18 h. Other research groups produced similar amounts of 
genistein (3.7 μM) with yeast microsomes containing IFS after 10 h.428  
An example of another artificial plant fusion of rcIFS-riceCPR (IFS from red 
clover fused to rice reductases) expressed in E. coli produced 63% genistein after 
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12 h in a growing cell assay (using LB medium),
307
 which was three times higher 
than when IFS fused to ATR2tr (this project). 
73A5tr-ATR2tr fusions 
The Arabidopsis CYP73A5 hydroxylates cinnamic acid to coumaric acid. Both 
fusions (73A5tr-lamATR2tr and 73A5tr-licATR2tr) were expressed in E. coli and 
activity was shown in resting cell assays. The conversion to coumaric acid was 
increased by altering the growth conditions prior to the resting cell assay. 
Expression overnight in M9 medium resulted in five fold higher activity (after 
24 h cell assay). The opposite effect was demonstrated for rcIFS-riceCPR 
expressed in E. coli, where the production of genistein was reduced to 35% when 
M9 instead of LB medium was used.
307
 At a yield of 35% genistein after 48 h the 
substrate naringenin is not used up (still 50% remained), which could be a result 
of low enzyme activity when the substrate concentration is too low. This can be 
tested by adding again naringenin. Another reason of this phenomen could be the 
consumption of the cofactor NADPH, which is only replaced when a carbon 
source in E. coli is available. Resting cell assays were usually perfomed in 50 mM 
potassium phosphate buffer (Chapter 2.15.3.4) without any additional carbon 
source. If the NADPH amount is the limiting factor can be tested by adding sugar, 
which will be transferred into the cell and transformed in the pentose phosphate 
pathway to create NADPH. 
Furthermore, in this project it was found that an expression at 15 °C and 200 rpm 
increased the conversion of more than 30%, whereas the activity of 73A5tr-
licATR2tr was 5% higher than for 73A5tr-lamATR2tr.  
The fusion 73A5tr-lamATR2tr was subjected as soluble protein to nickel-affinity 
chromatography to prove the presence of the fusion protein as confirmed in 
western blot and MALDI-MS analysis, however no activity was detected. Activity 
studies and western blot analysis of the different fractions (whole cells, total, 
soluble and insoluble fraction) indicated that 73A5tr-lamATR2tr was present as 
membrane associated protein and therefore found in the insoluble fraction. 
CYP73A4 from C. roseus (a homolog of CYP73A5) and CYP71D12 (tabersonine 
16-hydroxylase from C. roseus), both fused to the reductases from C. roseus were 
also found as active proteins in the membrane fraction.
299,301
 These observations 
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indicate that the association of the P450 with the endoplasmic reticulum is 
necessary for activity.  
82E4tr-ATR2tr fusions 
CYP82E4 from Nicotiana tabacum catalyses the N-demethylation of nicotine to 
nornicotine and both could be separated by HPLC. The novel fusions (82E4tr-
lamATR2tr and 82E4tr-licATR2tr) were expressed in E. coli and activity tested in 
resting cell assays. The substrate nicotine was removed for all tested samples (also 
the negative controls) in less than 1 h, which indicated that nicotine is not very 
stable under the reaction conditions. Moreover, a product peak for nornicotine 
could not be definitive allocated due to the presence of interfering peaks from 
E. coli extract, which appeared around the same retention time as nornicotine. 
Other research groups have avoided this problem by using 
14
C-labelled nicotine as 
substrate for thin layer chromatographic analysis, which is a more sensitive 
method.
427,429-431
  
Nicotine and its derivates were shown to be separated from urine using HPLC 
(reversed-phase C18 column).
432,433
 However, when a chiral column was used to 
identify nornicotine by adapting the method of Demetriou et al. 1993
434 
no 
improved separation could be seen when resting cell assay samples were separated. 
Further attempts to optimise this method were not made due to time constraints.  
These premliminary were unable to confirm whether fusions containing the 
CYP82E4 is active. In the future, GC-MS analysis could be used to detect both 
nicotine and nornicotine. 
81D8tr-ATR2tr fusions 
The Arabidopsis CYP81D8 was 30 times upregulated in a microarray experiment 
in Arabidopsis plants after TNT treatment.
363
 While activity towards TNT by the 
fusions (81D8tr-lamATR2tr and 81D8tr-licATR2tr) was not detected, when 7-
ethoxycoumarin was tested as potential substrate also no product appeared. So 
whether the fusions were active has not yet been confirmed.  E. coli can use TNT 
as nitrogen source.
435-437
 and TNT was reduced to hydroxylaminodinitrotoluenes 
in all samples by the nitroreductases naturally present in E. coli.  
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Two linkers (lic-linker with the amino acid sequence: RAFSS and lam-linker: 
GSTSSGSG) have been tested to create fusions of the P450s and the reductase 
ATR2tr. Generally, the lam-linker resulted in 5-10% higher activity than the lic-
linker when tested with IFS or 73A5 fusions. However, preliminary results 
suggested that the 73A5tr-licATR2tr when grown in M9 medium at 15 °C and 
200 rpm may have similar activity to 73A5tr-lamATR2tr.  
The artificial lam-linker was originally engineered by Prof. Koffas’ research 
group to create a junction of GSTSSGSG with the start of the truncated CPR, 
which should avoid the formation of secondary structure.
306
 In their work, they 
compared the activity of IFS-CPR connected with the lam-linker and the 
construct C, a fusion without a linker, where the IFS C-terminus was directly 
fused to the truncated CPR from C. roseus. Construct C did not produce any 
product when expressed in E. coli JM109, TOP10F’ or BL21Star. However, 
construct C showed activity when expressed in DH5α, which was 50% compared 
to IFS-CPR.
306
 Their findings showed the necessity of a linker to keep a distance 
between P450 and reductase. The same GST-linker was used successfully for the 
artificial plant fusion rcIFS-riceCPR (IFS from red clover fused to rice reductases) 
as rcIFS-CPR (IFS to C. roseus reductases) to allow the two enzymes a separate 
protein folding.
307
  
Previously, Prof. Schröder’s research group also used a ST-linker for engineering 
different plant fusions with the CPR from C. roseus.
299-302
 The dipeptide ST was 
chosen to avoid forming of extensive secondary structures, which can affect the 
electron transfer between the reductase and the P450. 
 
The detection of artificial plant fusion enzymes by western blot analysis seemed 
to be not straightforward, due to lack of data in the literature.
302,305-307
 An active 
fusion of CYP73A4-CPR was only detected when containing the membrane 
anchor of the P450, but then it was not active. Activity was found when the first 
69 amino acids of the P450 have been removed, however no protein signal was 
visible in the immunoblot.
299
 The flavonoid hydroxylase (CYP75 from C. roseus) 
was detected as fusion with the reductase from C. roseus and the reductase from 
Petunia hybrida by western blot analysis.
300
  
All fusions engineered with the Arabidopsis ATR2tr reductase were detected in 
the western blot analysis using anti His-antibodies. They were found mainly in the 
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insoluble protein fraction, which implied that these fusions are still membrane 
associated, despite lacking the hydrophobic N-terminus. The only exceptions with 
no signal in the SDS PAGE and the western blot were the IFS fusions containing 
the native IFS gene (IFSnat-lamATR2tr and IFSnat-licATR2tr), for which also no 
activity was detected, possibly caused by a too low protein expression. The 
presence of plant fusion proteins containing IFS from G. max or IFS from red 
clover was not confirmed so far.
306,307
 
 
This development of a vector, which contained the soluble Arabidopsis reductase 
ATR2tr, is usable for high-throughput cloning due to the Ligation Independent 
Cloning system. ATR2tr, one of the Arabidopsis reductase, would be expected to 
be an appropriate partner enzyme for crating fusion with the 178 Arabidopsis 
P450s with unknown function to discover their native role in the plant.  
This system provides a platform technology, where also other plant P450s can be 
cloned fast and easily as fusion enzymes, which then can be studied further for 
their potential function.  
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6 Comparison of plant Cytochromes P450 fused to 
different reductases 
6.1 Introduction 
The electron transfer from P450 reductases to P450s is species unspecific, in all 
cases examined; for example Nicotiana tabacum was transformed with the rabbit 
liver P450 and showed to be supported endogeneous N. tabacum reductases
438
. 
However, the specific activity of the membrane associated CYP75 (flavonoid 
hydroxylase) from Petunia hybridia fused to its own reductase showed twice 
much activity after recombinant expression in E. coli than when fused to the 
reductase of C. roseus.
300
 Thus, it could be predicted that the reductases in each 
organism should be the most efficient for the support of their corresponding P450s 
considering that they have evolved together. 
The CPR from C. roseus, firstly characterised from Madyastha and Coscia in 
1979 after purification from five day old, etiolated seedlings,
411
 was used as the 
partnering reductase for the creation of artificial plant P450 fusion systems 
(see Table 1.2, page 45). For all the plant-plant fusions, the hydrophobic N-
terminus of the CPR was deleted to avoid an association with the bacterial 
membrane and to increase the solubility.
299-302,306,307
  
The truncated form of ATR2 (ATR2tr) from Arabidopsis was expressed as a 
soluble and active reductase in E. coli (Chapter 4, page 111) and then used as 
partner enzyme to develop a platform technology of a plant P450 fused to a 
Arabidopsis reductase (Chapter 5, page 137). 
The RhF reductase is originally part of the native fusion P450 RhF from 
Rhodococcus sp. which catalyses the O-dealkylation of 7-ethoxycoumarin to 7-
hydroxycoumarin (Figure 1.12).
136,137
 Recently, it was used for the functional 
expression of bacterial P450 fusions.
145,146,439-441
 
 
 
 
6.2 Objectives 
A technology platform comprising plant P450s fused to the truncated Arabidopsis 
reductase ATR2tr was engineered as described in Chapter 5 and in this chapter, 
the system was developed further by testing additional reductases and E. coli 
strains. The reductases were fused to: cinnamate-4-hydroxylase (CYP73A5) from 
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Arabidopsis and isoflavone synthase I (IFS) from Glycine max and the activities 
in vivo compared. 
 
The IFS (CYP93C) gene was fused to three reductases:  
1) the CPR from C. roseus (fusion construct obtained from Prof. Mattheos Koffas, 
Chapter 5.1),  
2) the ATR2tr from Arabidopsis (developed in Chapter 5) and  
3) the RhF reductase from Rhodococcus sp.  
The IFS activity was tested by measuring the conversion of naringenin to 
genistein in growing and resting cell assays. 
 
The cinnamate-4-hydroxylase (CYP73A5) gene was fused to two reductases:  
1) the ATR2tr from Arabidopsis (developed in Chapter 5) and  
2) the RhF reductase from Rhodococcus sp.  
CYP73A5tr from Arabidopsis was chosen as its function in the phenylpropanoid 
pathway is known. The activity of CYP73A5tr was tested for the hydroxylation of 
cinnamic acid to coumaric acid in in vitro as well as in resting cell assays. 
 
 
6.3 Methods 
6.3.1 Expression of IFS-fusions 
6.3.1.1 Expression conditions of IFS-CPR 
The construct IFS-CPR (C-terminus of isoflavone synthase I from G. max fused to 
the N-terminus of the reductases from C. roseus) was kindly provided by 
Professor Koffas (University at Buffalo, The State University of New York)
306
 
and was used as positive control for the IFS-P450-reductase fusion systems. Two 
different E. coli strains were tested: JM109, used for expression of IFS-CPR by 
Leonard and Koffas 2007
306
, and Rosetta 2 (DE3), which contains an additional 
plasmid for eukaryotic rare codons (chloramphenicol resistance, Novagen) (E. coli 
strains, see Table 2.1). Both E. coli strains were transformed with the IFS-CPR 
fusion construct in the pTrcHis2/LacZ vector (ampicillin resistant, Invitrogen) 
(Chapter 2.8.4). 
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For the expression of IFS-CPR, the published protocol from Leonard and Koffas, 
2007
306
 was used. Briefly, a preculture of 10 ml LB medium containing 1% 
glucose and 100 μg/ml ampicillin (additionally 34 μg/ml chloramphenicol for 
Rosetta 2 cells) was inoculated with a single colony and incubated overnight 
shaking (200 rpm) at 37 °C. A volume of 100 ml LB containing 100 μg/ml 
ampicillin (and 34 μg/ml chloramphenicol for Rosetta 2) was inoculated with the 
preculture to an OD600= 0.1 and incubated shaking (200 rpm) at 37 °C. When 
OD600 had reached 0.8, 1 mM IPTG was added and the culture incubated at 30 °C 
under shaking for 3 h. Cells were then harvested and resuspended to an 
OD600= 0.6 in M9 minimal medium (final volume: 100 ml) containing 6 nM 
thiamine and 1 mM IPTG (Figure 6.1). 
 
 
Figure 6.1: Flow scheme of the protocol for the expression of IFS-CPR fusion 
construct according to Leonard and Koffas
306
 
 
 
6.3.1.2 Optimised conditions for the expression of the IFS-RhF fusion 
The fusion protein IFS-RhF (isoflavone synthase 1 from G. max fused to the 
reductases RhF from Rhodococcus sp.) was expressed under the conditions 
described in Materials and Methods (Chapter 2.10.1), with the following 
alteration: After inoculation, the main culture was incubated shaking at 28 °C for 
approximately 16 h. Cultures were then further incubated shaking at 37 °C until 
the OD600 reached 0.6 to 0.8. 
 
 
 
preculture
LB M9
mainculture
3h IPTG
harvested cells + IPTG
+ naringenin
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6.4 Results 
6.4.1 IFS fusions 
6.4.1.1 Expression of IFS-CPR 
The fusion IFS-CPR (isoflavone synthase I from G. max fused to the reductases 
from C. roseus) was expressed in E. coli JM109 and Rosetta 2 (DE3) cells. The 
presence of the plasmid in the strains was confirmed by PCR. 
 
Following the addition of IPTG, the cell density increased for all samples during 
the following 3 h incubation (Figure 6.2). However, following the addition of 
naringenin, during the subsequent growing cell assay, IFS-CPR expression in 
JM109 cells grew two-fold more slowly than the other cultures (Figure 6.2). 
 
 
Figure 6.2: Observation of the cell growth of E. coli JM109 and Rosettas 2 during 
the expression of IFS-CPR  
Data for IFS-CPR in JM109 and Rosetta 2 (DE3) cells represent the mean of three 
independent replicas ± standard deviation. 
 
In the cultures of Rosetta 2 (DE3) cells expressing IFS-CPR, 75% of the substrate 
naringenin was removed from the medium, whereas in the cultures of JM109 cells 
expressing IFS-CPR was no significant uptake of naringenin (Figure 6.3A), also 
small amount of 5 μM genistein was produced. The naringenin concentration 
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increased in the cultures of the untransformed JM109 and Rosetta 2 (DE3) cells, 
possibly due to water evaporation over time. The product genistein was produced 
with IFS-CPR in both E. coli strains, with the conversion five times higher in 
Rosetta 2 (DE3) than in JM109 (Figure 6.3B). Rosetta 2 (DE3) was therefore 
chosen for further experiments.  
 
 
Figure 6.3: Activity of Glycine max IFS fused to Catharanthus roseus CPR when 
expressed with E. coli JM109 and Rosetta 2 cells.  
A naringenin and B genistein concentration in the culture supernatant after an expression 
time of 1 and 24 h (IFS = isoflavone synthase 1 from G. max, CPR = P450 reductase from 
C. roseus). The error bars represent the mean of two to three independent 
replicas ± standard deviation. 
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6.4.1.2 Expression of IFS-RhF 
The expression of IFS-RhF (plant-bacterial fusion) was performed under the same 
conditions as stated for IFS-CPR (Chapter 6.3.1.1). However, activity of the 
isoflavone synthase was lower than IFS-CPR: just 2 μM genistein was produced 
after 24 h (Figure 6.4), which is 12.5 times less than for IFS-CPR.  
 
 
Figure 6.4: Activity of Glycine max IFS fused to Rhodococcus sp. RhF reductase  
In vivo conversion of naringenin to genistein by IFS-RhF. The error bars represent the 
mean of four independent replicas ± standard deviation. 
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By using the optimised protocol (Chapter 6.3.1.2), the in vivo genistein production 
in growing cells containing IFS-RhF over 24 h was improved 10-fold. Thus, the 
plant-bacterial fusion IFS-RhF (red in Figure 6.5) produced more genistein 
(23 μM after 48 h) than the plant-plant fusion IFS-CPR (green in Figure 6.5, 
18 μM after 48 h) in the growing cell assay at 20 °C. No activity was detected for 
the expression of IFS without reductases, the RhF reductases alone, IFS-RhF 
boiled control or E. coli Rosetta 2 (DE3) cells without any plasmid. 
 
 
Figure 6.5: Conversion of naringenin to genistein by IFS-RhF and IFS-CPR in a 
growing cell assay at 20 °C  
IFS = isoflavone synthase 1 from G. max, CPR = P450 reductase from C. roseus, 
RhF = P450 reductase domain from Rhodococcus sp. The error bars represent the mean of 
five independent replicas ± standard deviation. 
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When cells were grown at 15 °C, activity of IFS-RhF and IFS-CPR was reduced 
to around 15 μM genistein for both after 48 h (Figure 6.6). This was 3.2-fold and 
2.5-fold lower for IFS-RhF and IFS-CPR, respectively, than when cells were 
grown at 20 °C. 
 
 
Figure 6.6: Conversion of naringenin to genistein by IFS-RhF and IFS-CPR in a 
growing cell assay at 15 °C 
IFS = isoflavone synthase 1 from G. max, CPR = P450 reductase from C. roseus, 
RhF = P450 reductase domain from Rhodococcus sp. The error bars represent the mean of 
three independent replicas ± standard deviation. 
 
 
The activity seen for IFS-RhF was 10-fold higher than IFS-CPR in growing cell 
assays. Faster growth and an increase in cell mass may explain the rise in 
genistein production for IFS-RhF. Therefore, the OD600 of E. coli Rosetta 2 (DE3) 
was measured over a time course (Figure 6.7), however no significant difference 
was observed. The differences in genistein production might be due to the 
extraction method and the sensitivity in HPLC detection. 
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Figure 6.7: Observation of the optical density during the expression of IFS-CPR and 
IFS-RhF at 20 °C in M9 medium 
The error bars represent the mean of five independent replicas ± standard deviation. 
 
The level of the conversion of naringenin to genistein was similar for IFS-CPR 
and IFS-RhF when tested in a resting cell assay (Figure 6.8). 
 
 
Figure 6.8: Conversion of naringenin to genistein in a resting cell assay  
(nar = naringenin, gen = genistein, IFS = isoflavone synthase 1 from G. max, CPR = P450 
reductase from C. roseus, RhF = P450 reductase domain from Rhodococcus sp., 
control = plasmid containing RhF reductase expressed in E. coli.) The error bars represent 
the mean of five independent replicas ± standard deviation. 
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6.4.1.3 Comparison of the IFS fusions in their growing cell cultures 
The production of genistein by IFS fused to different reductase was compared in 
growing cell assays (Rosetta 2 (DE3), 20 °C and 200 rpm). The IFS-RhF 
produced almost 50% genistein after 48 h and was found to have the highest 
activity in comparison to the other fusions under these conditions (Figure 6.9). 
IFS-CPR showed the second highest activity with 35% genistein production. 
Interestingly, activity for the IFS fusions containing the Arabidopsis ATR2tr as 
reductase partner was only achieved after codon optimisation of the IFS gene. No 
such modification was required for the other two fusions (IFS-RhF and IFS-CPR). 
Rosetta 2 (DE3) harbouring the empty vector did not produce coumaric acid and 
the substrate concentration of cinnamic acid remained unchanged, verifying the 
activity of the created fusion enzymes. 
 
 
Figure 6.9: Production of genistein by IFS fusions in a growing cell assay  
(IFS = isoflavone synthase 1 from G. max, opt = codon optimised gene for E. coli 
expression, nat = native gene of IFS, ATR2tr = truncated version of P450 reductase from 
Arabidopsis ATR2, CPR = P450 reductase from C. roseus, RhF = P450 reductase domain 
from Rhodococcus sp.) The error bars represent the mean of at least four independent 
replicas ± standard deviation. 
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6.4.1.4 Detection of IFS fusion enzymes 
To show the presence of IFS-CPR and IFS-RhF fusions, SDS PAGE and western 
blot analysis (anti-His antibody) were conducted. Faint signals on western blot 
were detected for IFS-RhF in the soluble and insoluble fraction (Figure 6.10). No 
signal was detected for IFS-CPR by western blot analysis, a result of possibly 
through a very low expression of IFS-CPR by the host cells.  
 
Figure 6.10: SDS-PAGE and western blot analysis of Glycine max IFS fused to 
Catharanthus roseus CPR and to Rhodoccocus sp. RhF reductase in the soluble and 
insoluble fraction  
Soluble and the insoluble fraction after the sonication: A SDS-PAGE and B western blot 
(anti-His antibody); (1 = IFS-CPR, 80 kDa; 2 = IFS-RhF, red boxes, 95 kDa, 3 = RhF-
vector control, 36 kDa) 
 
The western blot was repeated with specific antibodies raised against the 
reductase RhF in order to confirm the results obtained using His-antibodies. 
The IFS-RhF fusion was detected in the soluble protein fraction as well as in the 
insoluble protein fraction (Figure 6.11). However, no signal difference was 
detected in the total protein fraction. No degradation product for the fusion (RhF 
alone, 35 kDa) was seen. The control RhF alone was detected in the total, the 
soluble and insoluble protein fraction. 
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Figure 6.11: SDS-PAGE and western blot analysis of Glycine max IFS fused to the 
RhF reductase from Rhodococcus sp. in total, soluble and insoluble protein fraction 
Total, soluble and the insoluble protein fraction after the sonication: A SDS-PAGE and B 
western blot (specific RhF antibody); (1 = IFS-RhF, 95 kDa; 2 = RhF control, 35 kDa) 
 
The fusions IFS-lamATR2tr and IFS-licATR2tr could be not detected by western 
blot analysis using anti His-antibodies. However, both were detected as fusion 
proteins by western blot analysis against specific ATR2 antibodies in the 
insoluble protein fraction (Figure 6.12). No signal was found in the soluble 
protein fraction and also not in the total protein fraction, possibly due to too low 
concentration. The control ATR2tr was visible in the total, soluble and insoluble 
protein fraction (line 3 in Figure 6.12B). ATR2tr alone was also detected in 
samples containing the IFS-fusions suggesting the degradation of the fusion into 
IFS and ATR2tr. 
 
 
Figure 6.12: SDS-PAGE and western blot analysis of Glycine max IFS fused to 
Arabidopsis reductase ATR2tr in total, soluble and insoluble protein fraction  
Total, soluble and the insoluble protein fraction after the sonication: A SDS-PAGE and B 
western blot (specific ATR2tr antibody); (1 = IFS-lamATR2tr, 131 kDa; 2 = IFS-
licATR2tr, 131 kDa, 3 = lamATR2tr control, 72 kDa) 
 
 
kDa        1    2          1     2          1     2
250
130
100
70
55
35
25
A    total          soluble       insoluble
kDa        1     2          1     2          1      2     
250
130
100
70
55
35
25
B total          soluble      insoluble
fusion                                                                           
RhF
kDa         1    2     3         1     2     3         1     2     3
250
130
100
70
55
35
25
A    total               soluble             insoluble
kDa        1    2     3          1     2     3         1     2     3
250
130
100
70
55
35
25
B total                 soluble           insoluble
fusion                                                                          
ATR2tr                                                                           
CHAPTER 6 – COMPARISON OF PLANT P450S FUSED TO DIFFERENT REDUCTASES 
 
179 
 
Reverse transcription PCR (Chapter 2.7) using primers to the IFS gene was used 
to test if the genes encoding IFS-RhF were transcribed (Figure 6.13). A band at 
the predicted size for IFS of 1500 bp was seen using cDNA from IFS-RhF 
expressing cells as E. coli Rosetta 2 (DE3) template. No signal was detected for 
the boiled IFS-RhF control (line b, Figure 6.13). 
 
 
Figure 6.13: Reverse transcription PCR for IFS-RhF  
b = boiled IFS-RhF control, c = RhF control, I = IFS-RhF 
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6.4.1.5 Purification of IFS-RhF 
Fractions of Ni-chromatography purified Rosetta 2 (DE3) expressed IFS-RhF 
were analysed by SDS-PAGE and western blot. IFS-RhF fusion was detected in 
the insoluble (line 2, Figure 6.14) and in the eluted (line 5) fractions. 
 
 
Figure 6.14: SDS-PAGE and western blot analysis of Glycine max IFS fused to 
Rhodococcus sp. RhF reductase after purification with Ni-affinity chromatography 
A SDS PAGE and B western blot of the purification of IFS-RhF (1 = soluble fraction 
after sonication, 2 = insoluble fraction after sonication, 3 = wash step, 4 = elution of 
unspecific protein, 5 = eluted IFS-RhF) 
 
 
6.4.2 CYP73A5tr fusions 
Resting cell assays were conducted on 73A5tr-lamATR2tr, 73A5tr-licATR2tr and 
73A5tr-RhF expressed in E. coli Rosetta 2 (DE3). All fusions converted cinnamic 
acid to coumaric acid, with 73A5tr-lamATR2tr and 73A5tr-licATR2tr producing 
33% and 23% after 24 h, respectively (Figure 6.15). The plant bacterial fusion 
73A5tr-RhF shown with 3.5% genistein production a much lower conversion after 
24 h. There were no decrease in cinnamic acid, nor increase in coumaric acid in 
the cells harbouring the empty vector only (data not shown). 
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Figure 6.15: Cinnamate-4-hydroxylase activity of Arabidopsis P450 73A5tr fused to 
Arabidopsis ATR2tr in a resting cell assay  
73A5tr = truncated version of cinnamate-4-hydroxylase, RhF = P450 reductase domain 
from Rhodococcus sp., ATR2tr = truncated version of P450 reductase from Arabidopsis 
ATR2. The error bars represent the mean of four independent replicas ± standard 
deviation. 
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Subsequent, SDS PAGE as well as a western blot analyses were performed for the 
soluble and the insoluble fraction of the expressed 73A5tr fusions (Figure 6.16 
and Figure 6.17). No bands at the predicted size of the fusion enzymes were found 
in the soluble protein fraction. However bands at the predicted size for all fusions 
(73A5tr-RhF = 91 kDA, 73A5tr-lamATR2tr = 127kDa, 73A5tr-licATR2tr 
= 127 kDa) and the RhF alone (36 kDa) were detected in the insoluble fraction. 
No band was visible for the negative Rosetta 2 cell control. 
 
 
Figure 6.16: SDS-PAGE and western blot analysis of Arabidopsis P450 73A5tr fused 
Arabidopsis ATR2tr or to Rhodococcus sp. RhF reductase in the soluble protein 
fraction  
A SDS PAGE and B western blot analysis against anti His-antibodies (1 = 73A5tr-
lamATR2tr, 2 = 73A5tr-licATR2tr 3 =  73A5tr-RhF, 4 = lamATR2tr control, 5 = RhF 
control, 6 = Rosetta 2 cells) 
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Figure 6.17: SDS-PAGE and western blot analysis of Arabidopsis P450 73A5tr fused 
Arabidopsis ATR2tr or to Rhodococcus sp. RhF reductase in the insoluble protein 
fraction 
A SDS PAGE and B western blot analysis against anti His-antibodies (1 = 73A5tr-
lamATR2tr, 2 = 73A5tr-licATR2tr 3 =  73A5tr-RhF, 4 = lamATR2tr control, 5 = RhF 
control, 6 = Rosetta 2 cells) 
 
 
6.5 Discussion 
The IFS-CPR fusion, an artificial fusion of IFS from G. max coupled to the 71 
amino acid truncated reductase CPR from C. roseus, was developed by Prof. 
Koffas’s research group.306 The genes were fused using an artificial linker λ 
(GST) to reduce the formation of secondary structure and different modifications 
of the IFS N-terminus were tested to try to increase activity as measured by the 
production of genistein from naringenin. In their studies, using JM109 cells, the 
highest yield with around 15 μM (30%) genistein was seen when the construct 
contained the IFS with a synthetic mammalian peptide at the N-terminus fused to 
the 71 amino acid truncated CPR (C. roseus) through the linker λ.306 The 
published work was repeated here using the same cell strain and experimental 
methods, and the fusion protein tested: just 5 μM (10%) genistein was produced 
after 24 h. Additionally, the Rosetta 2 (DE3) strain, which contained an additional 
plasmid for rare codons, was tested. Five times more genistein (25 μM = 50%) in 
vivo was produced by this strain after 24 h and thus it was chosen for further 
analysis.  
The plant P450 IFS was fused to the bacterial reductases RhF from 
Rhodococcus sp. creating the first plant-bacterial self-sufficient system. The RhF 
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reductase is part of a native P450-RhF fusion and was already used for 
engineering artificial fusions with various prokaryotic P450 such as P450cam and 
P450-XplA heme.
146
  
A conversion of 3% genistein was initially detected for IFS-RhF. This was 
optimized to almost 50% genistein production by simplifying the protocol to an 
expression in M9 minimal medium instead of changing the medium after 3 h pre 
expression in LB to M9. Under these optimised conditions, IFS-CPR made 12 μM 
genistein, which is 15% less than IFS-CPR in Rosetta 2 (DE3) under the 
conditions reported by Leonard and Koffas 2007
306
. 
Other groups tested the artificial plant fusion of the isoflavone synthase from red 
clover (Trifolium pratense) (rcIFS) fused to rice (Oryza sativa) reductase (rcIFS-
riceCPR) or the reductases from C. roseus (rcIFS-CPR). While the experimental 
conditions were not identical to those used here, making comparisons difficult, 
the rcIFS-riceCPR fusion showed 75% conversion to genistein when expressed 
in LB after 12 h in resting cell assays, whereas only 26% conversion was 
detected by using M9 medium.
307
  
In this project, two different expression temperatures (20 °C and 15 °C) were 
tested for IFS-CPR and IFS-RhF. The conversion of naringenin to genistein was 
reduced about 22% and 30% for IFS-CPR and IFS-RhF, respectively by dropping 
the temperature from 20 °C to 15 °C.  
Kim et al. reported the conversion of naringenin to genistein by rcIFS-riceCPR, 
performed at 28 °C in a growing cell assay with 63% after 12 h,
307
 which was 
higher than by IFS-RhF (5% conversion to genistein after 12 h at 20 °C, this 
project), possibly caused by the lower temperature used in the growing cell assay. 
The red clover IFS expressed in yeast produced 18% genistein, which was 
increased to 88% genistein when co expressed with the riceCPR in 
S. cerevisiae.
442
 The endogeneous reductase of S. cerevisiae did not transfer the 
electrons from the cofactor to the P450 rcIFS as effectively as the plant reductase 
riceCPR. 
While the isoflavone synthase activity was relatively easy to measure, detecting 
expressed IFS protein by SDS-PAGE or western blot analysis was difficult as 
these methods are less sensitive.  
Unfortunately, no signal was detected for IFS-CPR by western blot analysis (anti-
His-antibody), possibly through the protein fold not exposing the His-tag or 
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because this method is less sensitive than the enzyme assay and the level of IFS 
was below the limits of detection using this technique. Leonard and Koffas 
reported in their publication the in vivo activity of IFS-CPR without recognising 
any in vitro activity of purified enzyme or the detection of the fusion by SDS 
PAGE or western blot.
306
 The fusion IFS-RhF was detected after N-affinity 
chromatography by western blot analysis using His-antibodies. A stronger signal 
for the fusion IFS-RhF was received when blotted against specific RhF reductase 
antibodies. IFS fused to the Arabidopsis reductase ATR2tr (IFS-lamATR2tr and 
IFS-licATR2tr) was only detected in the insoluble protein fraction by western blot 
analysis with specific antibodies raised against the reductase ATR2tr, suggesting 
membrane associated fusion protein. Additional degradation of the fusion to IFS 
and ATR2tr was found. 
 
The Arabidopsis CYP73A5 (cinnamate-4-hydroxylase), lacking 26 amino acids at 
its N-terminus of the hydrophobic membrane anchor, was fused to the truncated 
version of the Arabidopsis ATR2tr and to the RhF reductase from Rhodococcus sp. 
to compare their activities. Both fusions showed the ability to hydroxylate 
cinnamic acid to coumaric acid in resting cell assays. The 73A5tr fused to ATR2tr 
resulted showed 20% higher activity than 73A5tr-RhF (3.5% coumaric acid after 
24 h) demonstrating in this case, that the coupling of a P450 and reductase 
originating from the same plant are more efficient than when the two enzymes are 
derived from different organisms. This is in agreement with the observation also 
made for the flavonoid-3’,5’-hydroxylase (CYP75) from C. roseus fused to the 
CPR of C. roseus, which had a two-fold higher specific acitivity than the 
hydroxylase CYP75 from C. roseus fused to Petunia hybrid reductase.
300
 
However, in conflict with this, studies by Mizutani found that the turnover 
number (amount of substrate molecules that the P450 can convert to product per 
catalytic site and per unit of time) of recombinant CYP73A5 expressed in insect 
cells was similar for the conversion of cinnamic acid to coumaric acid in 
combination with ATR2, or the reductase from Vigna radiate (mung bean) in-
vitro.
191,391
 Urban et al. detected a 4-fold higher turnover rate for cinnamate-4-
hydroxylase from barley (Helianthus tuberosus) co-expressed with yeast 
(S. cerevisiae) reductase in yeast microsomes.
326
 This research group compared 
also the Arabidopsis CYP73A4 co-expressed in yeast with a yeast reductase, 
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Arabidopsis ATR1 and ATR2 (yeast strains WAT11 and WAT21, respectively) 
and found that the turnover rate of CYP73A5 with yeast reductase was two-fold 
higher than with either of the two Arabidopsis reductases.
166
 
 
Additionally, two different linkers (lam- and lic-linker) connecting the P450 
73A5tr and the reductase ATR2tr were tested and the activity of the fusion 
containing the lam-linker was 10% higher than with the lic-linker. Similar was 
seen for the IFS fusions, where IFSsyn-lamATR2tr produced two-fold more 
genestein than IFSsyn-licATR2tr. Both linkers were dependent on the growth 
medium (Chapter 5, page 137). Modifications at the N-terminus, functioning as 
membrane anchor, and the linker reagion joining P450 and reductase may increase 
expression and activity.  
 
The reductases ATR2tr and RhF were expressed independently and in a soluble 
and active form in E. coli Rosetta 2 (DE3). The P450s, lacking their hydrophobic 
membrane anchor, fused to the reductases (ATR2tr or RhF) were expressed as 
active enzymes; however, they still appear to be associated to the membrane and 
are found in the insoluble protein and membrane fraction. This finding implies 
even so the membrane anchor has been removed that the P450 may still be 
associated to the membrane. 73A5tr-fusions lacking the membrane anchor were 
still present in the insoluble fraction. The solubility may be increased by 
modification of the P450 N-terminus, for example replacing the N-terminal region 
with a signal sequence, such as the endogeneous E. coli OmpA signal sequence
443
 
or the sequence of the bovine steroid 17α-hydroxylase (CYP17A), which would 
also be useful for in vitro assays
318,444
. 
 
Previous studies reported that plant P450s fused to a plant reductase have been 
actively expressed in E. coli. Here, optimisation studies have shown that the 
expression strain is important and expression in the Rosetta 2 strain resulted in the 
highest activity in resting cell assays. Additional codon optimisation for E. coli 
expression of IFS increased the activity more than 10% as well as the linker 
region connecting P450 and reductase. Future further optimisation areas to test 
would include the linker region and also the N-terminus of the P450. 
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Soluble expression of plant P450s has been notoriously difficult and proven a 
bottleneck in characterisation of these enzymes. This platform technology shows 
promise for the study of plant P450s using artificial fusions with plant or bacterial 
reductases, because of the advantages of expressing a single fusion enzyme 
instead of two separate ones. Additionally, the platform could be used for in vivo 
activity tests screening a range of substrates, or conversely, to screen a large 
number of P450s for activity to a specific product of interest with the aim of 
identifying and characterising new P450 functions. 
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7 Final Discussion 
Biotransformation is a fast growing sector in industry and is more and more 
displacing synthetic chemistry. The benefits of using biocatalysts for 
transformation include the ability to make enantio- and regiospecific products as 
well as frequently having more environmentally friendly production conditions 
when compared to traditional chemistries.
445,446
  
Cytochromes P450 are fascinating due to their occurrence in all kingdoms of life 
as well as their broad substrate range, regio- and stereospecificity. P450s require a 
corresponding reductase and the cofactor NAD(P)H for their reaction. Human 
P450s occur predominantly bound to the endoplasmic reticulum of liver cells, 
where they are involved in the metabolism of drugs and medicine, hence the 
activities of P450s are intensively studied. Bacterial P450 systems are cytosolic 
and have also been the subject of much research due to their solubility, as well as 
their roles in secondary metabolism. Plants possess significantly more P450s than 
found in mammals or bacteria, with often more than 200 P450s in a single plant 
species. Plant P450s are mainly involved in the reactions of secondary metabolism, 
and are stimulated under stress conditions. They are insoluble due to a strong 
association with an endoplasmic reticulum or organelle membrane, for example 
the membrane of the chloroplast by a serine-threonine rich sequence
351
, and are 
therefore not easy to express actively as recombinant proteins. As a result the 
plant P450s have been examined in much less detail than their counterparts in 
other kingdoms and so for most plant P450s a function is still not known. For 
example, a search of publications on Arabidopsis P450s (reviewed in Chapter 1) 
showed that for 75% of Arabidopsis P450s the native substrate has not yet been 
identified. Given these limitations, the development of a specific system to 
express and assay active plant P450s is necessary. 
A platform technology containing plant P450s fused to appropriate reductases was 
engineered in this project. This technology will provide a system for the study of 
artificial plant P450-reductase fusions and investigation of P450s with unknown 
function with the facility to readily clone P450s in frame, upstream of a reductase. 
Two great advantages of using fusion proteins are that just one protein needs to be 
prepared instead of two separate enzymes, and there is the potential to improve 
activity by more efficient electron transfer from the reductase to the P450. In this 
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project, attention was concentrated on P450s from Arabidopsis due to the 
availability of annotated gene sequences and that this species is of interest many 
members of the plant science community. Native Arabidopsis reductases were 
tested to optimise activity of the P450 fusions. Encoded in the Arabidopsis 
genome are three Arabidopsis P450 reductases: ATR1, ATR2 and ATR3. While 
ATR3 is involved primarily in embryo development
395
, ATR1 and ATR2 are 
expressed predominantly throughout the spatial and temporal development of the 
plant. Both proteins, along with their native membrane anchor regions, have been 
expressed and characterised as membrane proteins in yeast and insect cells.
166,391
 
Although, the main focus of this project is the rapid screening recombinant P450s 
for activity in vivo, expression of soluble fusions would be advantageous for more 
detailed biochemical characterisation. Hence, truncated forms of the reductases 
(ATR1tr and ATR2tr) were expressed without N-terminal hydrophobic membrane 
anchors and cloned into pET-YSBLIC
345
. Expression in E. coli and purification 
by nickel-affinity chromatography were optimised to attain soluble, active ATR1tr 
and ATR2tr. Activity assays, using cytochrome c
349
, showed that ATR2tr was 20 
times more active than ATR1tr. ATR2tr was therefore selected for creating the 
fusion platform technology and cloned into pET-YSBLIC using traditional, non-
LIC, cloning methods. A linker sequence was also inserted at the 5’ end of ATR2tr 
to connect the encoded P450 to the reductase. The lam-linker was developed 
based on the tripeptide linker GST which is often used for artificial plant P450 
fusion systems
306,307
. A second linker, called lic-linker, which has been 
successfully used for fusions of prokaryotic P450s with the RhF reductase from 
Rhodococcus
146,441
, was used. In addition to the ATR2tr, the RhF reductase was 
cloned and tested for activity in E. coli with plant P450s to create plant-bacterial 
P450 fusions. Four different P450s (CYP93C, CYP73A5, CYP81D8 and 
CYP82E4) were selected to show proof-of-principle of the novel plant fusion 
system (Table 7.1).  
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Table 7.1: List of P450-reductase fusion constructs created in this project and their 
tested substrates 
  
P450 
activity Conversion after 24 h in resting cell assays 
 substrate product CPR RhF lamATR2tr licATR2tr 
IFS 
(CYP93C) 
naringenin genistein 
23%
* 
28%
 
30%
* 
28%
 0%
*
 0%
*
 
IFSopt 
(CYP93C)  
naringenin genistein not tested not tested 7%
*
 3%
*
 
73A5tr 
(opt.) 
cinnamic 
acid 
coumaric 
acid 
not tested 4% 33% 23% 
CYP82E4 nicotine nornicotine not tested not tested 0% 0% 
81D8tr TNT, 
DNT, 
MTS, EC 
not tested 
not tested 0% 0% 0% 
opt = gene codon optimized for E. coli expression, TNT = 2,4,6-trinitrotoluen, 
DNT = 2,4-dinitrolouene or 2,6-dinitrotoluene, MTS = methyl-tolyl-sulphide, EC = 7-
ethoxycoumarin, 
*
 experiment performed as growing cell assay 
 
Comparison of reductases, codon usage and linker regions for fusion 
expression 
A comparison of isoflavone synthase (IFS) (CYP93C1 from Glycine max) fused 
to different reductases was performed to test that the P450 activity was dependent 
on the electron transfer by the reductase. As shown in Table 7.1, IFS-CPR and 
IFS-RhF resulted in the highest activities. While the activity of the nativeIFS-
ATR2tr fusion was improved following codon optimisation for expression in 
E. coli, activity was still less than for the IFS-CPR and IFS-RhF fusions.  
A similar comparison using the codon optimised Arabidopsis P450 cinnamate-4-
hydroxylase without the hydrophobic membrane anchor (73A5tr) revealed that, as 
shown in Table 7.1, 73A5tr-ATR2tr had higher activity than the CYP73A5-
bacterial fusion (73A5tr-RhF). 
Expression of native CYP82E4, N-demethylase from Nicotiana tabacum and 
native Arabidopsis CYP81D8 (of unknown function) fused to ATR2tr did not 
result in activity using the tested substrates.  
To assess linker sequences joining the P450 to the ATR2tr the lam- and lic-linkers 
were compared. Although results varied according to experimental conditions, 
overall the lam-linker gave higher activity. 
The results show that plant P450s work best when fused to a reductase from the 
same species. In the absence of a species-specific reductase, the bacterial RhF 
reductase from Rhodococcus could be used as a universal reductase. RhF is part of 
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a native bacterial fusion which has evolved to live in an environment alongside 
the P450. Although in the native fusion the P450 is fused to the C-terminus of 
RhF reductase (Figure 1.11B), in the studies here the plant P450 was fused to the 
N-terminus of the RhF reductase (Figure 7.1). The results also show that codon 
optimisation for expression in E. coli improves activity. As the costs in gene 
synthesis have dropped significantly in recent years, along with improvements in 
software tools to optimise for E. coli codon bias and additional modifications, 
discussed below, at a large (100-1000 sequences) scale, this could now be a viable 
step in enhancing performance of the screen.  
 
The plant P450-plant reductase fusions, or if the plant-specific reductase is 
unavailable, plantP450-RhF fusions, could be used as artificial fusion systems for 
preliminary, high-throughput substrate screens. A secondary screen for P450s not 
expressed during the preliminary screen, could be performed whereby activity is 
achieved by using codon optimisation for E. coli expression and alternative 
reductases. These procedures could also be applied to increase the expression and 
activity of promising P450s for more detailed characterisation.  
 
Improving performance in cell assays  
It was observed that the maximum conversion of substrate into product was 40 % 
(seen with cinnamic acid to coumaric acid after 48 hours). Given that substrate 
levels indicated no other products were being formed, this means that the assay is 
less sensitive than it could be, and potentially expensive, substrate is wasted. 
Analysis of the data (Figure 5.13) showed that the conversion was non-linear, 
with activity slowing down over time. Possible reasons for this are that the 
NADPH in the cells has been depleted to a limiting concentration. NADPH is 
produced via the pentose phosphate pathway. Adding glucose, as a supplemental 
carbon source, to the sample during the assay could address this possible 
limitation in substrate conversion in future experiments. Following Michaelis-
Menten kinetics, at limiting substrate concentrations, enzyme rates decrease with 
substrate concentration decrease. The amount of conversion, and therefore 
sensitivity, could be increased by the addition of more substrate. Ensuring that a 
non-limiting substrate concentration is used, activity with increasing substrate 
concentration could be monitored.  
CHAPTER 7 – FINAL DISCUSSSION 
 
192 
 
Enhancing solubility of the fusions  
All the reductases tested in this project were expressed as active, soluble forms in 
E. coli. However, while fusion proteins were found in both soluble and insoluble 
protein fractions, activity was only found in the insoluble fractions. These results 
indicate that active fusions are associated with a membrane even though the 
membrane targeting signal was removed during the cloning, and that this 
membrane association is P450-specific. Literature reported hydrophobic regions 
on the surface of the P450 like the F-G loop, which is also part of the substrate 
access channel, show interaction with membranes.
97,447
 Studying existing P450 
structures, as well as analysing each target P450 amino acid sequence (used for 
the fusion), would show hydrophobic parts of the enzyme. These could be 
modified if the gene is re-synthesised for codon optimisation, as discussed above, 
to improve solubility of the whole fusion protein. Optimising the N-terminal 
truncation of the P450s further could also lead to improvements in solubility and 
expression yield.
321
 Studying the hydrophobic regions of the P450s responsible 
for the insolubility by interacting with the membrane could identify regions to be 
modified. Beyond this, the mechanism of the electron transfer between reductase 
and P450 could be studied, with particular attention to the linker region, with the 
aim of improving efficiency.
306,441 
 
Future directions for P450-reductase fusion systems 
In this project two fusions systems containing plant P450s fused to the N-terminus 
of the Arabidopsis reductase ATR2tr (Figure 7.1A) or the Rhodococcus RhF 
(Figure 7.1B) reductase have been characterised. Overall, it was shown that both 
fusion systems resulted in active protein and the activity was dependent on the 
P450.  This is the first reported artificial plant P450-bacterial reductase fusion. 
Even though the bacterial and plant reductases are structurally divergent, it is 
remarkable that they both support the P450 reaction. 
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Figure 7.1: Schematic organisation of artificial A) plant-plant fusions (P450-
ATR2tr) and B) plant bacterial (P450-RhF) fusions 
Both fusions are lacking the hydrophobic membrane anchor at the N-terminus of the 
P450s and are fused C-terminally to the reductase. Due to hydrophobic regions on the 
surface of the P450 the fusion might be still membrane associated. 
 
The main outcome of this project is a platform technology that is a useful tool for 
the investigation of novel plant P450 activities. It can be employed for high-
throughput cloning via a ligation independent cloning system enabling a large 
number of P450s to be easily cloned, expressed as fusions in E. coli and screened 
using resting cell assays. However, there are still deficiencies to this system which 
can be addressed. In this way, this technology presents a new opportunity to 
search libraries of plant P450 fusions against a wide range of substrates to 
discover new activities and new biocatalysts for the industrial future. 
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Membrane of the ER
ATR2tr
NADPH+H+
NADP+
P450
RH+O2
ROH+H2O
FMN
FeS
NADPH+H+
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Membrane of the ER
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ROH+H2O
A               B
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Appendix A 
Table A1: Cytochromes P450 in Arabidopsis 
P450 (gene locus) reaction pathway  references 
51G1 (At1g11680) obtusifoliol 14α-
demethylase  
sterols/steroids  183,184 
51G2 (At2g17330) obtusifoliol 14α-
demethylase 
(pseudogene) 
 184 
71A12 
(At2g30750) 
hydroxylation and N-
demethylation of 
pyrazoxyfen 
metabolism of herbicide 
pyrazoxyfen, camalexin 
biosynthesis in roots 
185,186
 
71A13 
(At2g307700) 
dehydration of indole 
acetaldoxime to indole-3-
acetonitrile 
camalexin biosynthesis 187 
71A14 (At5g24960) putative P450   
71A15 (At5g24950) putative P450   
71A16 (At5g42590) putative P450   
71A17P pseudogene fragment   
71A18 (At1g11610) putative P450   
71A19 (At4g13290) putative P450   
71A20 (At4g13310) putative P450   
71A21 (At3g48320) putative P450   
71A22 (At3g48310) putative P450   
71A23 (At3g48300) putative P450   
71A24 (At3g48290) putative P450   
71A25 (At3g48280) putative P450   
71A26 (At3g48270) putative P450   
71A27P 
(At4g20240) 
pseudogene   
71A28 (At4g20235) putative P450   
71B2 (At1g13080) putative P450   
71B3 (At3g26220) putative P450   
71B4 (At3g26280) putative P450   
71B5 (At3g53280) putative P450   
71B6 (At2g24180) putative P450   
71B7 (At1g13110) deethylation of 7-
ethoxycoumarin (with 
cumene hydroperoxide as 
electron donor) 
 188 
71B8 (At5g35715) putative P450   
71B9 (At2g02580) putative P450   
71B10 (At5g57260) putative P450   
71B11 (At5g25120) putative P450   
71B12 (At5g25130) putative P450   
71B13 (At5g25140) putative P450   
71B14 (At5g25180) putative P450   
71B15 (At3g26830) conversion of s-
dihydrocamalexic acid to 
camalexin  
camalexin  189,190 
71A16 (At3g26150) putative P450   
71B17 (At3g26160) putative P450   
71B18P pseudogene   
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P450 (gene locus) reaction pathway  references 
71B19 (At3g26170) putative P450   
71B20 (At3g26180) putative P450   
71B21 (At3g26190) putative P450   
71B22 (At3g26200) putative P450   
71B23 (At3g26210) putative P450   
71B24 (At3g26230) putative P450   
71B25 (At3g26270) putative P450   
71B26 (At3g26290) putative P450   
71B27 (At1g13070) putative P450   
71B28 (At1g13090) putative P450   
71B29 (At1g13100) putative P450   
71B30P 
(At3g53290) 
pseudogene   
71B31 (At3g53300) putative P450   
71B32 (At3g53305) putative P450   
71B33  pseudogene   
71B34 (At3g26300) putative P450   
71B35 (At3g26310) putative P450   
71B36 (At3g26320) putative P450   
71B37 (At3g26330) putative P450   
71B38 (At3g44250) putative P450   
72A7 (At3g14610) putative P450   
72A8 (At3g14620) No native function known, 
hydroxylation of quinidine  
quinidine metabolism 341 
72A9 (At3g14630) putative P450   
72A10 (At3g14640) putative P450   
72A11 (At3g14650) putative P450   
72A12P pseudogene   
72A13 (At3g14660) putative P450 upregulated in response 
to cis-jasmone 
377
 
72A14 (At3g14680) putative P450   
72A15 (At3g14690) putative P450   
72C1 (At1g17060) exact substrate not identified 
(binds typhasterol) 
degradation of 
brassinosteroids  
293,448-450
 
73A5 (At2g30490) 4-hydroxylation of t-
cinnamic acid to p-coumaric 
acid; hydroxylation of 
cinnamic acid analogs 
phenylpropanoid 
pathway, lignin 
biosynthesis 
166,191,192
 
74A1 (At5g42650) allene oxide synthase for 
linoleic acid 
hydroperoxide and linolenic 
acid hydroperoxide 
jasmonate acid 
biosynthesis 
37,45,193-196
 
74B2 (At4g15440) hydroperoxide lyase for 
linoleic acid 
hydroperoxide and linolenic 
acid hydroperoxide  
oxylipin  pathway, 
jasmonate biosynthesis 
197-199
 
75B1 (At5g07990) 3’-hydroxylation of 
narigenin and 
dihydrokaempferol  
phenylpropanoid 
pathway, flavonoid 
biosynthesis 
200
 
76C1 (At2g45560) 10-hydroxylation of geraniol terpenoid indole alkaloid 
biosynthesis 
201
 
76C2 (At2g45570) putative P450 possibly involved in cell 
death 
451
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P450 (gene locus) reaction pathway  references 
76C3 (At2g45580) putative P450   
76C4 (At2g45550) putative P450   
76C5 (At1g33730) putative P450   
76C6 (At1g33720) putative P450   
76C7 (At3g61040) putative P450   
76C8P (At3g61035) pseudogene fragment   
76G1 (At3g52970) putative P450   
77A4 (At5g04660) epoxidation of unsaturated 
C18 fatty acids (oleic, 
linoleic, α-linolenic acid) 
fatty acid metabolism 178 
77A5P pseudogene   
77A6 (At3g10570) in-chain 10-hydroxylation of 
16-hydroxypalmitate 
cutin biosynthesis 202 
77A7 (At3g10560) putative P450   
77A8P pseudogene   
77A9 (At5g04630) putative P450   
77B1 (At1g11600) putative P450   
78A5 (At1g13710) putative P450   
78A6 (At2g46660) putative P450   
78A7 (At5g09970) putative P450   
78A8 (At1g01190) putative P450   
78A9 (At3g61880) putative P450 possibly involved in fruit 
development 
452
 
78A10 (At1g74110) putative P450   
79A2 (At5g05260) conversion of phenylalanine 
to oxime  
benzylglucosinolate 
biosynthesis 
203
 
79A3P 
(At5g35917) 
pseudogene   
79A4P 
(At5g35920) 
pseudogene   
79B2 (At4g39950) conversion of tryptophan 
and tryptophan analogs to 
oxime  
 
 
indole glucosinolate 
biosynthesis, camalexin 
biosynthesis, auxin 
biosynthesis 
204-209
 
79B3 (At2g22330) conversion of tryptophan 
and tryptophan analogs to 
oxime  
 
indole glucosinolate 
biosynthesis, camalexin 
biosynthesis, auxin 
biosynthesis 
204-209
 
79B4P pseudogene   
79C1 (At1g79370) putative P450   
79C2 (At1g58260) putative P450   
79C3P pseudogene   
79C4P pseudogene   
79C5P (At1g58265) pseudogene   
79F1 (At1g16410) N-hydroxylation of homo- to 
tetrahomo-methionine 
(n =  3 to 6)  
(short-chain methionine 
derivatives to 
their aldoximes)  
biosynthesis of aliphatic 
glucosinolates 
210-213
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P450 (gene locus) reaction pathway  references 
79F2 (At1g16400) N-hydroxylation  of long 
chain penta and 
hexahomomethionine to 
their aldoxime  
biosynthesis of aliphatic 
glucosinolates 
211-213
 
81D1 (At5g36220) putative P450   
81D2 (At4g37360) putative P450   
81D3 (At4g37340) putative P450   
81D4 (At4g37330) putative P450   
81D5 (At4g37320) putative P450   
81D6 (At2g23220) putative P450   
81D7 (At2g23190) putative P450   
81D8 (At4g37370) putative P450   
81D10 (At1g66540) putative P450   
81D11 (At3g28740) putative P450 induced by cis-jasmone 377,378 
81F1 (At4g37430) putative P450   
81F2 (At5g57220) 4-hydroxylation of indole-3-
ylmethyl to 4-hydroxy-
indole-3-ylmethyl 
glucosinolate 
indole glucosinolate 
biosynthesis 
214-216
 
81F3 (At4g37400) putative P450   
81F4 (At4g37410) putative P450 possibly involved in the 
indole glucosinolate 
biosynthesis 
217
 
81G1 (At5g67310) putative P450   
81H1 (At4g37310) putative P450   
81K1 (At5g10610) putative P450   
81K2 (At5g10600) putative P450   
82C2 (At4g31970) 5-hydroxylation of 8-
methoxypsoralen to 5-
hydroxy- 
8-methoxypsoralen 
metabolism of trytophan-
derived secondary 
metabolites, possibley 
involved in jasmonic 
acid induced indole 
glucosinolates 
218,219
 
82C3 (At4g31950) putative P450   
82C4 (At4g31940) 5-hydroxylation of 8-
methoxypsoralen to 5-
hydroxy- 
8-methoxypsoralen 
Fe deficiency response, 
possibly through an 
IDE1-like mediated 
pathway 
218,220
 
82F1 (At2g25160) putative P450   
82G1 (At3g25180) (E,E)-geranyllinalool and 
the sesquiterpenoid (E)-
nerolidol into the acyclic 
volatile C16-homoterpene 
4,8, 12-trimethylthdeca-
1,3,7, 11-tetraene (TMTT) 
and the C11-homoterpene 
4,8-dimethyl-1,3,7-
nonathene (DMNT), 
respectively 
 221 
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P450 (gene locus) reaction pathway  references 
83A1 (At4g13770) oxidation of methionine-
derived oximes  
oxidation of p-
hydroxyphenyl-
acetaldoxime, indole-3-
acetaldoxime, 
conversion of aldoximes to 
thiohydroximates 
biosynthesis of aliphatic 
glucosinolate  
222-224
 
83B1 (At4g31500) oxidation of indole-3-
acetaldoxime  
biosynthesis of  indole 
glucosinolate  
222,223,225
 
84A1 (At4g36220) 5-hydroxylation of 
coniferaldehyde, coniferyl 
alcohol and ferulic acid  
phenylpropanoid 
pathway, biosynthesis of 
lignin 
 
 
167,226,227
 
84A4 (At5g04330) putative ferulate-5-
hydroxylase 
 228,229 
85A1 (At5g38970) C6-oxidase for 6-
deoxycastasterone to 
castasterone, other steroids  
conversion of castasterone to 
brassinolide 
biosynthesis of 
brassinolide  
 
230-234
 
85A2 (At3g30180) C6-oxidase for 6-
deoxycastasterone to 
castasterone, other steroids  
conversion of castasterone to 
brassinolide  
biosynthesis of 
brassinolide  
 
230-233,235,236
 
86A1 (At5g58860) ω-hydroxylation of saturated 
and unsaturated C12 to C20 
fatty acids  
fatty acid metabolism, 
biosynthesis of cutin, 
biosynthesis of suberin 
 
237-240
 
86A2 (At4g00360) ω-hydroxylation of saturated 
and unsaturated C12 to C18 
fatty acids 
fatty acid metabolism, 
biosynthesis of cutin 
 
238,241,242
 
86A4 (At1g01600) ω-hydroxylation of saturated 
and unsaturated C12 to C18 
fatty acids 
fatty acid metabolism, 
biosynthesis of cutin 
 
202,238,242,243
 
86A7 (At1g63710) ω-hydroxylation of lauric 
acid  
fatty acid metabolism, 
biosynthesis of cutin 
 
238,242
 
86A8 (At2g45970) ω-hydroxylation of saturated 
and unsaturated C12 to C18 
fatty acids 
fatty acid metabolism, 
biosynthesis of cutin 
 
238,242,244
 
86B1 (At5g23190) ω-hydroxylation for long 
chain fatty acid (C22 and 
C24) 
biosynthesis of suberin,  
fatty acid metabolism, 
polyester monomer 
biosynthesis 
38,245
 
86B2 (At5g08250) putative P450   
86C1 (At1g24540) putative P450   
86C2 (At3g26125) putative P450   
86C3 (At1g13140) hydroxylation of fatty acids 
(C12, C14, C14:1, C16) 
fatty acid metabolism  246 
86C4 (At1g13150) putative P450   
87A2 (At1g12740) putative P450 possibly involved in 
auxin signaling 
453
 
87A3P pseudogene   
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P450 (gene locus) reaction pathway  references 
88A3 (At1g05160) oxidation of ent-kaurenoic 
acid to gibberillin A12 in 
three steps 
biosynthesis of 
gibberellins  
39,247
 
88A4 (At2g32440) oxidation of ent-kaurenoic 
acid to gibberillin A12 in 
three steps 
biosynthesis of 
gibberellins 
39,247
 
89A2 (At1g64900) putative P450   
89A3 (At5g61320) putative P450   
89A4 (At2g12190) putative P450   
89A5 (At1g64950) putative P450   
89A6 (At1g64940) putative P450   
89A7 (At1g64930) putative P450   
89A9 (At3g03470) putative P450   
90A1 (At5g05690) 23α-hydroxylation of 
steroids 
 
biosynthesis of 
brassinolide  
 
171,172,248,249
 
90B1 (At3g50660) 22α-hydroxylation of C27, 
C28, C29 sterols 
biosynthesis of 
brassinolide  
 
169,249-251
 
90C1 (At4g36380) C23-hydroxylation of sterols 
(typhasterol to castasterone) 
biosynthesis of 
brassinolide  
 
252-255
 
90D1 (At3g13730) C23-hydroxylation of sterols biosynthesis of 
brassinolide  
253-255
 
93D1 (At5g06900) putative P450   
94B1 (At5g63450) putative P450   
94B2 (At3g01900) putative P450   
94B3 (At3g48520) 12-hydroxylation of 
jasmonoyl-L-isoleucine  
oxidative catabolism of 
jasmonate, jasmonate 
mediated signaling 
pathway 
256,257
 
94C1 (At2g27690) ω-hydroxylation of saturated 
and unsaturated C12 to C18 
fatty acids and 
hydroxylation of ω-hydroxy 
fatty acid into  
dicarboxylic fatty acid 
fatty acid metabolism 240,258 
94D1 (At1g34540) putative P450   
94D2 (At3g56630) putative P450   
94D3P pseudogene   
96A1 (At2g23180) putative P450   
96A2 (At4g32170) putative P450   
96A3 (At1g65340) putative P450   
96A4 (At5g52320) putative P450   
96A5 (At2g21910) putative P450   
96A6P 
(At5g51900) 
pseudogene   
96A7 (At1g47630) putative P450   
96A8 (At1g47620) putative P450   
96A9 (At4g39480) putative P450   
96A10 (At4g39490) putative P450   
96A11 (At4g39500) putative P450   
96A12 (At4g39510) putative P450   
APPENDIX A 
 
200 
 
P450 (gene locus) reaction pathway  references 
96A13 (At5g02900) putative P450   
96A14P 
(At1g66030) 
pseudogene   
96A15 (At1g57750) hydroxylation of midchain 
alkane to alcohols and 
second hydroxylation to 
ketone 
biosynthesis of wax 259 
97A3 (At1g31800) ß-hydroxylation of carotene carotenoid metabolism 260,261 
97B3 (At4g15110) ß-hydroxylation of ß-
carotene to zeaxanthin via ß-
cryptoxanthin 
carotenoid metabolism 262 
97C1 (At3g53130) ε-hydroxylation of ß,ε-
carotene 
carotenoid metabolism  260,263 
98A3 (At2g40890) 3-hydroxylation of p-
coumarate to caffeic acid 
and 3-hydroxylation of 
coumaroyl-esters (shikimate 
and quinate esters) 
phenylpropanoid 
pathway, biosynthesis of 
lignin monomers and 
soluble phenolics 
168,264-267
 
98A8 (At1g74540) meta-hydroxylation of the 
three triferuloylspermidine 
phenolic rings, 
oxygenation of resveratrol 
alternative phenolic 
pathway, pollen 
development 
268,269
 
98A9 (At1g74550) meta-hydroxylation of the 
three triferuloylspermidine 
phenolic rings, 
oxygenation of resveratrol 
alternative phenolic 
pathway, pollen 
development 
268,269
 
701A3 (At5g25900) oxidation of ent-kaurene to 
ent-kaurenoic acid in three 
steps 
biosynthesis of 
gibberellin 
39,270-273
 
702A1 (At1g65670) putative P450   
702A2 (At4g15300) putative P450   
702A3 (At4g15310) putative P450   
702A4P pseudogene   
702A5 (At4g15393) putative P450   
702A6 (At4g15396) putative P450   
702A7P pseudogene   
702A8 (At3g30290) putative P450   
703A2 (At1g01280) in-chain monohydroxylation 
of saturated fatty acids (C10-
C16) 
biosynthesis of 
sporopollenin, pollen 
development 
274
 
704A1 (At2g44890) putative P450   
704A2 (At2g45510) putative P450   
704B1 (At1g69500) ω-hydroxylation of 
saturated, unsaturated and 
epoxy C16 and C18 fatty 
acids 
biosynthesis of 
sporopollenin, pollen 
development 
275,276
 
705A1 (At4g15330) putative P450   
705A2 (At4g15350) putative P450   
705A3 (At4g15360) putative P450   
705A4 (At4g15380) putative P450   
705A5 (At5g47990) conversion of thaliandiol to 
desaturated thaliandiol 
thalianol metabolic 
pathway 
277
 
705A6 (At2g05180) putative P450   
705A8 (At2g27000) putative P450   
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P450 (gene locus) reaction pathway  references 
705A9 (At2g27010) putative P450   
705A10P pseudogene   
705A11P pseudogene   
705A12 
(At5g42580) 
putative P450   
705A13 
(At2g14100) 
putative P450   
705A14P pseudogene   
705A15 
(At3g20080) 
putative P450   
705A16 
(At3g20083) 
putative P450   
705A17P pseudogene   
705A18 
(At3g20090) 
putative P450   
705A19 
(At3g20100) 
putative P450   
705A20 
(At3g20110) 
putative P450   
705A21 
(At3g20120) 
putative P450   
705A22 
(At3g20130) 
putative P450   
705A23 
(At3g20140) 
putative P450   
705A24 
(At1g28430) 
putative P450   
705A25 
(At1g50560) 
putative P450   
705A26P pseudogene    
705A27 
(At1g50520) 
putative P450   
705A28 putative P450   
705A29P pseudogene   
705A30 
(At3g20940) 
putative P450   
705A31P pseudogene    
705A32 
(At3g20950) 
putative P450   
705A33 
(At3g20960) 
putative P450   
705A34P pseudogene   
706A1 (At4g22690) putative P450   
706A2 (At4g22710) putative P450   
706A3 (At5g44620) putative P450   
706A4 (At4g12300) putative P450   
706A5 (At4g12310) putative P450   
706A6 (At4g12320) putative P450   
706A7 (At4g12330) putative P450   
707A1 (At4g19230) 8-hydroxylation of abscisic 
acid 
abscisic acid catabolism 278-280 
707A2 (At2g29090) 8-hydroxylation of abscisic 
acid 
abscisic acid catabolism 278-281 
707A3 (At5g45340) 8-hydroxylation of abscisic 
acid 
abscisic acid catabolism 278,279,281-286 
APPENDIX A 
 
202 
 
P450 (gene locus) reaction pathway  references 
707A4 (At3g19270) 8-hydroxylation of abscisic 
acid 
abscisic acid catabolism 278,279 
708A1 (At1g55940) putative P450   
708A2 (At5g48000) hydroxylation of thalianol to 
thaliandiol 
thalianol metabolic 
pathway 
277
 
708A3 (At1g78490) putative P450   
708A4 (At3g44970) putative P450   
709B1 (At2g46960) putative P450   
709B2 (At2g46950)  putative P450   
709B3 (At4g27710) putative P450   
710A1 (At2g34500) C22-desaturation of ß-
sitosterol to stigmasterol 
biosynthesis of sterols 287-289 
710A2 (At2g34490) C22-desaturation of ß-
sitosterol and 24-epi-
campesterol to stigmasterol 
andbrassicasterol 
biosynthesis of sterols 287 
710A3 (At2g28850)    
710A4 (At2g28860) C22-desaturation of ß-
sitosterol to stigmasterol 
biosynthesis of sterols 288 
711A1 (At2g26170) putative P450   
712A1 (At2g42250) putative P450   
712A2 (At5g06905) putative P450   
714A1 (At5g24910) C13-hydroxylation of ent-
kaurenoic acid to steviol 
gibberillin catabolism 277,290 
714A2 (At5g24900) putative P450 gibberillin catabolism 290 
715A1 (At5g52400) putative P450   
716A1 (At5g36110) putative P450   
716A2 (At5g36140) putative P450   
718 (At2g42850) putative P450   
720A1 (At1g73340) putative P450   
721A1 (At1g75130) putative P450   
722A1 (At1g19630) putative P450   
724A1 (At5g14400) 22α-hydroxylation of 
brassinosteroid 
biosynthesis of 
brassinolide  
 
291
 
734A1 (At2g26710) 
initially classified 
as CYP72B 
C26-hydroxylation  of 
brassinolide and castasterone 
brassinolide catabolism 173,292,293 
735A1 (At5g38450) trans-hydroxylation 
ofisopentenyladenine, 
tri/di/monophosphates 
biosynthesis of zeatin, 
cytokinin metabolism 
294
 
735A2 (At1g67110) trans-hydroxylation 
ofisopentenyladenine, 
tri/di/monophosphates 
biosynthesis of zeatin, 
cytokinin metabolism 
294
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Appendix B 
B1  Gene sequences used in Chapter 3 
CYP81D8 (from Arabidopsis) was isolated from plant cultivated in liquid culture. 
The truncated version of CYP81D8 (CYP81D8tr in italics) was created by 
deleting the hydrophobic N-terminal region.  
 
ATGGAAACCAAAACCCTAATTTTCTCAATTCTCTTCGTTGTTCTCTCTCTCATTT
ACTTAATTGGAAAACTCAAGCGAAAGCCAAATCTACCTCCGAGTCCGGCATGGTC
ATTACCGGTGATTGGTCATCTCCGCCTTCTCAAACCACCGATTCATCGCACATTC
CTCTCCCTCTCTCAATCCCTAAACAATGCTCCGATCTTCTCCCTCCGACTCGGTA
ACCGACTCGTTTTCGTGAACTCGTCACACTCGATCGCCGAGGAATGTTTCACCAA
AAACGACGTCGTACTGGCGAACAGACCAAACTTCATCCTCGCTAAACACGTTGCG
TACGATTACACAACCATGATCGCAGCTTCCTACGGTGACCACTGGCGTAACCTCC
GCCGCATCGGCTCCGTCGAGATATTCTCCAATCACCGTCTCAATAGCTTTTTGTC
TATTCGTAAAGACGAGATCCGACGACTTGTGTTTCGTCTTTCTCGGAACTTTTCA
CAAGAGTTTGTGAAAGTGGATATGAAATCAATGTTATCTGACTTAACATTCAACA
ACATTTTAAGAATGGTGGCCGGAAAACGTTACTACGGAGACGGTGTTGAGGATGA
TCCGGAGGCTAAACGTGTCCGGCAGCTTATAGCGGATGTGGTGGCTTGTGCTGGT
GCTGGAAACGCTGTTGATTACTTACCGGTTTTGCGGTTGGTTTCAGATTACGAGA
CACGGGTTAAGAAGTTGGCGGGTAGGCTCGACGAGTTCTTGCAAGGATTGGTTGA
TGAGAAACGAGAAGCTAAGGAGAAAGGAAACACTATGATCGATCACTTGCTTACT
CTGCAAGAATCCCAACCGGATTACTTCACGGATCGTATCATTAAAGGAAACATGC
TCGCTTTGATACTAGCAGGGACCGACACATCAGCGGTTACGTTAGAATGGGCATT
GTCGAACGTGTTGAACCATCCGGATGTATTGAACAAGGCGAGAGATGAAATCGAT
AGAAAGATAGGTTTAGACAGGCTTATGGATGAATCAGATATCTCAAACCTGCCTT
ATCTCCAAAACATTGTGTCTGAAACGTTGCGCCTTTATCCTGCGGCTCCCATGCT
TCTTCCTCACGTTGCCTCGGAAGATTGTAAAGTTGCAGGATACGATATGCCGCGT
GGCACGATACTATTGACCAATGTGTGGGCTATACACAGAGATCCTCAGCTATGGG
ATGATCCAATGAGCTTCAAGCCAGAGAGGTTTGAGAAAGAAGGAGAAGCTCAGAA
GCTAATGCCGTTTGGGTTAGGAAGAAGGGCGTGTCCTGGTTCTGGACTGGCTCAT
CGGCTTATAAACCTGACTCTTGGATCATTGATTCAGTGTTTGGAATGGGAGAAGA
TTGGAGAAGAAGTGGATATGAGTGAAGGCAAAGGTGTTACAATGCCTAAAGCCAA
GCCTTTGGAAGCCATGTGCAGAGCACGTCCCTCTGTTGTTAAAATCTTCAACGAG
TCCGTTTGA 
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CYP81D11 (from Arabidopsis) was isolated from plant cultivated in liquid 
culture. The truncated version of CYP81D11 (CYP81D11tr in italics) was created 
by deleting the hydrophobic N-terminal region.  
  
ATGTCATCAACAAAGACAATAATGGAAACTATATACCTAATTCTCTCTCTCTTCT
TCTTCTTCATCTTCCTATCTCTCAAACTCTTGTTCGGACCACGGCCGCGTAAACT
AAACCTACCGCCGAGTCCGAGTCGACCATTTCCGATCATCGGACACCTCCACCTT
CTAAAGCTACCACTCCACCGTAGATTTCTCTCTCTCTCAGAATCTTTAAACAACG
CCAAGATTTTCTCTCTCAGCCTCGGCTCTCGTCTAGTTTTTGTTGTTTCTTCTCA
CGCCGTCGCGGAAGAATGTTTCACTAAGAACGACGTCGTGTTAGCTAACCGGCCG
GAGTTTCTCGTCGGGAAACATATAGGGTACAACTCTACGACCATGGTTGGTGCGG
CTTATGGAGATAGTTGGAGGAATCTTCGACGTATTGGCACCATTGAGATCTTCTC
GTCTCTTAGGCTTAATAGCTTCGTATCTATCCGTCAAGATGAGATCCGACGGCTC
ATAATTTGTCTAGCGAAAAACTCTCAACATGGGTTTGTGAAAGTGGAGATGAAAC
CATTGTTTATGTGTTTAACTATCAACAACATCATTAGAATGGTGGCCGGAAAAAG
ATTCTACGGTGATGGAACAGAGAACGACAACGAGGCTAAACACGTGAGACAGCTA
ATTGCCGAGGTAGTTGTTAGCGGCGGCGCAGGGAACGCAGCAGACTACTTCCCTA
TCCTTCGTTACGTAACGAACTATGAGAAACATGTTAAGAAGTTAGCAGGTCGTGT
TGATGAGTTTTTGCAAAGTCTAGTTAACGAGAAACGTGTGGAGAAAGTAAAAGGT
AACACAATGATCGATCATTTACTTTCTCTACAAGAAACTCAGCCTGATTACTACA
CGGATGTGATCATCAAAGGAATCATACTTGTTATGATACTTGCCGGGACTGATAC
ATCAGCTGGAACGTTAGAATGGGCGATGTCGAATTTGTTGAACCATCCAGAAGTA
TTACGAAAGGCAAAGACCGAAATCGACGACCAAATCGGTGTAGACCGGTTAGTAG
AGGAACAAGACATTGTGAAACTTCCTTACCTTCAGCACATTGTGTCAGAGACTTT
ACGGCTTTATCCGGTGGCTCCAATGCTTTTACCCCACTTAGCATCAGAAGATTGT
ATAGTTGATGGCTATGACGTTCCACGCGGCACAATCATCTTGGTGAATGCATGGG
CCATCCATAGAGATCCAAAGTTATGGGAAGAGCCAGAAAAATTTAAGCCGGAGAG
GTTTGAGAAAAAAGGAGAGGATAAAAAGTTGATGCCATTTGGGATTGGACGACGA
TCTTGCCCTGGTTCAGGGCTAGCTCAACGGCTAGTGACTTTGGCTCTTGGATCAT
TGGTCCAATGTTTTGAGTGGGAGAGGGTTGAAGAAAAGTATCTAGACATGAGAGA
AAGTGAAAAAGGAACCACAATGCGAAAAGCTACATCGTTGCAAGCTATGTGTAAA
GCTCGTCCCATTGTCCATAA 
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CYP71D15 construct PM2-2
 
(limonene-3-hydroxylase from peppermint) was 
provided by Prof. Rodney Croteau (Institute of Biological Chemistry, Washington 
State University, Pullman, US).
367
 
 
ATGGCTCTGTTATTAGCAGTTTTTTGGTCGGCGCTTATAATCCTCGTAGTAACCT
ACACCATATCCCTCCTAATCAACCAATGGCGAAAACCGAAACCCCAAGGGAAGTT
CCCCCCGGGCCCGCCGAAGCTGCCGCTGATCGGGCACCTCCACCTCCTGTGGGGG
AAGCTGCCGCAGCACGCGCTGGCCAGCGTGGCGAAGGAGTACGGCCCCGTGGCCC
ACGTGCAGCTGGGTGAGGTGTTCTCCGTCGTCCTTTCGTCGCGGGAGGCGACGAA
GGAGGCGATGAAGCTGGTAGACCCGGCGTGCGCGAACCGGTTCGAGAGCATCGGG
ACGAGGATCATGTGGTACGACAACGAGGACATCATCTTCAGCCCCTACAGCGAGC
ACTGGCGCCAGATGCGCAAGATCTGCGTCTCCGAGCTCCTCTCCTCCCGCAACGT
CCGCTCCTTCGGCTTCATCCGGCAGGACGAGGTGTCGCGCCTCCTCCGCCACCTC
CGCTCCTCGGCAGGGGCGGCCGTGGACATGACGGAGAGGATAGAGACGCTGACGT
GCTCCATCATCTGCAGGGCGGCGTTCGGGAGCGTGATCAGGGACAACGCGGAGCT
GGTGGGGCTGGTCAAGGACGCGCTCAGCATGGCCTCGGGGTTCGAGCTCGCCGAC
ATGTTCCCCTCCTCCAAGCTCCTCAACCTCCTCTGCTGGAACAAGAGCAAGCTCT
GGAGGATGCGCCGCCGCGTCGACACCATCCTCGAGGCCATCGTCGACGAGCACAA
GTTCAAGAAAAGCGGCGAGTTCGGCGGCGAGGACATCATCGACGTCCTCTTCAGG
ATGCAGAAGGACACCCAGATCAAAGTCCCCATCACCACCAACTCCATCAAAGCCT
TCATCTTCGATACGTTCTCAGCAGGGACTGAGACATCCTCAACCACCACCCTATG
GGTGCTGGCGGAGCTGATGAGGAACCCGGCAGTGATGGCGAAAGCGCAGGCGGAG
GTGAGAGCGGCACTGAAGGAGAAGACGAACTGGGACGTGGACGACGTGCAAGAGC
TTAAGTACATGAAATCGGTGGTGAAGGAGACGATGAGGATGCACCCTCCGATCCC
GTTGATCCCGAGATCATGCAGAGAAGAATGCGTGGTTAACGGGTATACGATTCCG
AACAAGGCCAGAATCATGATCAACGTCTGGTCCATGGGCAGGAATCCTCTCTACT
GGGAAAAACCCGATACCTTTTGGCCCGAAAGGTTTGACCAAGTTTCAAAGGATTT
CATGGGAAATGATTTCGAGTTCGTCCCGTTCGGAGCGGGAAGAAGAATCTGCCCC
GGCTTGAACTTCGGGTTGGCAAACGTTGAGGTTCCATTGGCGCAGCTTCTTTACC
ACTTCGACTGGAAGTTGGCGGAAGGAATGAAACCTTCTGATATGGACATGTCTGA
GGCGGAAGGCCTTACCGGAATACTAAAGAACAATCTTCTTCTTGTTCCCACACCC
TACGATCCTTCATCATGA 
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B2  Gene sequence used in Chapter 4 
ATR1tr (P450 reductase from Arabidopsis) was isolated from plant cultivated in 
liquid culture. The truncated version of ATR1 was created by deleting the 
hydrophobic 46 amino acids of the N-terminal region. 
 
TGGAAGAAAACGACGGCGGATCGGAGCGGGGAGCTGAAGCCTTTGATGATCCCTA
AGTCTCTTATGGCTAAGGACGAGGATGATGATTTGGATTTGGGATCCGGGAAGAC
TAGAGTCTCTATCTTCTTCGGTACGCAGACTGGAACAGCTGAGGGATTTGCTAAG
GCATTATCCGAAGAAATCAAAGCGAGATATGAAAAAGCAGCAGTCAAAGTCATTG
ACTTGGATGACTATGCTGCCGATGATGACCAGTATGAAGAGAAATTGAAGAAGGA
AACTTTGGCATTTTTCTGTGTTGCTACTTATGGAGATGGAGAGCCTACTGACAAT
GCTGCCAGATTTTACAAATGGTTTACGGAGGAAAATGAACGGGATATAAAGCTTC
AACAACTAGCATATGGTGTGTTTGCTCTTGGTAATCGCCAATATGAACATTTTAA
TAAGATCGGGATAGTTCTTGATGAAGAGTTATGTAAGAAAGGTGCAAAGCGTCTT
ATTGAAGTCGGTCTAGGAGATGATGATCAGAGCATTGAGGATGATTTTAATGCCT
GGAAAGAATCACTATGGTCTGAGCTAGACAAGCTCCTCAAAGACGAGGATGATAA
AAGTGTGGCAACTCCTTATACAGCTGTTATTCCTGAATACCGGGTGGTGACTCAT
GATCCTCGGTTTACAACTCAAAAATCAATGGAATCAAATGTGGCCAATGGAAATA
CTACTATTGACATTCATCATCCCTGCAGAGTTGATGTTGCTGTGCAGAAGGAGCT
TCACACACATGAATCTGATCGGTCTTGCATTCATCTCGAGTTCGACATATCCAGG
ACGGGTATTACATATGAAACAGGTGACCATGTAGGTGTATATGCTGAAAATCATG
TTGAAATAGTTGAAGAAGCTGGAAAATTGCTTGGCCACTCTTTAGATTTAGTATT
TTCCATACATGCTGACAAGGAAGATGGCTCCCCATTGGAAAGCGCAGTGCCGCCT
CCTTTCCCTGGTCCATGCACACTTGGGACTGGTTTGGCAAGATACGCAGACCTTT
TGAACCCTCCTCGAAAGTCTGCGTTAGTTGCCTTGGCGGCCTATGCCACTGAACC
AAGTGAAGCCGAGAAACTTAAGCACCTGACATCACCTGATGGAAAGGATGAGTAC
TCACAATGGATTGTTGCAAGTCAGAGAAGTCTTTTAGAGGTGATGGCTGCTTTTC
CATCTGCAAAACCCCCACTAGGTGTATTTTTTGCTGCAATAGCTCCTCGTCTACA
ACCTCGTTACTACTCCATCTCATCCTCGCCAAGATTGGCGCCAAGTAGAGTTCAT
GTTACATCCGCACTAGTATATGGTCCAACTCCTACTGGTAGAATCCACAAGGGTG
TGTGTTCTACGTGGATGAAGAATGCAGTTCCTGCGGAGAAAAGTCATGAATGTAG
TGGAGCCCCAATCTTTATTCGAGCATCTAATTTCAAGTTACCATCCAACCCTTCA
ACTCCAATCGTTATGGTGGGACCTGGGACTGGGCTGGCACCTTTTAGAGGTTTTC
TGCAGGAAAGGATGGCACTAAAAGAAGATGGAGAAGAACTAGGTTCATCTTTGCT
CTTCTTTGGGTGTAGAAATCGACAGATGGACTTTATATACGAGGATGAGCTCAAT
AATTTTGTTGATCAAGGCGTAATATCTGAGCTCATCATGGCATTCTCCCGTGAAG
GAGCTCAGAAGGAGTATGTTCAACATAAGATGATGGAGAAGGCAGCACAAGTTTG
GGATCTAATAAAGGAAGAAGGATATCTCTATGTATGCGGTGATGCTAAGGGCATG
GCGAGGGACGTCCACCGAACTCTACACACCATTGTTCAGGAGCAGGAAGGTGTGA
GTTCGTCAGAGGCAGAGGCTATAGTTAAGAAACTTCAAACCGAAGGAAGATACCT
CAGAGATGTCTGG 
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ATR2tr (P450 reductase from Arabidopsis) was isolated from plant cultivated in 
liquid culture. The truncated version of ATR2 was created by deleting the 
hydrophobic 75 amino acids of the N-terminal region. 
 
GGTTCTGGGAATTCAAAACGTGTCGAGCCTCTTAAGCCTTTGGTTATTAAGCCTC
GTGAGGAAGAGATTGATGATGGGCGTAAGAAAGTTACCATCTTTTTCGGTACACA
AACTGGTACTGCTGAAGGTTTTGCAAAGGCTTTAGGAGAAGAAGCTAAAGCAAGA
TATGAAAAGACCAGATTCAAAATCGTTGATTTGGATGATTACGCGGCTGATGATG
ATGAGTATGAGGAGAAATTGAAGAAAGAGGATGTGGCTTTCTTCTTCTTAGCCAC
ATATGGAGATGGTGAGCCTACCGACAATGCAGCGAGATTCTACAAATGGTTCACC
GAGGGGAATGACAGAGGAGAATGGCTTAAGAACTTGAAGTATGGAGTGTTTGGAT
TAGGAAACAGACAATATGAGCATTTTAATAAGGTTGCCAAAGTTGTAGATGACAT
TCTTGTCGAACAAGGTGCACAGCGTCTTGTACAAGTTGGTCTTGGAGATGATGAC
CAGTGTATTGAAGATGACTTTACCGCTTGGCGAGAAGCATTGTGGCCCGAGCTTG
ATACAATACTGAGGGAAGAAGGGGATACAGCTGTTGCCACACCATACACTGCAGC
TGTGTTAGAATACAGAGTTTCTATTCACGACTCTGAAGATGCCAAATTCAATGAT
ATAAACATGGCAAATGGGAATGGTTACACTGTGTTTGATGCTCAACATCCTTACA
AAGCAAATGTCGCTGTTAAAAGGGAGCTTCATACTCCCGAGTCTGATCGTTCTTG
TATCCATTTGGAATTTGACATTGCTGGAAGTGGACTTACGTATGAAACTGGAGAT
CATGTTGGTGTACTTTGTGATAACTTAAGTGAAACTGTAGATGAAGCTCTTAGAT
TGCTGGATATGTCACCTGATACTTATTTCTCACTTCACGCTGAAAAAGAAGACGG
CACACCAATCAGCAGCTCACTGCCTCCTCCCTTCCCACCTTGCAACTTGAGAACA
GCGCTTACACGATATGCATGTCTTTTGAGTTCTCCAAAGAAGTCTGCTTTAGTTG
CGTTGGCTGCTCATGCATCTGATCCTACCGAAGCAGAACGATTAAAACACCTTGC
TTCACCTGCTGGAAAGGATGAATATTCAAAGTGGGTAGTAGAGAGTCAAAGAAGT
CTACTTGAGGTGATGGCCGAGTTTCCTTCAGCCAAGCCACCACTTGGTGTCTTCT
TCGCTGGAGTTGCTCCAAGGTTGCAGCCTAGGTTCTATTCGATATCATCATCGCC
CAAGATTGCTGAAACTAGAATTCACGTCACATGTGCACTGGTTTATGAGAAAATG
CCAACTGGCAGGATTCATAAGGGAGTGTGTTCCACTTGGATGAAGAATGCTGTGC
CTTACGAGAAGAGTGAAAACTGTTCCTCGGCGCCGATATTTGTTAGGCAATCCAA
CTTCAAGCTTCCTTCTGATTCTAAGGTACCGATCATCATGATCGGTCCAGGGACT
GGATTAGCTCCATTCAGAGGATTCCTTCAGGAAAGACTAGCGTTGGTAGAATCTG
GTGTTGAACTTGGGCCATCAGTTTTGTTCTTTGGATGCAGAAACCGTAGAATGGA
TTTCATCTACGAGGAAGAGCTCCAGCGATTTGTTGAGAGTGGTGCTCTCGCAGAG
CTAAGTGTCGCCTTCTCTCGTGAAGGACCCACCAAAGAATACGTACAGCACAAGA
TGATGGACAAGGCTTCTGATATCTGGAATATGATCTCTCAAGGAGCTTATTTATA
TGTTTGTGGTGACGCCAAAGGCATGGCAAGAGATGTTCACAGATCTCTCCACACA
ATAGCTCAAGAACAGGGGTCAATGGATTCAACTAAAGCAGAGGGCTTCGTGAAGA
ATCTGCAAACGAGTGGAAGATATCTTAGAGATGTATGG
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A2  Gene sequence used in Chapter 5 and 6 
ATR2tr sequence originated from the E. coli expression codon optimised ATR2 
gene sequence synthesised by GeneArt.  
 
GGTAGCGGTAATAGCAAACGTGTTGAACCGCTGAAACCGCTGGTTATTAAACCGC
GTGAAGAAGAAATTGACGACGGTCGTAAAAAAGTGACCATTTTTTTTGGCACCCA
GACCGGCACCGCAGAAGGTTTTGCAAAAGCACTGGGTGAAGAGGCAAAAGCACGT
TATGAAAAAACCCGCTTCAAAATTGTGGATCTGGATGATTATGCAGCCGATGATG
ATGAGTATGAAGAAAAACTGAAAAAAGAAGATGTGGCCTTTTTTTTCCTGGCAAC
CTATGGTGATGGTGAACCGACCGATAATGCAGCACGTTTTTATAAATGGTTTACC
GAAGGTAACGATCGTGGTGAATGGCTGAAAAATCTGAAATATGGTGTGTTTGGTC
TGGGTAATCGCCAGTATGAACACTTTAATAAAGTGGCCAAAGTGGTGGATGATAT
TCTGGTTGAACAGGGTGCACAGCGTCTGGTTCAGGTTGGTCTGGGTGATGATGAT
CAGTGTATCGAAGATGATTTTACCGCATGGCGTGAAGCACTGTGGCCTGAACTGG
ATACCATTCTGCGTGAAGAAGGTGATACCGCAGTTGCAACCCCGTATACCGCAGC
AGTTCTGGAATATCGTGTTAGCATTCATGATAGCGAGGATGCCAAATTCAACGAT
ATTAATATGGCCAATGGCAATGGCTATACCGTTTTTGATGCACAGCATCCGTATA
AAGCAAATGTTGCAGTTAAACGCGAACTGCATACACCGGAAAGCGATCGTAGCTG
TATTCATCTGGAATTTGATATTGCAGGTAGCGGTCTGACCTATGAAACCGGTGAT
CATGTTGGTGTTCTGTGTGATAATCTGAGCGAAACCGTTGATGAAGCACTGCGTC
TGCTGGATATGAGTCCGGATACCTATTTTAGCCTGCATGCAGAAAAAGAGGATGG
CACCCCGATTAGCAGCAGCCTGCCTCCGCCTTTTCCGCCTTGTAATCTGCGTACC
GCACTGACCCGTTATGCATGTCTGCTGAGCAGCCCGAAAAAAAGCGCACTGGTTG
CACTGGCAGCACATGCAAGCGATCCGACCGAAGCAGAACGTCTGAAACATCTGGC
AAGTCCGGCAGGTAAAGTTGATGAATATAGCAAATGGGTTGTGGAAAGCCAGCGT
AGCCTGCTGGAAGTTATGGCAGAATTTCCGAGCGCAAAACCGCCTCTGGGTGTTT
TTTTTGCCGGTGTTGCACCGCGTCTGCAGCCTCGTTTTTATAGCATTAGCAGCAG
TCCGAAAATTGCAGAAACCCGTATTCATGTTACCTGTGCACTGGTGTATGAAAAA
ATGCCGACCGGTCGTATTCATAAAGGTGTTTGTAGCACCTGGATGAAAAATGCAG
TGCCGTATGAAAAAAGCGAAAATTGTAGCAGCGCACCGATTTTTGTTCGTCAGAG
CAATTTTAAACTGCCGAGCGATAGCAAAGTGCCGATTATTATGATTGGTCCGGGT
ACAGGTCTGGCACCGTTTCGTGGTTTTCTGCAAGAACGTCTGGCACTGGTTGAAA
GCGGTGTTGAACTGGGTCCGAGCGTTCTGTTTTTTGGTTGTCGTAATCGTCGCAT
GGATTTCATCTATGAAGAAGAACTGCAGCGTTTTGTGGAAAGCGGTGCACTGGCC
GAACTGAGCGTTGCATTTAGCCGTGAAGGTCCGACCAAAGAATATGTTCAGCACA
AAATGATGGACAAAGCCAGCGATATTTGGAATATGATTAGCCAGGGTGCCTATCT
GTATGTTTGTGGTGATGCAAAAGGTATGGCACGTGATGTTCATCGTAGCCTGCAT
ACCATTGCACAAGAACAGGGTAGCATGGATAGCACCAAAGCCGAAGGTTTTGTTA
AAAATCTGCAGACCAGCGGTCGTTATCTGCGTGATGTTTGGTAA 
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Modified P450 gene sequences for P450-ATR2tr fusion platform: 
IFS native gene derived from Prof. Mattheos Koffas. The first six N-terminal 
residues (small letters) represent the synthetic mammalian peptide (amino acid 
sequence: MALLLAVF). The codon of the last amino acid (Serine) was changed 
from TCT to TCA to make it compatible for ligation independent cloning. 
 
atggctctgttattagcagtttttCTTGGTTTGTTTGTGTTAGCTTTGTTTCTGCACTT
GCGTCCCACACCAAGTGCAAAATCAAAAGCACTTCGCCACCTCCCAAACCCTCCA
AGCCCAAAGCCTCGTCTTCCCTTCATTGGCCACCTTCACCTCTTAAAAGATAAAC
TTCTCCACTATGCACTCATCGATCTCTCCAAAAAGCATGGCCCCTTATTCTCTCT
CTCCTTCGGCTCCATGCCAACCGTCGTTGCCTCCACCCCTGAGTTGTTCAAGCTC
TTCCTCCAAACCCACGAGGCAACTTCCTTCAACACAAGGTTCCAAACCTCTGCCA
TAAGACGCCTCACTTACGACAACTCTGTGGCCATGGTTCCATTCGGACCTTACTG
GAAGTTCGTGAGGAAGCTCATCATGAACGACCTTCTCAACGCCACCACCGTCAAC
AAGCTCAGGCCTTTGAGGACCCAACAGATCCGCAAGTTCCTTAGGGTTATGGCCC
AAAGCGCAGAGGCCCAGAAGCCCCTTGACGTCACCGAGGAGCTTCTCAAATGGAC
CAACAGCACCATCTCCATGATGATGCTCGGCGAGGCTGAGGAGATCAGAGACATC
GCTCGCGAGGTTCTTAAGATCTTCGGCGAATACAGCCTCACTGACTTCATCTGGC
CTTTGAAGTATCTCAAGGTTGGAAAGTATGAGAAGAGGATTGATGACATCTTGAA
CAAGTTCGACCCTGTCGTTGAAAGGGTCATCAAGAAGCGCCGTGAGATCGTCAGA
AGGAGAAAGAACGGAGAAGTTGTTGAGGGCGAGGCCAGCGGCGTCTTCCTCGACA
CTTTGCTTGAATTCGCTGAGGACGAGACCATGGAGATCAAAATTACCAAGGAGCA
AATCAAGGGCCTTGTTGTCGACTTTTTCTCTGCAGGGACAGATTCCACAGCGGTG
GCAACAGAGTGGGCATTGGCAGAGCTCATCAACAATCCCAGGGTGTTGCAAAAGG
CTCGTGAGGAGGTCTACAGTGTTGTGGGCAAAGATAGACTCGTTGACGAAGTTGA
CACTCAAAACCTTCCTTACATTAGGGCCATTGTGAAGGAGACATTCCGAATGCAC
CCACCACTCCCAGTGGTCAAAAGAAAGTGCACAGAAGAGTGTGAGATTAATGGGT
ATGTGATCCCAGAGGGAGCATTGGTTCTTTTCAATGTTTGGCAAGTAGGAAGGGA
CCCCAAATACTGGGACAGACCATCAGAATTCCGTCCCGAGAGGTTCTTAGAAACT
GGTGCTGAAGGGGAAGCAGGGCCTCTTGATCTTAGGGGCCAGCATTTCCAACTCC
TCCCATTTGGGTCTGGGAGGAGAATGTGCCCTGGTGTCAATTTGGCTACTTCAGG
AATGGCAACACTTCTTGCATCTCTTATCCAATGCTTTGACCTGCAAGTGCTGGGC
CCTCAAGGACAAATATTGAAAGGTGATGATGCCAAAGTTAGCATGGAAGAGAGAG
CTGGCCTCACAGTTCCAAGGGCACATAGTCTCGTTTGTGTTCCACTTGCAAGGAT
CGGCGTTGCATCTAAACTCCTTTCA 
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IFSopt gene was synthesised and codon optimised for the expression in E. coli by 
GeneArt. The codon of the last amino acid (Serine) was changed from AGC to 
TCA to make it compatible for ligation independent cloning. 
 
GCCCGTCCGACCCCGAGCGCAAAAAGCAAAGCACTGCGTCATCTGCCGAATCCGC
CTAGCCCGAAACCGCGTCTGCCGTTTATTGGTCATCTGCATCTGCTGAAAGATAA
ACTGCTGCATTATGCACTGATTGATCTGAGCAAAAAACATGGTCCGCTGTTTAGC
CTGAGCTTTGGTAGCATGCCGACCGTTGTTGCAAGCACACCGGAACTGTTTAAAC
TGTTTCTGCAGACCCATGAAGCGACCAGCTTTAATACCCGTTTTCAGACCAGCGC
AATTCGTCGTCTGACCTATGATAATAGCGTTGCAATGGTTCCGTTTGGTCCGTAT
TGGAAATTTGTGCGTAAACTGATCATGAACGATCTGCTGAATGCAACCACCGTTA
ATAAACTGCGTCCGCTGCGTACCCAGCAGATTCGTAAATTTCTGCGTGTTATGGC
ACAGAGCGCAGAAGCACAGAAACCGCTGGATGTTACCGAGGAACTGCTGAAATGG
ACCAATAGCACCATTAGCATGATGATGCTGGGTGAAGCCGAAGAAATTCGTGATA
TTGCACGTGAAGTGCTGAAAATCTTTGGTGAATATAGCCTGACCGATTTTATCTG
GCCTCTGAAATATCTGAAAGTGGGCAAATATGAAAAACGCATCGATGATATTCTG
AATAAATTTGATCCGGTGGTGGAACGCGTGATTAAAAAACGTCGTGAAATTGTTC
GCCGTCGCAAAAATGGTGAAGTTGTTGAAGGTGAAGCCAGCGGTGTTTTTCTGGA
TACCCTGCTGGAATTTGCCGAAGATGAAACCATGGAAATTAAAATTACCAAAGAA
CAAATTAAAGGCCTGGTGGTGGATTTTTTTAGCGCAGGCACCGATAGCACCGCAG
TTGCAACCGAATGGGCACTGGCAGAACTGATTAATAATCCGCGTGTTCTGCAGAA
AGCACGTGAAGAAGTTTATAGCGTTGTTGGTAAAGATCGTCTGGTTGATGAAGTT
GATACCCAGAATCTGCCGTATATTCGTGCCATTGTGAAAGAAACCTTTCGTATGC
ATCCGCCTCTGCCGGTTGTTAAACGTAAATGTACCGAAGAATGCGAAATCAACGG
TTATGTTATTCCGGAAGGTGCACTGGTTCTGTTTAATGTTTGGCAGGTTGGTCGT
GATCCGAAATATTGGGATCGTCCGAGCGAATTTCGTCCGGAACGTTTTCTGGAAA
CCGGTGCAGAAGGTGAAGCAGGTCCGCTGGATCTGCGTGGTCAGCATTTTCAGCT
GCTGCCGTTTGGTAGCGGTCGTCGTATGTGTCCGGGTGTTAATCTGGCAACCAGC
GGTATGGCAACCCTGCTGGCAAGCCTGATTCAGTGTTTTGATCTGCAGGTTCTGG
GTCCGCAGGGTCAGATTCTGAAAGGTGATGATGCAAAAGTGAGCATGGAAGAACG
TGCAGGTCTGACCGTTCCGCGTGCACATAGCCTGGTTTGTGTTCCGCTGGCACGT
ATTGGTGTTGCAAGCAAACTGCTGTCA 
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CYP73A5 (cinnamate-4-hydroxylase from Arabidopsis) was synthesised and 
codon optimised for the expression in E. coli by GeneArt. The truncated version 
of CYP73A5 (73A5tr) was created by deleting the hydrophobic N-terminal region 
and to improve the expression in E. coli and Alanin was added just after the start 
codon methionin (in bold).
321
 
The codon of the last amino acid (Cysteine) will be changed from TGC to TCA 
(Serine) to make it compatible for ligation independent cloning. 
 
ATGGCCCTGCGTGGTAAAAAACTGAAACTGCCTCCGGGTCCGATTCCGATCCCGATTTTT
GGTAATTGGCTGCAGGTTGGTGATGATCTGAATCATCGTAATCTGGTGGACTACGCCAAA
AAATTCGGTGACCTGTTTCTGCTGCGTATGGGTCAGCGTAATCTGGTTGTTGTTAGCAGT
CCGGATCTGACCAAAGAAGTTCTGCATACCCAGGGTGTTGAATTTGGTAGCCGTACCCGT
AATGTTGTGTTTGATATCTTTACAGGTAAAGGTCAGGATATGGTGTTTACCGTTTATGGT
GAACATTGGCGTAAAATGCGTCGTATTATGACCGTTCCGTTCTTTACCAATAAAGTTGTT
CAGCAGAATCGCGAAGGCTGGGAATTTGAAGCAGCAAGCGTTGTTGAGGACGTGAAAAAA
AACCCGGATAGCGCAACCAAAGGTATTGTTCTGCGTAAACGTCTGCAGCTGATGATGTAT
AATAACATGTTCCGCATCATGTTCGATCGTCGTTTTGAAAGCGAAGATAGTCCGCTGTTT
CTGCGTCTGAAAGCACTGAATGGTGAACGTAGCCGTCTGGCACAGAGCTTTGAATATAAC
TATGGCGATTTTATCCCGATTCTGCGTCCGTTTCTGCGTGGTTATCTGAAAATTTGCCAG
GATGTTAAAGATCGTCGTATTGCCCTGTTCAAAAAATACTTTGTGGACGAACGCAAACAA
ATTGCAAGCAGCAAACCGACCGGTAGCGAAGGTCTGAAATGTGCAATTGATCATATTCTG
GAAGCCGAACAGAAAGGCGAAATTAATGAAGATAATGTGCTGTACATTGTGGAAAACATT
AACGTTGCAGCCATTGAAACCACCCTGTGGTCAATTGAATGGGGTATTGCAGAACTGGTT
AACCATCCGGAAATTCAGAGTAAACTGCGTAATGAACTGGATACCGTTCTGGGTCCGGGT
GTTCAGGTTACCGAACCGGATCTGCATAAACTGCCGTATCTGCAGGCAGTTGTTAAAGAA
ACCCTGCGTCTGCGTATGGCAATTCCGCTGCTGGTTCCGCATATGAATCTGCATGATGCA
AAACTGGCAGGTTATGATATTCCGGCAGAAAGCAAAATTCTGGTTAATGCATGGTGGCTG
GCCAATAATCCGAATAGCTGGAAAAAACCGGAAGAATTTCGTCCGGAACGCTTTTTTGAA
GAAGAAAGCCACGTTGAAGCCAATGGTAATGATTTTCGTTATGTTCCGTTTGGTGTTGGT
CGTCGTAGCTGTCCGGGTATTATTCTGGCACTGCCGATTCTGGGTATTACCATTGGTCGT
ATGGTGCAGAATTTTGAACTGCTGCCTCCGCCTGGTCAGAGCAAAGTTGATACCAGCGAA
AAAGGTGGTCAGTTTAGCCTGCATATTCTGAACCATAGCATTATTGTGATGAAACCGCGT
AACTCA 
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CYP82E4tr (N-demethylase from Nicotiana tabacum) derived from Prof. Ralph 
Dewey. The truncated version of CYP82E4 (82E4tr) was created by deleting the 
hydrophobic N-terminal region. The codon TAT of the last amino acid (Tyrosine) 
will be changed from to ACA (Threonine) to keep the electrophilic charge and to 
make it compatible for ligation independent cloning. 
 
ACAAAAAAATCTCAAAAACCTTCAAAACCCTTACCACCGAAAATCCCCGGAGGAT
GGCCGGTAATCGGCCATCTTTTCCACTTCAATGACGACGGCGACGACCGTCCATT
AGCTCGAAAACTCGGAGACTTAGCTGACAAATACGGCCCCGTTTTCACTTTTCGG
CTAGGCCTTCCCCTTGTCTTAGTTGTAAGCAGTTACGAAGCTGTAAAAGACTGTT
TCTCTACAAATGACGCCATTTTTTCCAATCGTCCAGCTTTTCTTTACGGCGATTA
CCTTGGCTACAATAATGCCATGCTATTTTTGGCCAATTACGGACCTTACTGGCGA
AAAAATCGAAAATTAGTTATTCAGGAAGTTCTCTCCGCTAGTCGTCTCGAAAAAT
TCAAACACGTGAGATTTGCAAGAATTCAAGCGAGCATTAAGAATTTATATACTCG
AATTGATGGAAATTCGAGTACGATAAATTTAACTGATTGGTTAGAAGAATTGAAT
TTTGGTCTGATCGTGAAGATGATCGCTGGAAAAAATTATGAATCCGGTAAAGGAG
ATGAACAAGTGGAGAGATTTAAGAAAGCGTTTAAGGATTTTATGATTTTATCAAT
GGAGTTTGTGTTATGGGATGCATTTCCAATTCCATTATTTAAATGGGTGGATTTT
CAAGGGCATGTTAAGGCTATGAAAAGGACTTTTAAAGATATAGATTCTGTTTTTC
AGAATTGGTTAGAGGAACATATTAATAAAAGAGAAAAAATGGAGGTTAATGCAGA
AGGGAATGAACAAGATTTCATTGATGTGGTGCTTTCAAAAATGAGTAATGAATAT
CTTGGTGAAGGTTACTCTCGTGATACTGTCATTAAAGCAACGGTGTTTAGTTTGG
TCTTGGATGCAGCAGACACAGTTGCTCTTCACATAAATTGGGGAATGGCATTATT
GATAAACAATCAAAAGGCCTTGACGAAAGCACAAGAAGAGATAGACACAAAAGTT
GGTAAGGACAGATGGGTAGAAGAGAGTGATATTAAGGATTTGGTATACCTCCAAG
CTATTGTTAAAGAAGTGTTACGATTATATCCACCAGGACCTTTGTTAGTACCACA
CGAAAATGTAGAAGATTGTGTTGTTAGTGGATATCACATTCCTAAAGGGACAAGA
TTATTCGCAAACGTCATGAAACTGCAACGTGATCCTAAACTCTGGTCTGATCCTG
ATACTTTCGATCCAGAGAGATTCATTGCTACTGATATTGACTTTCGTGGTCAGTA
CTATAAGTATATCCCGTTTGGTTCTGGAAGACGATCTTGTCCAGGGATGACTTAT
GCATTGCAAGTGGAACACTTAACAATGGCACATTTGATCCAAGGTTTCAATTACA
GAACTCCAAATGACGAGCCCTTGGATATGAAGGAAGGTGCAGGCATAACTATACG
TAAGGTAAATCCTGTGGAACTGATAATAGCGCCTCGCCTGGCACCTGAGCTTACA 
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CYP81D8 (from Arabidopsis) was isolated from plant cultivated in liquid culture. 
The truncated version of CYP81D8 (81D8tr) was created by deleting the 
hydrophobic N-terminal region. The codon GTT (Valine) was changed to GTA 
(Valine) to make it compatible for ligation independent cloning. 
 
GGAAAACTCAAGCGAAAGCCAAATCTACCTCCGAGTCCGGCATGGTCATTACCGG
TGATTGGTCATCTCCGCCTTCTCAAACCACCGATTCATCGCACATTCCTCTCCCT
CTCTCAATCCCTAAACAATGCTCCGATCTTCTCCCTCCGACTCGGTAACCGACTC
GTTTTCGTGAACTCGTCACACTCGATCGCCGAGGAATGTTTCACCAAAAACGACG
TCGTACTGGCGAACAGACCAAACTTCATCCTCGCTAAACACGTTGCGTACGATTA
CACAACCATGATCGCAGCTTCCTACGGTGACCACTGGCGTAACCTCCGCCGCATC
GGCTCCGTCGAGATATTCTCCAATCACCGTCTCAATAGCTTTTTGTCTATTCGTA
AAGACGAGATCCGACGACTTGTGTTTCGTCTTTCTCGGAACTTTTCACAAGAGTT
TGTGAAAGTGGATATGAAATCAATGTTATCTGACTTAACATTCAACAACATTTTA
AGAATGGTGGCCGGAAAACGTTACTACGGAGACGGTGTTGAGGATGATCCGGAGG
CTAAACGTGTCCGGCAGCTTATAGCGGATGTGGTGGCTTGTGCTGGTGCTGGAAA
CGCTGTTGATTACTTACCGGTTTTGCGGTTGGTTTCAGATTACGAGACACGGGTT
AAGAAGTTGGCGGGTAGGCTCGACGAGTTCTTGCAAGGATTGGTTGATGAGAAAC
GAGAAGCTAAGGAGAAAGGAAACACTATGATCGATCACTTGCTTACTCTGCAAGA
ATCCCAACCGGATTACTTCACGGATCGTATCATTAAAGGAAACATGCTCGCTTTG
ATACTAGCAGGGACCGACACATCAGCGGTTACGTTAGAATGGGCATTGTCGAACG
TGTTGAACCATCCGGATGTATTGAACAAGGCGAGAGATGAAATCGATAGAAAGAT
AGGTTTAGACAGGCTTATGGATGAATCAGATATCTCAAACCTGCCTTATCTCCAA
AACATTGTGTCTGAAACGTTGCGCCTTTATCCTGCGGCTCCCATGCTTCTTCCTC
ACGTTGCCTCGGAAGATTGTAAAGTTGCAGGATACGATATGCCGCGTGGCACGAT
ACTATTGACCAATGTGTGGGCTATACACAGAGATCCTCAGCTATGGGATGATCCA
ATGAGCTTCAAGCCAGAGAGGTTTGAGAAAGAAGGAGAAGCTCAGAAGCTAATGC
CGTTTGGGTTAGGAAGAAGGGCGTGTCCTGGTTCTGGACTGGCTCATCGGCTTAT
AAACCTGACTCTTGGATCATTGATTCAGTGTTTGGAATGGGAGAAGATTGGAGAA
GAAGTGGATATGAGTGAAGGCAAAGGTGTTACAATGCCTAAAGCCAAGCCTTTGG
AAGCCATGTGCAGAGCACGTCCCTCTGTTGTTAAAATCTTCAACGAGTCCGTA 
 
 
ABBREVIATIONS 
 
214 
 
Abbreviations 
½ MS Murashige and Skoog medium half strength 
2-ADNT 2-amino-4,6-dinitrotoluene 
2-HADNT 2-hydroxylamino-4,6-dinitrotoluene 
4-ADNT 4-amino-2,6-dinitrotoluene 
4-HADNT 4-hydroxylamino-2,6-dinitrotoluene 
A adenine 
aa amino acids 
Abs optical absorbance 
ADE 2d selection marker for adenine auxotrphy 
ALA 5-aminolevulinic acid 
ampR ampillin resistence gene 
ATR1 Arabidopsis thaliana cytochrome P450 reductase 1 
BLAST Basic Local Alignment Search Tool 
bp base pairs 
BSA bovine serum albumine 
C cytosine 
cDNA complementary DNA 
CO carbon monoxide 
CPO chloroperoxidase 
CPR cytochrome P450 reductase 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
dNTP dinucleotide triphosphate 
DTT dithiothreitol 
[E] enzyme concentration 
EDTA ethylenediaminetetraacetic acid 
ER endoplasmic reticulum 
et al. et alii 
EtOH ethanol 
f1 ori f1 phage origin of replication 
FAD flavin adenine dinucleotide 
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FMN flavin mononucleotide 
g grams 
G guanine 
heme Protoporphirin IX bound to one iron atom 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid 
His 6x histidines residues 
HiTEL High Throughput Expression Laboratory 
HPLC high performance liquid chromatography 
K2HPO4 dipotassium hydrogen phosphate 
kanR kanamycine resistence gene 
kb kilo base pairs 
kcat maximum turnover rate 
KCl potassium chloride 
kDa kilodaltons 
kg kilogram 
KH2PO4 potassium dihydrogen phosphate 
KM Michaelis-Menten constant 
l litre 
LacI repressor gene for IPTG induction 
LacZ ß-galactosidase gene 
LB Lysogeny Broth 
LIC Ligation independent cloning 
LiCl lithium chloride 
LIC-vector pETYSBLIC3C vector 
m meter 
M molar 
M13 ori origin of replication of filamentour phage M13 
MALDI-TOF Matrix-Assisted Laser Desorption/Ionization - Time-of-Flight  
MgSO4 magnesium phosphate 
min minute(s) 
mRNA messenger RNA 
NaCl sodium chloride 
NaCl sodium chloride 
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NAD
+ 
 nicotinamide adenine dinucleotide, oxidised form 
NADH nicotinamide adenine dinucleotide, reduced form  
NADP
+ 
 nicotinamide adenine dinucleotide phosphate, oxidised form 
NADPH  nicotinamide adenine dinucleotide phosphate, reduced form 
NaOH sodium hydroxide 
NCBI National Center for Biotechnology Information 
NDSB 201 3-(1-Pyridinio)-1-propanesulfonate 
NEB New England Biolabs 
(NH4)2SO4 ammonium sulphate 
NOS nitric oxide synthase 
OD600 optical density at 600 nm 
oLAC Lac operator 
PAGE polyacrylamide gel electrophoresis 
pBR322 ori origin of replication of the plasmid pBR322 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PEG poly-ethylene glycol 
pGAL galactose promoter 
PMSF phenylmethanesulfonylfluorife 
pT7 T7 promotor 
RBS ribosome binding site 
RDX hexahydro
 
-1,3,5-trinitro
 
-1,3,5-triazine, Royal Demolition Explosive 
RNA ribose nucleic acid 
rpm revolutions per minute 
RT reverse transcriptase 
[S] substrate concentration 
SDS sodium dodecyl sulfate 
sec second(s) 
SGI synthetic media for yeast   
SRS substrate recognition site 
SSNMR Solid State Nuclear Magnetic Resonance 
STDEV one standard deviation from the mean 
T Thymine 
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tac  tac promoter 
TCA trichloroacetic acid 
TE Tris/EDTA  
Temed N, N, N’, N’-Tetramethylethylendiamine 
TFA trifluoroacetic acid 
TNT 2,4,6-trinitrotoluene 
tPGK phosphoglycerate kinase terminator 
Tris 2-amino-2-hydroxymethyl-1,3-propanediol 
Triton X-100 4-octylphenol polyethoxylate 
tT7 T7 terminator 
URA3 selection marker for uracil auxotrophy 
UV ultra violet (light) 
v/v volume to volume ratio 
Vmax maximal reaction velocity 
w/v weight to volume ratio 
X-Gal bromochloroindolylgalactopyranoside 
YPGA yeast medium containing yeast extract, bactopeptone, glucose and adenine 
YPGE yeast medium containing yeast extract, bactopeptone, glucose and ethanol 
ZnCl2 zinc chloride 
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